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Abstract
Although researchers have made great strides toward understanding the biological processes under-
lying cancer pathology, this has not led to major improvements in the management of the disease.
Development of new treatments to combat cancer remains imperative. Nanosized therapies show
promise to improve tumor treatment response by localizing therapy while reducing treatment-related
toxicity. Understanding how nanotherapies are taken up and cause their effects at the intact tumor
level in vivo will complement ex vivo histological and in vitro biochemical studies and facilitate the
translation of nanotherapy treatments to the clinic. Currently, few in vivo methods exist to study
nanotherapy uptake and response at the intact tumor scale. Magnetic resonance imaging (MRI)
and positron emission tomography (PET) are imaging methods that provide different but comple-
mentary information about the tumor microenvironment and nanotherapy uptake/response. Direct
spatiotemporal correlation of PET and MRI data via their simultaneous acquisition has the poten-
tial to be powerfully synergistic, especially for the study of physiological processes that are time
sensitive or where good spatial coregistration of the multimodal data is important. As the field of
hybrid PET/MRI is still in its infancy, with only a handful of active systems worldwide, it is vital
that continued PET/MRI technology development be pursued to realize its full potential.
The objective of this thesis is to develop noninvasive, multimodal PET/MRI methods to study
the uptake and response of cancer nanotherapies. Three studies were pursued toward this goal. First,
we describe the development of a quantitative, small animal simultaneous PET/MRI system that is
capable of dynamic, intratumoral imaging. The results show that the system provides quantitative
images that are highly correlated with ex vivo autoradiography. The system was able to follow the
uptake of a radiolabelled antibody inside the tumor over time, visualizing antibody movement from
the vascular space to the tumor mass. Second, we adapted a functional MRI technique, diffusion
MRI, to monitor treatment response of the cancer nanotherapy CRLX101. CRLX101-treated ani-
viii
mals showed a significant diffusion MRI response within 2 days of treatment, before significant size
changes were observed. Modeling of the diffusion MRI data was able to predict the potent antipro-
liferative effect of CRLX101, commensurate with histological data. Finally, we developed MRI and
PET/MRI methods to study the tumor response to the tumor-penetrating peptide iRGD, which has
shown good potential to improve cancer nanotherapy uptake. The results show that iRGD can have
a variable tumor response, which may be dependent on the tumor microenvironment.
The primary contributions of this thesis work is the development of small animal hybrid PET/MRI
technology to enable multimodal intratumoral studies and the development of clinically-applicable
imaging methods to monitor the uptake and response of cancer nanotherapies.
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1Chapter 1
Introduction
1.1 The Fight against Cancer
Cancer is a set of diseases characterized by the uncontrolled growth and spread of abnormal cells.
Great advances have been made in understanding the underlying biology of cancer [1, 2]. Apart
from the discovery of an ever-increasing number of genetic abnomalities and signalling-pathway
defects stemming from proliferating cancer cells themselves, recent research has also highlighted
the complex interplay between cancer cells and their tumor microenvironment [3]. In situ cancer
tumors are heterogeneous, consisting not only of cancer cells (which themselves are not homoge-
neous inside the tumor, as demonstrated by the recent discovery of cancer stem cell populations [4]),
but also various types of stromal support cells [5], blood vessels [6], and immune cell populations.
How these different components interact and support the growing tumor can greatly affect tumor
progression. The large number of potential therapeutic targets within the tumor generated from
these discoveries have led to the development of many novel drugs targeting specific components
of tumors (figure 1.1) . In particular, nanotherapy, which describes the class of agents with a size
range of ~1–100 nm, is a promising drug design strategy that is being actively investigated. Cancer
nanotherapies show great promise for oncological treatment, since they can be engineered to over-
come barriers of uptake posed by the tumor micronenvironment [7]. Additionally, nanotherapies
can reduce treatment-related toxicity by concentrating delivery of drugs into the tumor mass.
Translating this basic biological understanding and engineering progress to effective clinical
endpoints (i.e.increased patient survival) remains a challenge. Survival rates from several types
of cancer remain low (figure 1.2, [8]). A major issue contributing to this is the fact that our un-
2Figure 1.1: Therapeutics targeting different aspects of cancer growth are under development
(adapted from [1]).
3derstanding and evaluation of tumor progression and response to treatment in individual patients
remain limited. For example, consider a tumor type studied in this work, Burkitt’s lymphoma (BL).
The genetic profiles of well-defined BL are known; however patients often present a phenotype in-
termediate between BL and other aggressive lymphomas, making diagnosis difficult [9]. Although
the disease has been shown to be quite chemosensitve, no concensus treatment exists [10]. Often, a
high-intensity chemotherapy regimen is administered to the patient over 3–6 cycles, which can take
3–6 months to complete. Treatment evaluation is then documented 4–8 weeks posttreatment. The
criteria for treatment response is based mainly on anatomical reduction of tumor burden, comple-
mented by laboratory tests and tissue biopsies to confirm response after completion of therapy [11].
While recent response rates are quite good, even close to 100%, some variants of BL in adolescents
and young adults have poor prognosis. If cancer nanotherapy is to be successfully translated to
the clinic to treat diseases such as BL, tools that enable us to understand the causes of poor tumor
treatment response and identify individual patients that do not respond well early in the treatment
regimen will be highly desirable. noninvasive molecular imaging is one such tool.
1.2 Personalized Non Invasive Molecular Imaging to Improve Cancer
Treatment
Noninvasive imaging has become indispensible for both research and clinical management of cancer
during the past 20–30 years. Visualization of the tumor mass with high-resolution anatomical imag-
ing modalities such as x-ray, computer tomography (CT), and magnetic resonance imaging (MRI)
enables cancer diagnosis and staging. This has been augmented by the availability of 18F-fluoro-
deoxyglucose (18F-FDG) positron emission tomography (PET) to locate tumors. These imaging
modalties now play a vital role in forming the criteria for tumor response [11].
Advances in the field of molecular imaging are enabling researchers to address questions about
the complex dynamics between various components of the tumor and the therapies used to treat
them. Studies with the imaging modalities mentioned above are moving beyond mere size measure-
ment and tumor staging. Imaging techniques and imaging probes are being developed to monitor
specific molecular aspects of tumor growth [12]. The imaging modalities mentioned are noninva-
4(a) Five year cancer survival rates, stratified by stage at diagnosis.
(b) Five year cancer survival rates, stratified by race.
Figure 1.2: Five year cancer survival rates in the United States, 2001–2007. Adapted from [8].
5sive, allowing real-time studies of the intact tumor during growth and/or therapy. They are also
quantitative, which enable comparisons intra- and intersubjects across multiple time points. There
is also increasing recognition that studies integrating information from multiple modalities can be
synergistic, providing information not available in unimodal situations. The most spectacular ex-
ample of this synergy is the widespread adoption of PET/CT systems. CT gives high-resolution
anatomical context to the PET data, and the combination has demonstrated clear clinical benefit
[13]. Recent developments in hybrid PET/MRI promises to offer even more synergistic value [14].
MRI not only provides high-resolution anatomical images, but can also provide functional informa-
tion that is complementary to PET. The field of hybrid PET/MRI is still in its infancy; continued
development of PET/MRI technology is necessary to realize its full potential.
Progress in the design and development of cancer nanotherapies are informed by their inter-
actions with the tumor microstructure in situ. Most investigations to understand the interaction of
nanotherapies and the tumor microenvironment are done in vitro [15, 16], ex vivo [17], or invasively
[18], which may not always simulate in situ situations well. Noninvasive imaging modalities, such
as PET/MRI, will be very useful to study cancer nanotherapy uptake and response. Researchers
have begun to use noninvasive imaging to study the uptake of nanotherapies, mostly focusing on
examining the gross uptake of therapies into the tumor mass [19, 20].
The goal of this thesis is to develop clinically applicable, noninvasive imaging technologies,
specifically PET and MRI, to understand the uptake and response of cancer nanotherapies beyond
simple tumor size measurements and the gross uptake of nanotherapies into tumors. We first de-
scribe the development and evaluation of a small animal hybrid PET/MRI system to study the het-
erogeneous uptake of antibodies into the tumor. The second part of the thesis concerns the devel-
opment of a functional imaging technique, diffusion MRI, to model and follow the early response
of a nanotherapy currently in clinical trials. The final part of the thesis describes work to develop
PET/MRI methods to study the effects of the tumor modulating peptide iRGD, which has the po-
tential to significantly improve the uptake of nanotherapies into the tumor.
61.3 Outline and Scope of Thesis
This thesis describes work developing and validating a first-generation small animal, simultaneous
PET/MRI imaging system and the application of both PET and MRI (individually or together)
techniques to study the uptake and response of different targeted cancer nanotherapies.
1.3.1 Review of Targeted Cancer Nanotherapies, Tumor-modulating Peptides and
Multimodal Noninvasive Imaging
Chapter 2 first reviews the current status of targeted nanotherapies for cancer. We describe the dif-
ferent design approaches being investigated to improve targeting of drugs into the tumor site. Tumor
microenvironmental factors which may affect the kinetics and biological activity of targeted thera-
pies are described. Next, we review recent attempts to improve tumor drug uptake by modulating
the tumor microenvironment. Treatments which attenuate barriers to drug access in the tumor may
act synergistically with carefully designed targeted therapies to enhance therapeutic response.
The second half of the chapter reviews the application of noninvasive imaging to study cancer
therapy uptake and tumor response. The basic physics of PET, MRI, and DWBA, as well as their
use in imaging cancer nanotherapy are reviewed. Advances in the nascent field of hybrid PET/MRI
imaging are outlined.
1.3.2 Developing Simultaneous PET/MRI for Robust In Vivo Studies
Hybrid PET/MRI systems are being built. However, thorough characterization and verfication of
such systems are required before being used in meaningful in vivo studies. Chapter 3 describes the
characterization and development of a first-generation small animal PET/MRI system to enable ro-
bust physiological studies. First, we examine potential interference effects of the PET insert on MRI
image quality with direct regards to in vivo studies that we wish to pursue. Next, we present work
on the development of a reliable image coregistration strategies between simultaneously acquired
PET and MRI images.
Making believable physiological inferences from high-resolution PET and MRI datasets re-
quires that the images are faithful to real contrast distributions in the imaged tissue. We describe
7work that validated the imaging ability of the PET/MRI system to reveal intratumoral uptake pat-
terns as compared to a commercial PET system and DWBA.
To enable robust physiologyical studies, complete integration of the PET and MRI hardware
and software is necessary. In the last part of the chapter we describe our efforts to streamline the
hybrid PET/MRI system technology and consider MRI interference effects on the PET insert that
need to be addressed in next generation systems.
1.3.3 Serial Diffusion MRI to Monitor and Model Early Treatment Response to the
Targeted Nanotherapy CRLX101
Successful translation of targeted cancer nanotherapies to the clinic requires robust tools to evaluate
effective patient response. noninvasive imaging techniques show great promise in this regard and
can be directly translated from preclinical studies to clinical trials. Chapter 4 describes work on
the evaluation of a functional MRI method, diffusion MRI, to monitor the response of CRLX101
in a preclinical murine model of Burkitt’s lymphoma. We also applied the diffusion MRI data to a
logistical model of tumor growth to evaluate the model’s ability to predict CRLX101’s activity.
1.3.4 Imaging the Tumor Response to the Tumor-penetrating Peptide iRGD
IRGD is a tumor-penetrating peptide that has been shown to improve tumor delivery of drugs by
modulating the tumor microenvironment. Translation of this peptide to the clinic requires a robust
assay of its efficacy. Chapter 5 describes preliminary results in developing noninvasive (PET and
MRI) assays of iRGD response.
1.3.5 Summary and future work
Future directions raised by the current work are presented in chapter 6.
Additional information and studies related to work described in this thesis are presented in the
appendices.
8Chapter 2
Background and Review
2.1 Targeted Cancer Nanotherapies
Therapies such as chemotherapy or small molecule molecularly targeted therapeutics (e.g.kinase
inhibitors) are powerful anticancer treatments and form the standard of care in current clinical man-
agement of cancer. However, these agents distribute non-specifically in the body, and since cancer
targets are often the overexpression of normally expressed markers, these agents can cause toxicity
to both cancer and normal cells. Treatment-associated toxicity (TRT) can limit achievable dosage
within the tumor and result in suboptimal treatment. Furthermore, many tumor types can develop
resistance to these small molecule therapies.
Nanotherapies, which describes the class of agents with a size range of ~1–100 nm, are be-
ing actively explored to overcome the issues of small molecule therapies [21, 4, 22]. Often, small
molecule therapies are directly attached or encapsulated within a “carrier” nanostructure for drug
delivery. Structures being explored range from polymers [23, 24] and carbon nanotubes [25] to
liposomes [26] and viral protein cages [27]. Gold nanorods can be delivered to the tumor to provide
localized photothermal heating. This can cause direct tumor toxcity or improved uptake of a com-
plementary drug carrier [7]. Alternatively, existing peptides and protein constructs can be modified
to improve their targeting efficacy. An example of this is the development of immunocytokines,
whereby cytokine peptides are engineered onto antibodies to target their effects locally to the tumor
site [28, 29].
Nanotherapies overcome toxcity and resistance issues by several mechanisms. First, size and
surface characteristics of nanotherapies can be tuned to extend their circulation time in the body
9by reducing reticuloendothelial and renal clearance. Next, the nanotherapies can target the tumor
by harnessing the properties of the tumor environment. The most characterized property is the
enhanced permeability and retention effect (EPR). The fast growing tumor requires a continuous
nutrient supply and thus releases factors to recruit and grow blood vessels. Imbalance of angiogenic
signals lead to highly disorganized and leaky tumor blood vessels. This, along with compromised
tumor lymphatics, allow macromolecules above ~50 kDa to accumulate in the tumor interstitium.
The nanotherapy considered in this work, CRLX101 [30], has been postulated to accumulate via
EPR (see chapter 4 for further discussion).
Figure 2.1: Enhanced permeability and rentention. Dysregulation of the angiogenic signals within
tumors lead to immature and leaky blood vessels in the tumor. This enables macromolecules and
nanoparticles to enter the tumor interstitium. This, along with compromised lymphatics, lead to
retention of these large-sized particles in the tumor (adapted from [4]).
Tumor targeting can be further improved. Specific targeting of cell populations via receptor
targeting can be achieved by the attachment of receptor ligands or antibody fragments onto the
nanotherapy surface. Transferrin or folate receptors, which are often over-expressed in tumors, are
common targets [31, 32]. Targets along the tumor endothelium (e.g.αvβ3 integrin receptors) have
also been explored for antivascular agents [33]. Other properties, such as the pH of the tumor [34]
and the overexpression of enzymes [35] in the tumor have also been explored as tumor localizing
targets. Recent work suggests that combining several of these targeting mechanisms into a single
nanotherapy system is synergistic [7].
10
Tumors can become chemoresistant via multiple mechanisms. The best known is the P-glycoprotein
efflux pump pathway [36]. Nanotherapies can potentially overcome these effects since they uptake
into cancer cells via different pathways compared to conventional therapies [37].
2.2 Modulation of the Tumor Microenvironment to Enhance Drug
Uptake
Improved tumor targeting is the primary rationale behind the development of cancer nanotherapies
[38]. However, nanotherapies currently in clinical trials show modest improvements over conven-
tional treatment [39]. Studies exploring the factors preventing enhanced efficacy have highlighted
the heterogeniety of nanotherapy uptake within the complex tumor microenvironment. Although
leaky blood vessels form the basis of EPR, their vessel-wall structure are often abnormal, lead-
ing to vessel collapse and thus hetereogeneous delivery [40]. Similarly, lymphatic drainage is also
compromised in tumors with a result of fluid retention within the tumor mass and tumor intersitial
hypertension [41]. This may impede penetration of nanotherapies throughut the tumor. Moreover,
the tumor microenvironment consists not only of tumor cells, but support matrix such as collagen
fibers and glycosaminoglycan [15, 42]. Depending on the size and structure of nanotherapies these
structures (which are also heterogeneous within the tumor) can impede nanotherapy penetration and
limit their efficacy [18].
Strategies have been investigated to modulate the tumor in order to improve nanotherapy pene-
tration. Judicious use of antiangiogenic agents have been used to “normalize” tumor blood vessels
[43]. This improves vascular perfusion within the tumor and reduces interstitial fluid pressure.
However, these effects may be transient and actually remove the leakiness desired from EPR. The
leakiness of the blood vessel have also been modulated via other means, such as the application of
VEGF or metronomic chemotherapy regimens [44, 45]. The tumor matrix can also be modulated
via degradation of the collagen matrix and decreasing the levels of glycosaminoglycans, improving
the uptake of antibodies and viral particles [46, 42].
Another strategy to improve therapy uptake in the tumor is the use of cell-penetrating peptides.
Peptides are generated with specific targets such as tumor blood vessels or the cell nucleus, most
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often via phage display [47]. These peptides are then often fused to a cargo of interest, such as
nanoparticles or siRNA to improve the drug or particle uptake [48]. Interestingly, a recent paper re-
ports that a tumor-penetrating peptide (iRGD) can improve the uptake of a variety of drug therapies
ranging from small molecules to nanoparticles into tumors without direct conjugation to the agent
of interest [49]. This suggests that iRGD has tumor modulating effects beyond pure tumor homing.
Although the exact mechanism of action in vivo remains elusive, iRGD is purported to target the
tumor via the αv integrin receptors on tumor blood vessels. A cleavage mechanism then occurs,
exposing a peptide modif (the CendR motif [50]) which interacts with the neuropilin-1 receptor and
mediates downstream effects leading to drug tumor penetration [48, 49, 50]. Neuropilin-1 is asso-
ciated with the VEGF pathway suggesting that modulation of tumor blood vessels may play a role
in this process. The imaging of iRGD effects were investigated in this work. Further discussion of
iRGD is found in chapter 5.
2.3 Imaging in Oncology
The research and clinical management of cancer has been revolutionalized by imaging [12]. Cur-
rently, several imaging modalities are being developed and used. For successful translation of imag-
ing assays from the benchtop to bedside, it is imperative that all aspects of the imaging assay be
considered, ranging from the biological process being considered, the chemistry of the probes and
the imaging hardware, to the methods of image analysis [51].
Here, we review imaging considerations with regards to the two modalities considered in this
work: PET and MRI.
2.3.1 PET Basics
PET is an imaging technique that relies on the emission of coincident annihilation photons emitted
indirectly from positron emitting radionuclides [52]. Attachment of radionuclides to specific biolog-
ical molecules or compounds can provide highly sensitive assays of many physiological processes
[51]. The biodistribution of these molecules in the body are dependent on their pharmacokinetics
and pharmacodynamics. PET images showing their biodistribution allow us to infer the mechanism
of specific physiological processes in a dynamic and noninvasive manner. Radiolabelled compounds
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have been developed to monitor many processes including metabolism [53, 54], receptor binding
[55, 56], antibody trafficking [57], gene expression [58], and perfusion [59].
As the unstable radionuclide attached to the molecule of interest decays, positrons are emitted as
byproducts. The positron travels a short distance (the positron range), losing its kinetic energy, and
then annihilates with an electron. The annihilation process converts the masses of the positron and
electron into two 511 keV photons emited in coincidence almost simultaneously (~nanoseconds,
ns). Detection of these photons defines a line volume (line of response) along which the annihi-
lation process occurred. Detection of these photons at multiple angles around the object allows
the definition of multiple line integrals of activity distributions. Image reconstruction algorithms
[60, 61] can be applied to this information to create images of radioactivity distribution (and hence
the molecules attached). The spatial resolution of PET systems is on the order of ~1–5 millimeters
and is a function of the positron range, deviations from colinearity of emitted coinicidence photons,
and the effectiveness of the detector to resolve lines of response.
With proper correction and calibration of the line integral data and reconstructed image data, the
pixel intensities of resultant images should be proportional to the radioactivity present at the pixel
location and thus would provide implicitly the concentration of the radiolabelled probe of interest.
For further discussion of both hardware and software calibration required for well-calibrated PET,
we refer the reader to [52, 51] and chapter 3.
As discussed earlier, successful PET studies require prudent integration of hardware, software,
biology and chemistry. Of interest to the work described herein is the need to choose the correct
radioisotope to explore the physiological processes of interest. Several positron-emitting isotopes
are currently routinely used in PET (table 2.1). Three important factors need to be considered in
choosing the isotope for any study:
1. Chemistry: Different radioisotopes are linked to the molecule of interest with a variety of
methods. Halogens such as 18F and 76Br are covalently linked to the molecule, while radio-
metals such as 64Cu and 68Ga [62] are conjugated to the molecule via a chelate (such as
DOTA) [63]. Careful consideration needs to be made to determine whether the molecule of
interest can be labeled with the isotope, and whether chemistry of the labelling will affect
the pharmacokinetics or biological interpretation of the PET signal. Moreover, while the
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chemistry of radioisotopes are the same as the non-radioactive isotopes, the radiolabelling
process needs to be well within the half-life of the isotope of interest to allow enough signal
for imaging.
2. Half–life: The half-life of the isotope needs to be fitted to the physiological question of in-
terest. For example, the kinetics of nanotherapies are on the order of hours to days. If the
question at hand is to determine the kinetics of the agent, then a relatively long half-life iso-
tope such as 64Cu or 124I would be desirable. However, a short half-life isotope such as 18F or
11C may be more applicable for fast acting physiological processes or diagnositic purposes,
where radiation overexposure becomes a critical concern.
3. Branching fraction: The branching fraction for a isotope defines the fraction of particles
which will decay via a particular decay mode. Specifically, we are concerned with the per-
centage of positron emission. One may need to design imaging protocols, the injected dose
or make alterations to the calibration to account for the lower sensitivity of certain isotopes
during PET imaging. This is particularly relevant for 64Cu, as only 17% of all decays are
positrons.
Table 2.1: Common positron-emitting isotopes
Isotope Half-life (hours) β+decay fraction (%) β+energies (keV)
68Ga 1.13 90 1899
11C 0.34 99 960
15O 0.034 99 1732
18F 1.83 100 634
64Cu 12.7 17.4 653
61Cu 3.3 62 1220
76Br 16.2 6.3 871
5.2 990
25.8 3382
6 3941
89Zr 78.4 22.7 897
86Y 14.7 11.9 1221
5.6 1545
124I 100.3 11.8 1535
10.9 2138
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2.3.2 MRI Basics
MRI leverages the quantum mechanical phenomenon whereby nuclei with non-zero magnetic spin
quantum numbers achieve splitting of spin energy levels when placed in an external magnetic field.
Classically, one can visualize this spin property as a charge rotating about an axis. This rotation
creates a small magnetic moment (dipole) that can be characterized by a vector. In the absence of an
external magnetic field, the dipoles are randomly orientated and the vector sum of the dipoles within
a region (e.g.an imaging voxel) is zero. When placed in an external magnetic field, the dipoles align
to the field parallel or antiparallel to the field, corresponding to different energy levels. An excess
of spins align in the lower energy state, resulting in a net magnetization vector aligned with the
external B0 field. The aligned spins precess about the field axis with a fixed angular frequency ω
and is related to B0 by the Lamor equation:
ω = γB0, (2.1)
where γ is the gyromagnetic ratio for the nuclei in question.
When aligned, the magnetization “signal” from any population of spins cannot be differentiated
with the stronger B0 field. To detect the magnetization signal, spins need to be “tipped” from the
longitudinal to the transverse plane. This can be achieved by excitation of the spins with RF pulses
at the Larmor frequency ω . Energy released as excited spins relax back to the longitudinal plane
can be detected using receiver coils to general a MR signal.
Differentiation of different types of nuclei and substances are determined by their frequency
of precession about B0, and their characteristic relaxation signature after excitation. Traditionally,
the two major relaxation rates examined are T1, the rate at which the longitudinal magnetization
recovers post RF excitation and T2, the rate at which the magnetization in the transverse plane
disappears [64]. A number of other relaxation mechanisms have also been described [65]. Different
tissues (e.g.fat, water) have their own characteristic T1 and T2 values, which can alter depending on
changes in temperature and structure.
Finally, this information can be combined with spatial encoding techniques to generate a MR
image. Magnetic gradient fields can be introduced across a tissue sample, encoding each location
with specific frequency and phase information. Knowledge of this enables decoding of the RF
15
relaxation information across the tissue sample in three dimensions.
Conventional MRI combine RF pulsing and gradient encoding together into a MRI pulse se-
quence to generate images. Combined with knowledge of the relaxation behavior of different tis-
sues and structures, one can design and alter multiple parameters in pulse sequences to achieve
certain image contrasts. The reader is referred to the following texts for a more detailed treatment
[66, 64, 67]. Here, we discuss in particular two functional MRI techniques used in the work herein.
2.3.2.1 Diffusion MRI
Diffusion is the random movement of particles from regions of higher concentration to regions of
lower concentration. Biologically, we are mostly concerned with the movement of water. Diffusion
of water in vivo is not free; fiber tracts in the brain, intact cell membranes and structural tissues can
restrict water diffusion in single or multiple directions.
MRI methods have been developed to produce in vivo images that are sensitive to the diffusion
of (mainly) water. As discussed above, traditional anatomical MRI image contrast is determined
by the relaxation characteristics of the tissue being imaged. Consistency of proton spin precession
relies on the presence of a homogeneous magnetic field. If during the pulse sequence an extra
gradient pulse is applied, the field is distorted and proton spins begin to disperse in phase. This
dispersion can be reversed by the application of another gradient pulse opposite in magnitude to
the first pulse to rephase the spins. However, this rephasing will be imperfect for spins that have
diffused along the direction of the gradient pulse during the time interval and will lead to signal
loss. The diffusion sequence was developed for NMR by Stejskal and Tanner [68] and adapted for
MRI by Le Bihan (figure 2.2) [69]. The equation governing the signal from this sequence is:
S= S0e−bADC, (2.2)
where S0 is the signal intensity with no diffusion weighting, S is the signal with the diffusion gradient
applied, b is a scaling factor that incorporates the effect of gradients in the sequence and ADC,
the apparent diffusion coefficient, is the aggregate diffusion coefficient value calculated from the
imaging voxel. The ADC can be calculated by acquiring images at multiple b values and performing
a curve fit.
16
In recent years, more complicated models of diffusion have also been applied to this to analysis
the diffusion data, probing different compartments and aspects of the in vivo diffusion process [70,
71, 72, 73, 74].
Figure 2.2: A basic pulsed gradient SE sequence for diffusion MRI imaging. Two diffuson gradi-
ents (Gdi f f ) are incorporated into a standard SE sequence sensitive to different diffusion rates along
the gradient direction. d = duration of the diffusion-encoding gradient, D = diffusion time inter-
val, Gphase = phase-encoding gradient, Gread = readout gradient, Gslice = section-selective gradient.
These aquisition parameters are encapsulated into the b factor described in the text (adapted from
[73]).
2.3.2.2 Dynamic-Contrast Enhanced MRI (DCE-MRI)
Conventional MRI provides high resolution images of anatomy. Paramagnetic contrast agents can
alter local tissue relaxation parameters to aid image contrast enhancement and highlight specific
structures. Many different MRI contrast agents have been developed (table 2.2) which can alter
tissue T1 or T2. DCE-MRI most commonly refers to MRI that dynamically alter the T1-weighting of
tissues [75, 76, 77].
These contrast agents have characteristic pharmacokinetic properties, which researchers and
clinicians have harnessed to study the functional properties of tissues. Most commonly, contrast
agents are injected intravenously and a time series of MRI images are acquired to follow the wash-
in and wash-out of the contrast agent. The vascular function of tissues such as viable tumors and
17
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livers can be inferred by the behavior of the contrast agent over time (figure 2.3). Other studies have
also used contrast agents to study the dynamics of cellular processes like inflammation [78] and
pharmacological response [79].
Several methods can be applied to analyze DCE-MRI [80, 81, 82]. Most were adopted from
the field of nuclear medicine. Semiquantitative metrics such as the area under the curve (AUC), the
slopes of contrast agent (CA) uptake and washout curves as well as the peak CA uptake have been
applied to DCE-MRI. Alternatively, quantitative metrics based on pharmacokinetic modeling can
be derived. The most widely used model is the two-compartment Kety model from which volume
transfer constants (Ktrans, kep) between compartments and volume of the tissue compartments (ve,
vp) can be calculated.
It is important to remember that the image enhancement observed in these studies are not a
direct measure of [CA], but the enhancement due to water exchange with CA. Recently, the effects
of water-compartmentalization on CA-water exchange have been studied. Kinetic models which
consider these trans-cytolemmal effects have been proposed and explored for DCE-MRI analysis
[83, 84, 85, 86].
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Figure 2.3: DCE-MRI can infer tissue vascular function. MRI-visible contrast agents injected intra-
venously can be visualized by MRI in plasma and also vascularized tissues. The pharmacokinetics
of the image enhancement is related to the structure of the CA (e.g.small molecule CA have fast
first-pass circulation vs. large molecule CA). Image enhancement curves can be fitted to pharmaki-
netic models to infer quantitative parameters of vascular function. Shown here is the commonly
used two-compartment model.
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2.3.3 Combining PET and MRI
2.3.3.1 Why Hybrid PET/MRI?
While both PET and MRI are powerful imaging modalities individually, each has their own strength
and weaknesses. These are summarized in table 2.3.
Table 2.3: Comparison between PET and MRI
PET MRI
Strength
Very sensitive (~nM) high-resolution
soft–tissue and
anatomical information
(<1 mm)
Can monitor multiple
biological processes
Metabolic (MRS) and
physiological information
available (e.g.diffusion,
DCE-MRI)
Multiple contrast
mechanisms: flexible
No ionizing radiation
Weakness
Poor spatial resolution
(~1–2 mm)
Not sensitive (~mM)
Limited anatomic
information
Multiple contrast
mechanisms:
complicated
Ionizing radiation
From the table, it is clear that PET and MRI are quite complimentary and information from the
two modalities should be synergistic [14]. Yet, this alone would not justify the efforts to develop
integrated systems. The key advantage of integrated systems is the ability to obtain simultaneous
(or near-simultaneous) PET and MRI information. Here, we discuss why the integrated approach is
worthwhile.
There are several reasons why integrated PET/MRI is useful. Although mundane, the ability
to acquire two images at once can save time, which is important both in the lab and the clinic.
Further, one modality can aid the image quality of the other. The most obvious application has
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been the use of MRI information to improve PET quantification. MRI data can offer information
for attenuation correction [87, 88] and motion correction [89]. Hybrid PET/MRI systems can also
be combined with bimodal PET/MRI probes to quantify tissue CA uptake and aid interpretation of
the CA imaging signal [90]. In all of these cases, robust coregistration of the PET and MRI image
space enables MRI data to directly correct the PET data.
Ultimately though, it is the physiological applications possible with PET/MRI that will drive the
widespread adoption of PET/MRI technology. subvoxel coregistration in space, which is difficult to
achieve especially outside the head, enables us to make solid biological inferences between spatial
distributions observed in PET and MRI at a fine scale. This aspect of PET/MRI integration forms
the scope of our investigations in chapter 3. Synchrony of the PET and MRI signals enables us to
make inferences between PET and MRI assays of time-sensitive physiological processes: this is the
motivation for the investigations in chapters 4 and 5. The ability to obtain the two modalities in near
real-time also enables the information obtained from one modality to drive studies performed with
the alternate modality and vice versa (figure 2.4).
MRI anatomical imaging PET functional imaging
Localize PET ROI
Functional 
information alter MRI 
variables
MR  techniques 
(e.g.MRS/ MRA/ fMRI)
Infer mechanisms
Real-time processing and 
analysis
Contrast drives 
studies
Infer mechanisms
Activation 
guide   
studies
Figure 2.4: Real-time paradigm for PET/MRI studies.
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2.3.3.2 Current State of Hybrid PET/MRI Systems
Current approaches for hybrid PET/MRI systems are summarized in table 2.4. Four main ap-
proaches are followed:
1. Sequential PET/MRI with PET and MRI hardware separate from each other.
2. Sequential PET/MRI with integrated PET/MRI hardware, but powered separately.
3. Simultaneous PET/MRI with radical redesign of MRI and PET hardware.
4. Simultaneous PET/MRI with novel PET hardware to fit in conventional MRI (PET insert).
The PET/MRI system developed in this work is the PSAPD-based PET insert (figure 2.5) [105].
Detailed description about the system implementation is described in [106] and chapter 3.
Figure 2.5: PSAPD-based MR-compatible PET insert. The insert consists of 16 LSO-PSAPD de-
tectors arranged in a single ring. The insert is placed inside the bore of a 7 T small animal MRI.
The RF coil and animal subject is placed in the PET insert.
2.3.4 Digital Whole-body Autoradiography
Digital whole-body autoradiography (DWBA) is used as an ex vivo assay of radioactivity distribu-
tion in tissues [107, 108, 109]. The tissue of interest is sliced and placed onto the DWBA phosphor
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Table 2.4: Current state of hybrid PET/MRI systems
Approaches Description
Sequential PET/MRI, separate
hardware
Sequential clinical PET/MRI system. Mature PET and MRI
technologies integrated with a moving patient table (Phillips,
Netherlands) [91, 92].
Sequential PET/MRI, separate
powering
Field-cycling method whereby the MRI field is turned on for
MRI acquisition then turned off for PET acquisition. MRI and
PET are integrated, enables conventional PET PMT detectors to
be used. MRI works at low field (0.3 T) [93].
Simultaneous PET/MRI with
radical redesign of MRI and
PET hardware
Design of a split-magnet to house extended PMT PET detectors.
MRI and PET are integrated, mature PET PMT detectors
designed into the system. MRI works at low field (1 T) [94].
Integrated clinical whole-body PET/MRI system consisting of
APD-based detectors housed between RF coils and MRI
gradients (Siemens, Germany). MRI and PET are integrated [95]
.
Simultaneous PET/MRI with
novel PET hardware to fit in
conventional MRI
PMT-based ring inserts placed inside a open 0.2 T , 0.3 T and 3 T
MRIs. Long fiber-optic cables are used to couple the scintillation
elements to the PMTs and electronics [96, 97, 98, 99].
APD-based head insert for 3 T clinical MRI (Siemens,
Germany). The FOV is limited to the brain [100].
APD-based PET ring system based on the RatCAP PET, can be
placed in 9.4 T MRI. Insert can be removed [101].
Integrated PET insert based on APD-LSO detectors, developed
for small animal 7 T MRI. Insert can be removed [102].
SiPM-based PET ring insert for small animals, tested in clinical
3 T and 0.15 T MRI. Inserts can be removed [103, 104].
Integrated PET insert based on PSAPD-LSO detectors,
developed for small animal 7T MRI. Insert can be removed
[105].
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imaging plate. The phosphor imaging plate is designed to detect high energy radiation. Excitation
of the BaFBr:Eu2+ crystals on the plate causes oxidation from Eu2+ to Eu3+ and the trapping of the
electron in the “color-center” of the BaFBr– complex. The plate can be read by shining red light
(~633 nm) onto the plate and imaging the photon released during Eu3+ reduction back to Eu2+ [110].
DWBA has been used extensively in pharmaceutical research to study drug distributions and
receptor binding. It has been used to verify isotope distributions observed in PET [111]. This is
aided by DWBA’s relatively high spatial resolution (~100 mm) and high sensitivity. The same tissue
of interest can be imaged by DWBA several half-lives after a PET study to verify biodistribution
[112], and forms an ideal “gold-standard” for PET.
2.3.5 Imaging of Targeted Nanotherapy Uptake
Knowledge of the biodistribution of targeted therapies is traditionally performed from ex vivo as-
says. Drug kinetics are determined by measuring drug content in tissues of interest (in animals)
harvested at specific time points [113, 30]. However, a wide intersubject variability of drug up-
take may exist and thus requires a large number of animals to make robust statistical inferences.
Increasingly, these data are being complemented by in vivo imaging data [114, 19] that can be
acquired longitudinally within single subjects. Biodistribution studies of radiolabelled antibodies
and nanoparticles can be peformed using PET or SPECT due to the high sensitvity of radioactivity
[115, 116, 117, 118]. Although MRI is a less sensitive modalitity, researchers have also developed
MRI approaches to monitor the targeting of nanotherapies in the tumor [119]. MR-visible agents
can be linked to tumor-targeting antibodies [120] and nanoparticles [121, 48] and can utilize in-
trinsic properties of tumors (e.g.the presence of certain enzymes like matrix metalloproteinases) to
activate the localized signal [35].
Most of these studies focus on imaging the gross uptake of targeted therapies into tumors, that
is, whether the therapy will reach and stay in the tumor. However, there is recent interest in un-
derstanding how the tumor microenvironment may modulate this uptake intratumorally. Ex vivo
studies suggest that uptake of targeted nanotherapies can be related to structrual factors such as
the distribution of blood vessels [113, 122]. Kobayashi et al. observed that MRI of breast tumor
mouse models showing different vascular structures can be correlated with gross tumor antibody
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uptake [123]. Thurber and colleagues have begun to investigate these factors by developing models
to explain these distributions and verifying these models with fluorescent imaging [16, 20, 124].
Imaging studies that enable the dynamic visualization of the tumor microenvironment (which can
be probed by MRI and PET) in concert with the distribution of the targeted therapy will contribute
to the development of these models for clinical application.
2.3.6 Imaging of Targeted Nanotherapy Response
At present, clinical imaging of tumor response to targeted nanotherapies focuses on evaluating size
changes of tumors as determined by the RECIST criteria [11]. Tumor size and growth are evaluated
using MRI or PET/CT to monitor changes in size [125, 126]. This mirrors the standard of care for
evaluating small molecule chemotherapy response. For example, the clinically approved liposomal
formulation of doxirubicin (Doxil) has been monitored by PET/CT in phase I/II studies [127, 128],
while albumin-bound palitaxel (Abraxane) have been followed by PET/CT and MRI [129].
Functional imaging techniques, such as diffusion MRI [130], DCE-MRI [131] and 18F-FDG-
PET and 18F-FLT-PET [53] and are being investigated for early treatment monitoring for small
molecule anticancer drugs. These techniques have the ability to determine changes in the tumor
prior to tumor size changes, and to probe changes of biological processes within the tumor. More-
over, such functional imaging data can be applied to models of tumor growth to enable prediction
of tumor response [132, 133]. DCE-MRI have been used to evaluate responses to bevacizumab and
its antivascular effects [134]; but fewer preclinical [126, 135, 136] or clinical studies have been pur-
sued to investigate the utility of such techniques to monitor tumor response in other nanotherapies.
The reader is referred to chapter 4 for further discussion of this topic.
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Chapter 3
Development of Simultaneous PET/MRI
Technology for Robust In Vivo Studies
3.1 Further Considerations of PET Insert Effects on In Vivo MRI Per-
formance
Initial studies with the MR-compatible PET insert demonstrated good SNR and uniformity of MRI
images with little distortion and narrow FWHM values of single-pulse water proton spectra in the
presence of the PET [106]. Here, we address aspects of MRI image quality that are relevant for
robust in vivo studies.
3.1.1 Materials and Methods
3.1.1.1 B0 Effects within the MR FOV
A glass spherical phantom (diameter = 3 cm) containing water doped with Gd-DTPA (such that the
solution had T1, T2 = 200 ms at 7 T) was placed in a home built birdcage RF coil (ID = 35 mm)
positioned in the isocenter of the MRI for all imaging studies. B0 maps were acquired using the
FieldMap routine implemented in Paravision 5.1. The routine consists of a 3D double gradient echo
dataset acquisition (TR = 20 ms, TE1/TE2 = 1.43/5.43 ms, FA = 20°, Matrix size = 64 × 64 × 64,
FOV = 80 × 80 × 80 mm3 centered in the isocenter of the MRI, SNR threshold = 5), followed by
a phase difference calculation on the reconstructed datasets, and finally a phase unwrapping and
conversion to a B0 frequency fieldmap. B0 fieldmaps (and magnitude images) were generated by
the MAPSHIM macro and converted to units of ppm (assuming 300 MHz at 7 T). B0 maps were
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obtained for three conditions:
1. No PET insert.
2. PET insert in the MRI, unpowered.
3. PET insert in the MRI, powered.
Magnitude images were used to identify voxels which bore real signal in the fieldmaps using a signal
intensity threshold. Voxels which had viable spatial ∆B0 values for all three conditions were com-
pared. ∆B0 linewidths with and without the PET were plotted against each other and the differences
between the conditions calculated.
B0 fieldmaps were also obtained with and without the presence (powered) of the PET insert for
a glass cylindrical phantom (OD = 28 mm, length = 61 mm, volume = 20 mL) containing distilled
water doped with CuSO4 ([CuSO4] = 1.3 mM, T1 = 440 ms, T2 = 350 ms at 7 T, FieldMap routine:
TR = 20 ms, TE1/TE2 = 2/5.81 ms, FA = 20°, matrix size = 177 × 177 × 80, FOV = 35.35 × 35.35
× 60 mm3 centered in the isocenter of the MRI, SNR threshold = 5).
3.1.1.2 B1 Measurements within the MR FOV
Relative B1 maps with (powered) and without the presence of the PET insert were acquired using
the CuSO4 solution phantom described in section 3.1.1.1. Maps were obtained with an extended
multi-flip angle method that accounts for inhomogeneous B0 and B1 fields [137]. A series of 21,
slab selective, 3D gradient echo images were acquired (TR = 1500 ms, TE = 5 ms, matrix size = 32 ×
32 × 16, FOV = 35.35 × 35.35 × 58 mm3, bandwidth = 50 kHz, second phase direction: axial). The
reference pulse gain was altered across an attenuation range of 42.6 dB to 3.3 dB. This corresponded
with a FA range of 10° to 400° at 20° increments. A relatively short 0.3 ms rectangular RF pulse
with FWHM of 4.3 kHz was used to suppress the influence of remaining B0 inhomogenieties during
excitation besides those resulting from the slab excitation gradient. The magnitude signals from the
image series were fitted to the following equation:
S(I) = κ
√
(sin(
pi
2
−θ(I))sin(α(I)))2+(cos(pi
2
−θ(I))sin(pi
2
−θ(I))(1− cos(α(I)))2, (3.1)
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where I is the coil current applied for each flip angle α , S is the image signal intensity, and κ is a
constant term incorporating the proton spin density, coil sensitivity, and geometry. In the presence
of field inhomogenieties, excitation of the sample may be off-resonance. For this scenario, the
effective excitation field Be f f about which magnetization is being rotated is deflected out of the
tranverse (xy) plane towards B0 (z plane) and is described by
Be f f =
1
γ
(∆ωez+ω1exy), (3.2)
where ω1 is the angular frequency of the rotation around the axis of the excitation field in the
transverse plane, ∆ω is the difference in angular velocity between the Larmor precession about B0
and the rotation of the excitation field. For a given ∆ω and B1u (B1 per unit current), the angle θ
between Be f f and the transverse plane is given by
θ(I) = tan−1(
∆ω2pi
B1uIγ
). (3.3)
The actual FA in the presence of off-resonant excitations is
α(I) = τ
√
(∆ω2pi)2+(B1uIγ)2. (3.4)
τ is the duration of the RF excitation pulse.
The coil current I at different flip angles were not measured for this study. Instead, relative B1u
maps with and without the PET insert were compared. Coil current was derived from the nominal
FA assuming a B1u field strength of 1 mT/A and using the on-resonance FA equation:
α = γτB1uI. (3.5)
3.1.1.3 T1 Measurements within the MR FOV
Robust quantitative MRI studies (such as DCE-MRI) require the derivations of quantitative T1 maps.
We evaluated the variations of T1 measurements due to the presence of the PET insert. A glass
cylinder (diameter = 4 mm) filled with Gd-DTPA doped water placed on the side of the animal
holder during routine animal studies was used for this evaluation. T1 maps were calculated using
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a variable flip angle method. Gradient echo images (FLASH, FA = 12°, 24°, 36°, 48°, 60°, matrix
size = 140 × 80, voxel size = 0.25 × 0.25 mm2, slice thickness = 1 mm, 9 slices) were obtained
at the center of the MRI with (TR/TE = 400/ 2 ms) the PET insert powered on in the bore and
the PET insert removed (TR/TE = 200/2 ms). The TR values were different since the temperature
requirements of the PET precluded the use of sequences with short TR. Voxel-by-voxel T1 maps
were derived from ROIs manually drawn at the center slice of each dataset and fitted to
S= S0
sinθ(1− e−TR/T1)
(1− cosθe−TR/T1) , (3.6)
where S is the signal intensity measured from the image. T1 maps obtained with and without
the PET on five separate studies each were analyzed. A nonlinear Levenberg-Marquardt algorithm
implemented in MATLAB was used for the data fitting.
3.1.1.4 Signal Drift
Feasibility of simultaneous dynamic PET/MRI was evaluated. A T1-weighted DCE-MRI sequence
(FLASH, TR/TE = 400/2 ms, FA = 30°, matrix size = 140 × 80, voxel size = 0.25 × 0.25 mm2, slice
thickness = 1 mm, 11 slices, time resolution = 30 s, 90 repetitions) was run with and without the PET
insert installed to image tumor-bearing mice. 0.2 mmol/kg Gd-DTPA was injected via the tail vein
into each mouse 5 minutes into each scan. A dynamic R2*-weighted sequence (FLASH, TR/TE =
600/8.5 ms, FA = 30°, Matrix size = 128 × 128, Voxel size = 0.2 × 0.2 mm2, slice thickness = 0.754
mm, 9 slices, time resolution = 60 s, 200 repetitions) was run with the PET insert installed to image
the mouse brain. 20 mg/kg Fe ferumoxytol was injected into each mouse via the tail vein 20 minutes
into the scan. Tumor, brain and glass cylinder (filled with olive oil, inner diameter = 1.5 mm) ROIs
drawn in the appropriate datasets were used for image analysis. The following parameters [138]
were measured:
1. The temporal drift of the mean signal intensity across the rod ROIs. A second-order polyno-
mial to the time series was fitted. The difference between the minimum and maximum of the
fitted curve was then determined. The result is expressed as a ratio to the signal mean.
2. Fast temporal fluctuations of the mean signal (root mean squared error, RMSE). The slow
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temporal drift of the mean signal from the rod ROIs was first removed. The RMSE was
determined from the ratio of the detrended signal SD to overall signal mean.
The parameters was calculated from three separate datasets for each separate condition.
3.1.2 Results
3.1.2.1 B0 Effects within the MR FOV
∆B0 comparison for the spherical phantom with and without the presence of the PET is shown in
figure 3.1. Fieldmaps are shown in figure 3.2. No significant difference was observed between
the PET powered off and powered on conditions compared to the no PET condition. Linewidth
differences (in ppm) were −0.04±0.29 and −0.01±0.32 respectively. Fieldmaps for the cylindrical
phantom with and without the PET are shown in figure. A∆B0 comparison for this phantom is
shown in figure 3.4. The linewidth difference (in ppm) between the PET powered on and no PET
condition for this phantom was −0.16±0.36. For both phantoms, the linewidth remained at <1
ppm wthin most of the imaging volume with or without the PET insert. This is consistent with the
specifications of the manufacturer which state that the main magnetic field has an inhomogeniety
<1 ppm in a spherical volume with a diameter of 11 cm.
3.1.2.2 B1 Measurements within the MR FOV
Relative B1u maps for the cylindrical phantom with and without the PET insert are shown in figure
3.5. A voxel-by-voxel comparison of the B1u values is plotted in figure 3.6. Mean, SD, and CoV of
the relative B1u values are shown in table 3.1.
Table 3.1: Relative B1u values with and without the PET insert
Condition Relative B1u (mT/A) CoV
No PET installed 0.22±0.03 0.16
PET installed and powered on 0.24±0.03 0.14
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Figure 3.1: B0 comparisons with and without the PET insert for the spherical phantom. Fieldmap
voxels from matching spatial locations in the presence or absence of the PET insert (powered on
and off) were compared in a scatter plot. No significant difference in ∆B0 between the PET on
and off conditions were seen. The fieldmap within the MRI imaging volume were within the B0
inhomogenieties specified by the manufacturer (<1 ppm, defined by the red box) regardless of the
presence of the PET insert inside the MRI.
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(a) Fieldmaps calculated at the MRI isocenter (left) and 10 mm lateral to the isocenter
(right) for different PET insert conditions for the spherical phantom. No significant
differences in the fieldmaps were seen in the presence of the PET insert.
(b) Magnitude images of corresponding fieldmaps shown in (a). Slices are in
sagittal orientation.
Figure 3.2: B0 fieldmaps in the presence of the PET insert for the spherical phantom.
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(a) Fieldmaps calculated for the cylindrical phantom without (left) and with (right) the PET insert. The average linewidth
within the phantom were <1 ppm whether the PET was present or not. Inhomogeneities >1 ppm were observed for both
conditions at outer edges of the phantom, corresponding to the cap and the bottom surface.
(b) Magnitude images of corresponding fieldmaps shown in (a). Slices are in sagittal orientation.
Figure 3.3: B0 fieldmaps in the presence of the PET insert for the cylindrical phantom.
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Figure 3.4: B0 comparisons with and without the PET insert for the cylindrical phantom. Fieldmap
voxels from matching spatial locations in the presence or absence of the PET insert (powered on),
within the central 30 mm of the MR FOV (along the axial direction), were compared in a scatter
plot. No significant difference in ∆B0 between the PET on and off conditions were seen. The
fieldmap within the MRI imaging volume were mostly within the B0 inhomogenieties specified by
the manufacturer (<1 ppm, defined by the red box) regardless of the presence of the PET insert
inside the MRI. A small group of voxels lying outside the 1 ppm threshold corresponds with the
bottom glass surface of the phantom (figure 3.3).
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Figure 3.5: Relative B1 maps with and without the PET insert.
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Figure 3.6: B1u comparisons with and without the PET insert for the cylindrical phantom. Fieldmap
voxels from matching spatial locations in the presence or absence of the PET insert (powered on)
were compared in a scatter plot.
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3.1.2.3 T1 measurements within the MR FOV
T1 rod measurements with and without the PET insert is shown in Table 3.2. The presence of the
PET insert resulted in a slight increase of the mean and SD of T1 values measured from the rod.
However, this increase was not significantly different (two-sided t-test, p = 0.2).
Table 3.2: T1 measurements with and without the PET insert
Condition T1 (ms)
No PET installed 473±27
PET installed and powered on 552±50
3.1.2.4 Signal Drift
Representative time traces from T1- and R∗2-weighted sequences are shown in figure 3.7. No major
signal drift was observed in the presence of the PET insert. Signal changes due to the injection
of contrast agents were clearly seen with or without the PET insert. This observation was con-
firmed from the quantitative signal drift and RMSE metrics (figure 3.8). However, there were small
increases in signal drift and RMSE when the PET insert installed; the latter was statistically signifi-
cant.
3.1.3 Discussion
Characterization of MRI performance show that ∆B0 maps did not differ significantly in the presence
of the PET insert. Small differences were observed for relative B1u values obtained with and without
the PET insert. B1 inhomogeneity is a recognized issue for quantitative high field (>3 T) MRI
[139, 140, 141]. However, this did not result in significant differences of the T1 values measured
during typical PET/MRI study situations. These observations are consistent with studies performed
on other hybrid systems [138]. Variation between individual scans can be attributed to multiple
factors. The phantoms were removed from the MRI during installation of the PET insert and thus
could not be exactly repositioned. The presence of additional shielding material in the bore when
the PET is installed may also introduce unwanted eddy currents and reduce SNR [142].
The slight decrease in SNR is reflected in the quantitative measurements of dynamic MR drift.
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(a) T1-weighted DCE-MRI traces with and without the PET insert. Sudden increase of signal in
the tumor corresponds to CA injection (~5 minutes into the scan).
(b) R2∗-weighted time trace with the PET insert installed. Signal decrease in brain at ~20 minutes
corresponds to injection of iron oxide contrast agent.
Figure 3.7: Dynamic MRI time traces with and without the PET insert.
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Figure 3.8: Signal drift quantification with and without the PET insert for T1- and R∗2-weighted
sequences. A slight increase in both signal drift and RMSE were observed when the PET was
installed (p <0.05 for RMSE).
Both signal drift and RMSE increased in the presence of the PET for DCE-MRI datasets. Unlike the
drift observed by Wehrl et al. [138], these drift increases were not directional and mainly reflect the
SNR attenuation in the presence of the PET. They noted that drift in both the PET and MRI signals
over time on their system are influenced by temperature fluctuations. We too have observed this
phenomenon, and thus utmost care is taken to maintain stable temperature during all our PET/MRI
studies.
It is important to note that our drift assessments were performed on an oil-filled rod. The
lower SNR of oil, compared to Gd-DTPA and CuSO4 used in other studies, would contribute to the
relatively lower drift and RMSE values. Gd-DTPA doped water and a rod with a larger diameter
is now used for quality control of the signal drift. Importantly, qualitative assessments of signal
changes due to contrast agent (both T1 and T2∗ agents) injection showed a clear signal trace in
in vivo tissue with and without the PET. This shows that the dynamic PET/MRI studies we wish
to pursue are quite feasible since they all involve contrast agent injection. Further assessment is
needed to explore the signal drift without contrast agents (e.g.BOLD studies).
In summary, we have characterized various aspects of the MRI system performance important
for robust in vivo imaging in the presence of the PET insert. The results suggest that while the
presence of the PET insert does affect the quality of MR images produced, the effects are small and
should not hinder the acquisition of meaningful in vivo simultaneous PET/MRI data.
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3.2 A Robust Coregistration Method for In Vivo Studies Using a First
Generation Simultaneous PET/MRI Scanner
3.2.1 Abstract
3.2.1.1 Purpose
Hybrid positron emission tomography (PET)/magnetic resonance (MR) imaging systems have re-
cently been built that allow functional and anatomical information obtained from PET and MR to be
acquired simultaneously. The authors have developed a robust coregistration scheme for a first gen-
eration small animal PET/MR imaging system and illustrated the potential of this system to study
intratumoral heterogeneity in a mouse model.
3.2.1.2 Methods
An alignment strategy to fuse simultaneously acquired PET and MR data, using the MR imaging
gradient coordinate system as the reference basis, was developed. The fidelity of the alignment
was evaluated over multiple study sessions. In order to explore its robustness in vivo, the alignment
strategy was applied to explore the heterogeneity of glucose metabolism in a xenograft tumor model,
using 18F-FDG-PET to guide the acquisition of localized 1H MR spectra within a single imaging
session.
3.2.1.3 Results
The alignment method consistently fused the PET/MR datasets with subvoxel accuracy (registra-
tion error mean = 0.55 voxels, <0.28 mm); this was independent of location within the field of
view. When the system was used to study intratumoral heterogeneity within xenograft tumors, a
correlation of high 18F-FDG-PET signal with high choline/creatine ratio was observed.
This section is published in Medical Physics: Thomas S. C. Ng, Daniel Procissi, Yibao Wu, and Russell E. Jacobs
(2010) A robust coregistration method for in vivo studies using a first generation simultaneous PET/MR scanner. Medical
Physics , 37 (5). pp. 1995–2003.
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3.2.1.4 Conclusions
The authors present an implementation of an efficient and robust coregistration scheme for mul-
timodal noninvasive imaging using PET and MR. This setup allows time-sensitive, multimodal
studies of physiology to be conducted in an efficient manner.
3.2.2 Introduction
Noninvasive, multimodal imaging is increasingly being adopted for both clinical and preclinical
studies, as researchers realize that information available from different image contrasts can com-
plement each other to provide more insights into physiological processes of intact, living animals
[143, 144, 58, 145, 146]. The most prominent example of this has been the widespread adoption of
combined positron emission tomography (PET) and computed tomography (CT) systems. Anatom-
ical information from the CT has been very useful in giving context to the PET image, especially
in oncology research [147, 148, 149, 150]. In both clinical and small animal PET/CT systems,
a combination of careful hardware alignment along with image registration via fiducial markers,
phantoms, and/or matching of expected uptake patterns in the two images allows accurate spatial
fusion of PET and CT images [151, 152, 153, 154].
Magnetic resonance (MR) imaging is another imaging modality widely used for noninvasive, in
vivo imaging. It can provide high-resolution, soft tissue details, along with functional and metabolic
information via techniques such as blood oxygenation level dependent (BOLD) imaging [155], dif-
fusion [156], and spectroscopy [157]. Recognizing the complementary nature of PET and MR
information, especially the utility of the information from multimodal images acquired simultane-
ously [158], researchers have developed hardware for hybrid PET/MR systems. Approaches range
from MR-compatible PET systems using avalanche photodiode (APD) technology for simultaneous
PET/MR imaging [105, 102], a split magnet that can house current state-of-the-art PET detector
systems [94], to field-cycling approaches that allow PET and MR images to be obtained sequentially
[159].
As the combined PET/MR technology matures, it is necessary to develop techniques and imag-
ing strategies that maximize the capabilities of such systems to study interesting and novel biolog-
ical and clinical questions. An important consideration for multimodal systems is a robust method
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to merge individual datasets. For small animal PET/CT systems, significant efforts are devoted
to ensure good intermodality spatial registration. Two main methods are used: A set of PET and
CT visible fiducial markers are imaged with the animal to allow retrospective image registration
[151, 154]. Alternatively, a registration transform is defined between the fields of view (FOVs) of
the PET and CT scanners through judicious design of PET/CT phantoms that span the FOV of both
systems, coupled with a reproducible method to position physically the animal holder in both FOVs
[153].
Conceivably, one can adopt similar alignment approaches for PET/MR systems. Two main is-
sues need to be considered specifically in PET/MR systems for spatial alignment purposes. First,
the geometry is more constrained in PET/MR than for PET/CT setups. The typical ring diameter
for a commercial small animal PET/CT is ~15 cm or greater, compared to 6 cm for the current
APD-based PET/MR inserts [102, 160]. The animal subject, radiofrequency (RF) coil, and phys-
iological maintenance and monitoring devices need to fit inside this ring. Moreover, to maximize
signal-to-noise ratio (SNR) for MR images, it is often desirable to position the excite/receive RF
coils close to the animal. All these factor limit the imaging of fiducial markers concurrently with
an animal without specialized invasive approaches [161]. Second, the FOV of the MR is not fixed
between scans. An advantage of MR imaging is the flexibility to alter the FOV geometry and reso-
lution of the acquired data depending on the biological region of interest (ROI) within the animal.
For example, fMRI BOLD imaging in monkeys and humans often use oblique brain slices to isolate
specific functional brain areas; cardiovascular imaging applications may need oblique slices to im-
age structures such as the aortic arch; while dynamic MRI scans may require a tight FOV to obtain
sufficient spatial and time resolution. In such cases, we cannot determine the MR imaging FOV a
priori to facilitate direct PET to MR image alignment. For the purposes of flexible simultaneous
PET/MR imaging, we require a reliable strategy to efficiently determine the intersection of the PET
and MR FOVs for all scans during the imaging session. Subsequent to the imaging, we also require
a method to register the reconstructed PET/MR images to form a multimodal dataset.
In a previous study, Judenhofer et al. [102] showed that fusion of individual simultaneous PET
and MR phantom images using a rigid body transform is possible using an APD-based PET/MR
system, with the registration error on the PET/MR image sets after transformation within the spatial
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resolution of the PET system. This suggests that APD-based PET systems produce images that can
be aligned consistently to the MR datasets. In this paper, we extend this observation to develop and
evaluate an efficient acquisition and processing setup of simultaneously acquired PET/MR data
using a position sensitive APD-based, small animal MR-compatible PET insert. The setup ensures
robust spatial alignment of the PET and MR images by first aligning the PET FOV and a fixed MR
FOV using a PET/MR visible phantom. The registration accuracy of using a single PET to fixed
MR FOV registration for the alignment of images from multiple study sessions was then evaluated.
Further, we describe an algorithm to relate multiple MR FOVs to the fixed MR FOV (and hence
the PET FOV), harnessing the fact that MR gradients responsible for spatial encoding of images
remain fixed throughout all studies. Using the described setup, PET/MR information was acquired
in real-time to follow the functional and metabolic status of the in vivo tumor microenvironment.
Moreover, we show that the setup allows one modality to guide studies with the other within a single
imaging session.
3.2.3 Materials and Methods
3.2.3.1 MR-compatible PET Insert for Simultaneous PET/MR Studies
Studies were done using a MR-compatible PET insert. The insert consists of a concentric ring
of 16 lutetium oxyorthosilicate (LSO) scintillators and positionsensitive avalanche photodiodes
(PSAPDs) detector modules. The intact system is designed to fit within the bore of a Bruker Biospin
7 T magnet fitted with a Bruker B-GA12 gradient coil set (12 cm ID, 40 G/cm maximum, 0.2
G cm A). The FOV offered by this PET setup is 35.35 × 35.35 × 12 mm3. Previous reports demon-
strated little to no interference between the PET and MRI electronics enabling PET and MRI images
to be obtained at the same time [105]. PET data were acquired using in-house developed software
[162], while the MR console was run by PARAVISION (Bruker Biospin Inc., Billerica, MA) soft-
ware. Since the gain of the PSAPD detectors is temperature dependent, the detectors were kept at
−12.5ºC for all studies using a continuous flow of chilled dried air.
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3.2.3.2 PET/MR Image Alignment
We explored whether alignment using an external phantom can give accurate registration over the
course of a study day, as well as over multiple days. An “alignment” phantom consisting of rods
filled with ~50 mCi 18F-fluoro-deoxyglucose (FDG) solution was imaged simultaneously with both
PET and MR. The rods used were glass capillary tubes (OD/ID = 1.2/0.68 mm) sealed at the ends
with tube sealer (Becton Dickenson, Franklin Lakes, NJ). A model of the alignment phantom is
shown in figure 3.9. For all PET studies, counts were acquired over 300 s and reconstructed with
a maximum a posteriori algorithm [61] to a matrix size of 128 × 128 × 15 and a pixel size of
0.276 × 0.276 × 0.754 mm3. MRI images were obtained with a 2D spoiled gradient echo (FLASH)
sequence (TR/TE = 350/4 ms) with a matrix size of 128×128, and 40 contiguous slices resulting
in a pixel size equivalent to that of the PET images. The FOV of the MR (35.35 × 35.35 × 25.6
mm3) is larger than the PET (35.35 × 35.35 × 12.8 mm3) to ensure that the whole PET FOV is
captured by the MR FOV and hence allow proper alignment between the two image bases. This
MR FOV is denoted hereafter as the home FOV, FOVhome. Setting the FOVhome as the reference
basis, a semiautomatic alignment procedure was adopted to match the two spaces. First, the rod
phantoms along the z direction (axial) were matched manually between the PET and MR images.
As the spatial resolution of the PET along the axial direction as well as the outer diameter of the
rods themselves dictate that one rod in the alignment phantom will traverse multiple PET slices, the
central slice of the rod in both PET and MR was used to match the two bases along the z direction.
The centroid of the rod cross sections perpendicular to the z direction served as inputs for alignment
in the xy plane. Voxels within five voxels of the local maximum and with intensity above 20%
of the local maximal intensity were considered in a center of mass calculation of each centroid.
Points were fed into a least-squares 2D affine transformation algorithm implemented in MATLAB
[163]. These two steps combine to derive a 3D affine transformation matrix. This matrix obtained
at the beginning of the imaging session was stored and used for all subsequent image alignment.
We measured the centroid registration error between the MR images and transformed PET images
of the alignment phantom using the same transformation matrix over the course of a single day
of imaging as well as over several days of imaging, with the centroid of the rod cross sections on
multiple image slices as the metric. The alignment phantom was unloaded and loaded between these
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scans to simulate a normal in vivo imaging session day.
Figure 3.9: PET/MR FOV alignment phantom. (a) Rendering of PET/MR phantom. The phantom
consisted of five rods, three in the z-direction for xy plane alignment and two parallel to the xy
plane for z slice alignment. The latter are spaced 5 mm apart. The rods were filled with 18FFDG
solution. (b) PET/MR phantom image overlay. MR image rendering is given as narrow rendered
objects (black); PET image rendering is wrapped around the MR rods (light grey).
To estimate the positioning accuracy of this alignment scheme as a function of location within
the FOV, a phantom consisting of glass capillaries (OD/ID = 0.85/0.4 mm), filled with ~50 mCi
FDG diluted in 0.05 M Prohance, and located 0, 4, 8, and 12 mm radially from the center of the
FOV was imaged simultaneously with PET/MR and aligned using an independently determined
transformation matrix derived as above, using the alignment phantom shown in figure 3.9. PET/
MR images of this phantom are shown in figure 3.10. The centroid registration error as a function
of distance from the center of the FOV was then evaluated as above. One-way ANOVA analysis was
used to evaluate whether there were significant differences in registration between rods at different
locations within the PET FOV. In section 3.2.7.1, we compare the alignment accuracy between im-
ages acquired with different MRI pulse sequences, with and without the PET insert, demonstrating
good geometric matching between images taken with different sequences, also with and without the
PET insert. In section 3.2.7.2, we compare the alignment accuracy between images registered with
different transformations, showing that registration with the affine transformation is slightly better
than using the rigid body transform.
The fidelity of this registration scheme was further tested with a third phantom and 18F-FDG
studies on mice containing small subcutaneous tumors (MC38.CEA colorectal adenocarcinoma).
Experiments involving the use of animals were done in accordance with protocols approved by the
Animal Care and Use Committee of the California Institute of Technology.
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Figure 3.10: PET/MR FOV alignment strategy registers other phantom sets robustly. (a)–(c) Struc-
tured phantom used to evaluate alignment accuracy as a function of location within the FOV. Rods
were located at 0, 4, 8, and 12 mm from the center of the PET/MR FOV. Alignment accuracy was
evaluated after registration using a transformation derived from the alignment phantom. (a) MR
image of the phantom. (b) PET image of the phantom. (c) Fused dataset. A large circular water
phantom, shown as the large circle in (a) and (c), was inserted into the phantom to facilitate shim,
frequency, and gain adjustments of the MR. One capillary rod was filled with water only and thus
was visualized in the MR but not in PET (arrow). (d)–(f) The transform derived to form the overlay
in figure 3.9 was used to fuse an image containing an alternative phantom arrangement. (f) Fused
PET/MR image of a seven rod phantom shows the fidelity of the transform. (Scale bars=10 mm).
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Alignment of Multiple MR FOVs
Often it is advantageous to optimize the orientation and size of the MRI FOV to accommodate a
specific imaging goal. For simultaneous PET/MR imaging, care needs to be taken to ensure that
the alternate MR FOV (FOValt) overlaps adequately with the PET FOV for the desired region of
interest. For quick visualization of the PET and MR FOVs during an imaging session, we use
the geometry defined by the MRI metadata to generate Cartesian coordinates of the centroids and
vertices for each voxel of both the PET FOV and the alternate MR FOV. These values are used to
visualize the “bounding box” of both FOVs in the same coordinate system, which allows a quick
determination of the suitability of the FOValt for PET/MR imaging.
To generate aligned PET/MR datasets, the PET image registered to FOVhome, as described in
section 3.2.3.2, is first resliced to an isotropic voxel size of 0.276×0.276×0.276 mm3. It then under-
goes a rigid body transformation using the transformation matrix from MRI metadata, and subse-
quently resliced to the voxel size of the alternate MR FOV. The whole data stream is implemented
in MATLAB; a trilinear interpolation is used for all rotations and reslicing.
To demonstrate the feasibility of this method, we simulated the mapping on phantom images
using different geometries that we typically encounter in our studies. An oblique slicing simulating
an acquisition along an aortic vessel and a geometry that is offset and sampled at a different matrix
size than the home FOV were aligned with simultaneously acquired PET data. This method was
also used to remap a PET dataset to a mouse anatomical reference image.
3.2.3.3 Biological Studies with PET/MR: a Real-time Feedback Scheme
TgCEA+C57BL/6 mice (N = 2) were implanted with MC38.CEA colorectal adenocarcinoma cells
in the groin and shoulder seven days prior to imaging. Mice were fasted 8-12 h prior to the imaging
session to minimize extraneous 18F-FDG signals. One hour prior to the imaging session, each
mouse was injected intraperitoneally with 200 mCi 18F-FDG. The mouse was then placed in the
PET/MRI system and kept at ~37°C with warm air blowing through the RF coil and anesthetized
using 1.5% isofluorane mixed in air. The holder was designed in such a way that the mouse was
kept comfortable while the PET insert remained stable at its operating temperature. Using the known
alignment matrix, we shifted the expected region of functional interest, in this case the tumor, within
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the PET FOV using the motorized stage. Once aligned, high-resolution anatomical MRI (2D RARE
TR/TE = 3500/4.5 ms, matrix size = 128 × 128 × 34, resolution = 0.276 × 0.276 × 0.754 mm3)
and PET (300 s duration) scans were obtained simultaneously. Both PET and MR images were
respiratory gated to acquire data during the expiration phase.
Alignment time per PET dataset was 5–15 min (AMD, 4× Dual-Core Opteron 885 2.6 GHz,
32 GB memory). This relatively rapid calculation time allows processing and analysis of the PET/
MR data while the animal is still in the scanner. Analysis of the processed PET/MR images of
18F-FDG uptake within the MC38.CEA tumors was used to guide the next stage of the experiment.
Heterogeneous PET signal within the tumor was verified using 1H (MRS). We used the PET signal
distribution to delineate ROIs for metabolic studies using 1H MRS (PRESS with VAPOR water
suppression, spectral width 8 kHz, 900 averages with 8192 sample points, TR/TE = 1685/10 ms,
3×3×3 mm3, duration = 26 min). Three voxels were used for MRS imaging; one in the tumor at
the region of high FDG uptake, one in the tumor at a region of low FDG uptake, and one in the
contralateral muscle. The resultant spectra were processed and analyzed using Bruker TOPSPIN
software (Bruker Biospin, Fremont, CA). A two-sided student’s t-test was performed to compare
the ratios between the high and low FDG regions.
3.2.4 Results
3.2.4.1 PET/MR Image Alignment
Figure 3.9 shows the overlay of PET and MR surface rendering of the alignment phantom images.
Slices along the z-axis in figures 3.11 show the alignment along both the z direction and in the xy
plane and demonstrate the difference in the resolution of the PET and MR images. Rods orthogonal
to the z direction span multiple slices in the PET images. This is due to a combination of two factors.
First, because the outer diameter of the rods is 1.2 mm and the mean positron range of the glass is
~190 mm, annihilation events from the 18F-FDG can occur at the outer edge of the rod, which spans
multiple image slices. Second, the spatial resolution of the PET along the axial direction is lower
than the image slice thickness (~2 mm). Table 3.3 shows the mean and standard deviation of the
centroid registration error in all three orthogonal directions for the alignment phantom images over
the course of one and multiple days. In all directions, registration remained consistently at subvoxel
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accuracy (maximum mean alignment error = 0.21 mm, voxel size = 0.276 × 0.276 × 0.754 mm3)
and well within the resolution limits of PET. This alignment procedure ably aligned alternate second
rod phantom, as shown in figure 3.10 and table 3.3.
Figure 3.11: Different spatial resolution of the PET and MR images. (a) MR xy slices of aligned
phantom. (b) PET slices corresponding to (a). Due to the lower spatial resolution of the PET along
the axial direction and the positron range in glass matching the thickness of the capillary walls, the
rod which was mostly displayed within one slice in the MR image spans almost three slices in the
PET image. (Scale bar = 10 mm).
Table 3.4 shows the registration error as a function of location within the FOV. The alignment
remained within <0.28 mm in accuracy throughout the whole FOV, with the mean centroid regis-
tration error ranging from about 0.18 mm in the center of the FOV to 0.28 mm at 12 mm from
the center of the FOV. One-way ANOVA analysis show no significant difference between the mean
registration errors at 0, 4, 8 and 12 mm from the center of the FOV in both the x (p = 0.8) and y (p
= 0.5) directions.
We tested the alignment accuracy in vivo by imaging small xenograft tumors. Figure 3.12 shows
aligned mouse PET/MR images at the level of the tumor and heart, with high 18F-FDG uptake in
both cases well within the expected anatomical regions.
3.2.4.2 Alignment of Multiple MR FOVs
Figure 3.13 shows the MR, PET and overlaid PET/MR datasets for common geometries used for
PET/MR studies. In all cases, voxel grid alignment of the aligned PET images yielded good fit to
the MR dataset.
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Figure 3.12: (a) PET/MR overlaid images at the level of a subcutaneous MC38.CEA flank tumor
showing alignment of high 18F-FDG uptake at the tumor site. (b) Image volume rostral to (a)
showing corresponding high 18F-FDG uptake at the left ventricle and aorta (T = tumor, LV = left
ventricle, A = aorta, L = left, R = right, V = ventral, scale bar = 6 mm).
Figure 3.13: PET/MR alignment using different geometries. (a) MR slicing of a phantom along the
coronal direction, at an oblique angle (40° on the left/anterior plane). (b) MR slicing along the axial
direction, rotated 30°. The home coordinate system of the MR gradient set is noted to the left. (c)
FDG-PET image of a mouse tumor obtained with axial slices at a FOV (35 × 28 × 3 mm3) smaller
than FOVhome (35.35 × 35.35 × 25.6 mm3). Voxel grid alignment of PET image shows intratumoral
heterogeneous uptake while accurately aligning high activity within the ureters (T = tumor, U =
ureters, scale bars = 10 mm).
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Table 3.4: Centroid alignment error as a function of location within the transaxial field of view, as
measured by the phantom shown in figure 3.10. Units are in millimeters.
Location from center of PET/MR FOV
0 4 8 12
(mm) mean SD mean SD mean SD mean SD
X error 0.12 0.01 0.19 0.13 0.21 0.16 0.28 0.27
Y error 0.19 0.11 0.18 0.12 0.17 0.12 0.24 0.22
3.2.4.3 Real-time Feedback Studies with PET/MR Allows Multimodal Imaging of Biological
Processes
Large tumors exhibit heterogeneous structures due to many factors [164]. Figure 3.14 shows that
heterogeneous uptake of the glyolytic marker 18F-FDG is seen within a thigh tumor. This hetero-
geneity was not readily apparent in the anatomical MR image. To explore this heterogeneity, MRS
was obtained in ROIs guided by the variability of 18F-FDG uptake shown in the PET images. 1H
MR spectra centered in regions of high 18F-FDG uptake in the tumor showed a higher choline/
creatine ratio compared to ROIs in low 18F-FDG areas and muscle (table 3.5).
Figure 3.14: PET guided MRS assay of MC38.CEA tumor. Regions of differential 18F-FDG uptake
within the tumor were used to define the ROIs for 1H MRS of the tumor. Spectra show differences
between regions of high FDG uptake, low uptake, and contralateral muscle. (Scale bar = 3 mm).
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Table 3.5: FDG-PET signal from xenograft tumors (N = 2) were used to guide 1H MRS in different
PET signal regions. Choline/creatine ratio were significantly different between high and low FDG
regions (p = 0.02).
Region Choline/creatine ratio
High FDG tumor region 3.4±0.4
Low FDG tumor region 1.9±0.3
Muscle Negligible
3.2.5 Discussion
In this study, we demonstrate the feasibility of performing robust in vivo studies with simultaneous
PET/MR imaging using a PET insert placed in a small animal MR scanner. Given the spatial con-
straints within the PET insert and animal holder, a method in lieu of the traditional fiducial marker
system is required to ensure robust registration of the two modalities. Once the PET insert is fixed
within the MR scanner, the relative orientation of the PET (as determined by the placement of the
LSO crystal detectors) and MR (as determined by the placement of the imaging gradient set) co-
ordinate systems is also fixed. Thus the transformation matrix that registers images using a single
alignment phantom also brings together all subsequent PET/MR images. We confirm this by re-
peatedly registering the PET and MR images of the alignment phantom over a study session and
over multiple days with subvoxel accuracy (table 3.3) using one transform matrix. This alignment
is not dependent on the location within the FOV (table 3.4). Images of an alternate phantom and
tumor bearing mice also support this alignment accuracy (figure 3.12). Straightforward registration
of the PET and MR image spaces using a predetermined transformation matrix allows for an un-
complicated multimodal imaging scheme, whereby neither a specially designed PET/MR holder
nor an animal mold [112, 165] is required for image alignment. This setup provides imaging flex-
ibility; first, there are no potential intensity spillover effects due to an external radioactive marker,
which may make low activity ROIs or ROIs close to the marker difficult to discern. Second, this
method of alignment allows alternate MRI transmit/receive coil setups to be used without the need
for a new alignment scheme, since the registration is based on the spatial encoding provided solely
by MR gradient coils. This will be useful for studies that use a surface coil to achieve high SNR.
Ideally, the alignment method used should be fully automatic, although previous reports have indi-
cated that partial manual manipulation of images during processing may yield sufficient alignment
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accuracy [166]. We adopt a manual alignment of the z direction because of the disparate FOV sizes
between the PET and MR along that axis. As we make no prior assumption about the physical FOV
alignment along this axis, a large MR FOV is taken to ensure full coverage of the PET FOV. From
our observations, the removal and replacement of the PET insert within the MR scanner can cause
up to 1.5 slices (~1 mm) displacement between the PET FOV and that of the MRI. Studies are in
progress to design a phantom alignment setup along the lines of previous designs for PET/CT sys-
tems [153, 151, 152] that will allow fully automated alignment. Nevertheless, the general alignment
strategy will remain the same as described here regardless of the phantom setup used.
One notable difference between MR and CT acquisition is the need to alter the imaging geom-
etry in MR to maximize the SNR and to obtain images at the desirable orientation or resolution.
This is especially relevant for in vivo applications; a compromise must be struck between a realistic
scan duration time and the resolution of the acquired image. In MR-only studies, the FOV can only
be determined once the animal is loaded inside the scanner. The limited PET FOV adds an extra
geometry constraint for PET/MR studies. We have developed a simple software GUI visualizing
the overlay of the PET and MR FOVs to allow a quick check to ensure that our anatomical regions
of interest lie completely in the useful PET FOV prior to image acquisition.
The constrained geometry of the PET/MR system (which limits the use of external fiducial
markers) and the imaging flexibility of the MR require a robust method to coregister PET and MR
images with multiple FOV geometries. In previous studies, this has been addressed by making
assumptions about the anatomical distribution of the functional PET signal [167, 168, 169] using
a transmission source or implanting fiducial markers [165]. The first two strategies may not yield
an optimal solution if the distribution of the PET signal is unknown or heterogeneous, while the
latter is invasive. Given the fact that the PET is fixed physically within the MR during a single
imaging session, a simple algorithm was developed that aligns the voxel grids of the “home” PET/
MR FOV to any alternate MR FOVs. We make the assumption here that the MR gradients behave
consistently between different scans such that the images acquired at a set geometry in software is
the same in the hardware. Common Fourier imaging, as described by the k-space formalism [170],
relies on spatial encoding determined by spatially and temporally varying magnetic fields created
by the MR gradients. Advances in hardware design of gradient coils [171] and post-acquisition
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processing [172, 173, 174] means that most commercial scanners have robust gradient performance,
especially for the pulse sequences using Cartesian k-space trajectories (see [64, 175] for discussion
of gradient coil design, specifications, and performance). From a simultaneous PET/MR viewpoint,
the pertinent concern is that the presence of the PET insert inside the gradient set may distort the
generated gradient fields. Previous characterization of APD-based PET inserts has demonstrated
that MR images acquired in the presence of the PET insert show negligible geometric distortions
compared to those acquired without the PET [105, 102] (see also section 3.2.7.1).
In our implementation, we transform the PET image to match that of the MR images. We
chose this approach because the resolution of the PET is lower than the MR, so there would be less
potential loss of information from image interpolation. Also, the PET FOV is fixed and typically
smaller than the MR FOV, so this approach also simplifies the formation of the fused dataset. Other
interpolation methods, apart from trilinear interpolation, can be adapted to improve the quantitative
value of the transformed images [176, 177]. However, the interpolation method we adopted should
suffice for PET images. Simulation of some common geometries that require this schema show that
the registered PET images align well with the corresponding MR image (figure 3.13). The algorithm
described is time efficient; all datasets generated took 20 min or less.
Simultaneous PET/MR imaging allows examination of the different signals in both spatial and
temporal registration. In figure 3.14, we see heterogeneity within a tumor microenvironment high-
lighted with both 18F-FDG-PET imaging and high-resolution anatomical MRI. 1H MRS, guided by
the 18F-FDG signal, confirms the heterogeneous profile of the tumor. Rapid reconstruction, process-
ing, and visualization of the aligned initial PET/MR images provide the information necessary to
perform the later MRS study within the same imaging session. Thus, obtaining feedback between
the two modalities during a single imaging session is eminently doable with this system. This will
have multiple uses. Phantom alignment information allows us to position the mouse to maximize
PET signal in the FOV. While new versions of the PET insert will aim to have whole body cover-
age, this is typically not feasible in clinical systems or in situations where one may want to sacrifice
coverage for higher sensitivity and resolution. The feedback schema can also be performed during
the experiment to guide study directions. The ability to process and align the PET/MR images
quickly within an imaging session allows basic analysis of the combined dataset. In our study, this
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allowed us to determine regions of tumor functional heterogeneity via 18F-FDG accumulations and
subsequently, 1H MRS studies, to assess corresponding heterogeneity in metabolite concentration.
Again, the external means of image registration proved useful in this situation; no assumption of the
expected distribution of the image intensities in either image was used for alignment, allowing us
to delineate the heterogeneity within the tumor. Although there is a correlation between the regions
of high 18F-FDG uptake and high choline/creatine ratio (table 3.5), more studies are required to de-
termine the significance of this observation as the relationships between phospholipid metabolism
and glycolysis remain unclear [178, 179, 54, 180, 181]. Further studies along these lines will in-
volve correlating the tumor characteristics such as perfusion [182] and hypoxia [183] with these
functional markers.
Simultaneous PET/MR technology has the potential to impact both preclinical and clinical
realms. The time savings that can be obtained by doing two scans at once will facilitate the effi-
ciency of longitudinal studies. Cross-modal image corrections methods such as MR-guided PET
motion and attenuation correction, which rely on robust PET/MR coregistration, will improve im-
age quality and aid image interpretation [89, 88]. Perhaps more importantly, like the development
of multicolor fluorescent proteins and dyes that allow multiple processes to be studied concurrently
[184, 12], simultaneous PET/MR will enable similar interactive studies to be done within intact
mammalian systems. Molecular imaging agents are being developed with both PET and MR con-
trast that can look at biological processes such as gene expression [58], receptor binding [120, 57],
cell tracking [185], and vascular inflammation [186]. Combining these agents within one study will
allow multiple physiological processes to be probed simultaneously.
3.2.6 Conclusions
We describe a coregistration design for performing time-sensitive in vivo studies using a simultane-
ous PET/MR scanner. Robust image registration between PET and MR is shown, based on the fixed
relative orientation of the PET detectors and MR imaging gradient set. Using this setup, we demon-
strate heterogeneous metabolic activity within a tumor using 18F-FDG-PET, which was found to
correlate with choline/creatine ratios determined using MRS guided by the 18F-FDG signal levels.
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3.2.7 Supplemental Data
3.2.7.1 Comparison of Alignment Accuracy Between Images Acquired with Different MRI
Pulse Sequences
Methods. A hot rod phantom filled with water was imaged with three different MR pulse se-
quences at the same FOV and matrix size (35.35 × 35.35 × 0.754 mm3 and 128 × 128 × 1 respec-
tively):
1. A 2D spoiled gradient echo FLASH sequence (TR/TE = 500/4.4 ms)
2. A 2D spin echo RARE sequence (TR/TE = 2000/11 ms)
3. A 2D EPI sequence (TR/TE = 1000/20.4 ms), acquired in 4 shots. The Bruker native gradient
adjustment macro EPI_ADJUST, which compensates for the time lage of the gradients and
filters and the first order eddy currents, as execuated prior to image acquisition. No other
correction was applied.
The acquired images were then coregistered to determine the registration error between them. A
rigid body registration algorithm was used [163]. We calculated the translational and rotational
mismatches from the resultant transformation matrices.
This was repeated with and without the PET insert being powered on. Five images were acquired
for all pulse sequences for both conditions. Registration differences were compared for all images
in a combinatorial manner.
Results. Figure 3.15 shows sample images acquired with the three sequences. Both translation
and rotation differences between images acquired by the three pulse sequences are shown in rable
3.6. Alignment between the RARE and FLASH images show lower translational and rotational
registration difference compared to EPI. This is expected, as the EPI sequence is inherently more
prone to geometric distortions compared to the other two pulse sequences. A two-way ANOVA
examining the translational differences of the three different image comparisons with and without
the PET powered on showed no significance differences between the comparison groups (p = 0.06)
and whether the PET is on or off (p = 0.69). In contrast, analysis of the rotational differences shoed
a significant difference between groups (p = 0.01), PET power status (p <0.01) and their interaction
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(p = 0.05). Although this is the case, it must be noted that the absolute values of the rotational
differences are <0.01°. Coupled with the <0.2 mm translational offset for all the comparison groups,
this alignment difference remains well within the spatial resolution of PET and supports the claim
that our methodology is robust enough to coregister PET/MR images accurately. Of course, this
is under the proviso that the MR images are properly corrected, as one would do for any MR-only
experiment.
Figure 3.15: Images acquired with different pulse sequences and with PET on and off show no
noticeable geometric distortions, enabling robust PET/MR coregistration; see table 3.6 (Scale bar =
10 mm).
Table 3.6: Alignment displacements between images acquired by different pulse sequences. Images
were aligned by a 2D rigid body algorithm; the translational and rotational terms were used to
determine the displacement and rotational offset between images.
Translation offset (mm) Rotation offset (degrees)
Sequence A Sequence B PET powered status mean SD mean SD
EPI RARE On 0.05 0.09 0.001 0.01
EPI RARE Off 0.04 0.05 0.009 0.01
EPI FLASH On 0.07 0.1 0.002 0.01
EPI FLASH Off 0.07 0.11 0.008 0.01
RARE FLASH On 0.03 0.03 0.001 0.001
RARE FLASH Off 0.06 0.01 0.001 0.001
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3.2.7.2 Comparison of Alignment Accuracy Between Images Registered with Different Trans-
formations
Methods. The same dataset used in section 3.2.3.2 was coregistered by two additional methods:
1. Same as section 3.2.3.2, except a rigid body transformation algorithm was used.
2. A 3D rigid body algorithm, as implemented in 3D-Slicer version 3.4 (www.slicer.org), was
used.
For method 2 above to work, PET images had to be pre-processed manually to approximately align
the PET and MR space before being fed into the 3D algorithm. Without the pre-processing step, the
algorithm tends to over-rotate the PET image, pushing one of the rod sources out of the FOV
Results. Table 3.7 and table 3.8 show the registration alignment error by both the 2D and 3D rigid
body algorithm respectively. Both algorithms yielded good registeration, which was not signifi-
cantly different from the affine (p = 0.76). The affine transformation was slightly better than the
rigid body algorithms (the Euclidean distance of the mean alignment errors for the affine, 2D rigid
body and 3D rigid body transformations were 0.34, 0.38, 0.36 mm respectively). It must also be
noted that a manual preprocessing step is required to approximately align the PET/MR dataset for
the 3D algorithm to work.
Table 3.7: Centroid alignment error of phantoms using the PET/MR transformation scheme over
multiple days, using a 2D rigid body transformation. Two-way ANOVA analysis comparing be-
tween x, y, z errors showed no significant differences between groups (p = 0.66), nor between rigid
and affine transformations (p = 0.51). Both rigid and affine transforms yielded alignment errors well
within the PET spatial resolution.
PET/MR positioning phantom
(mm) Day 1 Day 1 Day 2 Day 2 Day 2 Day 3 Day 3 mean SD
X error 0.2 0.2 0.22 0.18 0.2 0.27 0.22 0.21 0.03
Y error 0.16 0.74 0.17 0.18 0.2 0.18 0.15 0.25 0.22
Z error 0.09 0.23 0.18 0.25 0.29 0.14 0.16 0.19 0.07
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Table 3.8: Centroid alignment error of phantoms using the PET/MR transformation scheme over
multiple days, using a 3D rigid body transformation. Two-way ANOVA analysis comparing be-
tween x, y, z errors showed no significant differences between groups (p = 0.64), nor between rigid,
affine and 3D rigid transformations (p = 0.76). All transforms yielded alignment errors well within
the PET spatial resolution.
PET/MR positioning phantom
(mm) Day 1 Day 1 Day 2 Day 2 Day 2 Day 3 Day 3 mean SD
X error 0.25 0.2 0.19 0.38 0.21 0.24 0.3 0.25 0.07
Y error 0.2 0.19 0.25 0.19 0.17 0.14 0.25 0.2 0.04
Z error 0.13 0.03 0.43 0.51 0.46 0.05 0.32 0.17 0.2
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3.3 Phantom Designs for Robust In Vivo Coregistration of Hybrid
Imaging Systems: Comparison of Semiautomatic and Automatic
Approaches
3.3.1 Introduction
Increasing efforts are being devoted to develop and validate hybrid techniques for multimodality
imaging of biological processes in vivo. Several dual modality platforms have been successfully
developed and tested. For example, positron emission tomography (PET) has been combined with
computed tomography (CT), magnetic resonance imaging (MRI) [105] and optical tomography
[187]. The major advantage of these methods lies in the possibility of imaging the same living
subject in a single session, in some cases simultaneously. A vital component for multimodal imaging
is the requirement of accurate spatial coregistration of the separate image spaces. Significant efforts
have been devoted to cross-modal registration in small animal imaging, based upon optimizing
animal holders and utilizing manually segmented phantom designs. Hybrid imaging systems adds
an extra complexity; the geometry constraints of integrated systems along with the disparate field of
view between the individual modalities require a modification to previous approaches. A registration
phantom design that can be adapted for different hybrid systems and can perform image registration
automatically is highly desirable.
Here, we evaluate a phantom design adapted for use in a MR-compatible PET insert for simul-
taneous PET/MRI imaging. The phantom design allows simple image acquisition, fully automatic
segmentation of the phantom components and subsequent image coregistration. We compare the
registration error of this fully automated strategy with our previous semiautomatic alignment strat-
egy outlined in section 3.2. Both strategies aligned the PET and MR image spaces to within single
voxel accuracy throughout the whole field of view of the combined scanner with no significant
difference of registration errors (two-sample t-test: p = 0.2). In addition to providing equivalent
coregistration results the automatic alignment strategy guarantees a non-biased, fast and versatile
tool which could be adapted easily for other types of combined imaging systems.
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3.3.2 Materials and Methods
3.3.2.1 Semiautomatic Alignment Phantom
The semiautomatic alignment phantom was constructed as described in section 3.2.3.2.
3.3.2.2 Fully Automatic Alignment Phantom
The fully automatic alignment phantom consists of rods placed within a tuncated 50 mL Falcon tube
(BD). A Falcon tube was truncated to a length of 60 mm. Holes were drilled in the end caps (the
native lid of the tube or a thick plastic cylinder) according to the pattern outlined in the schematic
shown in figure 3.16. Holes were drilled to fit glass capillary rods (OD/ID = 0.7/0.5 mm, Wales
Apparatus) snugly. The central rod was fitted diagonally across the diameter of the tube. Rods were
filled with ~50 mCi of 18F-FDG prior to placement in the tube. A tube filled with water (ID = 6.5
mm, Micronic) was placed along the inner edge of the tube in line with the central rod to facilite
MRI imaging.
Figure 3.16: Schematic of automatic phantom. End cap view (left) and side view (right) of the
phantom, with associated distance measurements are shown. The current phantom is implemented
with a 50 mL Falcon tube. The asymmetric distributions of rods on either side of the central rod
facilitates their segmentation. The presence of the water tube facilitates MRI.
3D renderings of both the semiautomatic and automatic alignment phantoms from PET/MRI
datasets are shown in figure 3.17.
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Figure 3.17: Semiautomatic (a) and automatic (b) alignment phantom models. Red denotes MR-
visible portion of the phantom. Blue denotes PET/MR visible portion of the phantom. Glass capil-
lary tubes filled with 18F-FDG and saline enable multimodal visualization. In (b), large red portions
are present to allow robust MRI shimming and adjustments.
3.3.2.3 Simultaneous PET/MRI Imaging
Phantoms were imaged using the MR-compatible PET insert combined with a 7 T Biospec small
animal MRI. PET images were acquired with durations ranging between 300 and 600 s and recon-
structed as described in section 3.2.3.2. MRI were obtained using a gradient echo FLASH (TR/TE
= 350/4 ms, FOV = 35.35 × 35.35 mm2, slice thickness = 0.754 mm, 34 slices).
3.3.2.4 Semiautomated Alignment Strategy
PET and MRI datasets of the semiautomatic alignment phantom were aligned as described in section
3.2.3.2.
3.3.2.5 Fully Automated Alignment Strategy
PET and MRI datasets of the fully automatic alignment phantom were aligned using the following
steps:
1. Each individual rod in the alignment phantom seen in both the MRI and PET images was seg-
mented using an intensity-based algorithm. A predefined threshold of 25% of the maximum
intensity of the image and a radius of ~4 mm was used to segment voxels belonging to each
rod. The central rod was identified by the fact that it showed the greatest x/y displacement
across the image slices. The other rods were identified using the fact that they were situated
in a known orientation about the central rod. The result of a sample segmentation is shown in
figure 3.18.
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2. The axial FOVs of the MRI and PET datasets are different (25.6 and 12.8 mm respectively).
We first aligned MRI and PET images along the axial directions using a procedure outlined
in [151]. Briefly, the ratio of the distances between the central rod and two other rods in the
phantom, as shown in figure 3.18, are calculated across all the imaging slices. These values
were plotted as a function of slice number. A quadratic curve was fitted to the plots to reduce
the effect of image noise or segmentation errors. At equivalent locations in the phantom, these
ratios should be similar. Thus, the displacement between the minima of the PET and MRI
plots corresponds to the axial displacement between the two datasets. Sample plots outlining
this process is shown in figure 3.19.
3. Once axially aligned, the PET and MRI phantoms were aligned using a 3D affine transforma-
tion [188]. Rod coordinates from every slice were treated as individual points as an input to
this algorithm. All alignment software was implemented in MATLAB.
Figure 3.18: Automatic phantom rod delineation. a) MR image of phantom. Pink dashed line shows
trajectory of central rod. White arrows show the two distances from which a ratio is derived. This
changes according to axial position. b) PET image of phantom with circles showing automatic rod
segmentation.
3.3.2.6 Evaluation of Alignment Accuracy
A separate PET/MRI image scan (acquired with the same parameters described in section 3.3.2.3) of
the automatic phantom was used to evaluate the alignment accuracy of both methods. PET and MRI
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Figure 3.19: Automatic axial alignment of images. Due to the disparate field of views between
modalities, we first approximately align in the axial direction. Ratios between a central, moving,
rod and other rods were used to landmark slice positions. A quadratic fit reduced noise errors. The
red X marks the minima of the PET and MR curves for axial matching.
images from this dataset were aligned with transformations derived from either the semiautomatic
or automatic phantom alignment. The centroid alignment error of individual rods within aligned
images were then calculated as per section 3.2.3.2.
3.3.3 Results
PET/MRI images of the semiautomatic and automatic phantoms are shown in figure 3.20. Figure
3.20 e shows an overlay of an automatic phantom image using a automatic alignment transform.
The centroid alignment error over x/y/z directions are shown in table 3.9. Both strategies aligned
PET and MRI images within the image resolution of both systems (<0.3 mm). Although the mis-
registration error for the semiautomatic alignment approach was slightly higher than the automatic
approach, this was not significant (p = 0.2).
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Figure 3.20: PET/MRI images of semiautomatic (a)-(b) and automatic (c)-(e) phantoms. Note in
(b), the axial rods traverse multiple slices, which may lead to alignment errors. The configuration
in (c)-(e) may reduce alignment errors and simplify registration. (Scale bar = 10 mm).
Table 3.9: Alignment error comparison between automatic and semiautomatic alignment methods.
Alignment error (mm)
Method mean SD
Semiautomatic alignment 0.26 0.16
Fully automatic alignment 0.11 0.1
3.3.4 Discussion
In this study, we developed a phantom that enabled automatic alignment of PET and MRI image
spaces. Prudent design of rod locations within the phantom allowed facile automatic rod segmen-
tation in both PET and MRI image sets. The presence of a sloping rod across the axial direction
enabled automatic identification of axial location and subsequent alignment. This was necessary in
our case because the FOVs of the PET and MRI were quite different, such that direct application of
standard 3D alignment transform found in common image processing programs did not work.
Once the phantoms were axially aligned, we applied a closed-form algorithm for full 3D-
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alignment. We chose this method over more common alignment algorithms again because of the
different FOV sizes. Commonly found 3D alignment transforms [189] are iterative in nature. In
phantom images with sparse signal, such as those encountered here, these algorithms can often re-
sult in a failure to converge to a reasonable solution. A closed-form solution based on matching
points returns an exact result that can be easily implemented into an automatic pipeline.
Both semiautomatic and automatic alignment strategies were able to align the PET and MRI
image spaces well within the spatial resolution limits of PET (~1–2 mm, whereas the alignment
error was <0.3 mm) and were not significantly different. The automatic strategy returned slightly
lower errors overall. This may be due to the fact that the automatic phantom contained more rods
covering a larger portion of the FOV, thus improving the accuracy of the overall FOV alignment.
Accruacy of the FOV alignment can be further improved by increasing the number of rods in the
FOV, at the expense of increased computing time to segment the rods.
On a day-to-day basis, the semiautomatic phantom is an easier phantom to make and use since
it requires fewer rods (5) than the automatic phantom (8). However, incorporation of a long half-
life agent (such as 68Ge) in the rods would enable a more permanent implemention of the automatic
phantom. In this scenario, the automatic alignment phantom would be a simple and accurate method
to ensure robust coregistration of the PET and MRI image spaces. Such a phantom is being explored
for use in the second generation PET/MRI system.
In summary, we have developed a phantom that can align multimodal image spaces automat-
ically. The phantom is straightforward to make and can fit in the tight geometries found in novel
hybrid imaging systems. Alignment accuracy with this phantom was comparable with a previously
developed semiautomatic approach. These phantom designs, when coupled with appropriate con-
trast agents (e.g.PET/MRI/CT/SPECT/optical dyes), can be used to align images acquired from
multiple modalities with high accuracy.
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3.4 Quantitative, Simultaneous PET/MRI for Intratumoral Imaging
with a MR-compatible PET Scanner
3.4.1 Abstract
Noninvasive methods are needed to explore the heterogeneous tumor microenvironment and its
modulation by therapy. Hybrid PET/MRI systems are being developed for small animal and clinical
use. The advantage of these integrated systems depends on their ability to provide MR images that
are spatially coincident with simultaneously acquired PET images, allowing combined functional
MRI and PET studies of intratissue heterogeneity. Although much effort has been devoted to devel-
oping this new technology, the issue of quantitative and spatial fidelity of PET images from hybrid
PET/MRI systems to the tissues imaged has received little attention. Here, we evaluated the ability
of a first-generation, small animal MR-compatible PET scanner to accurately depict heterogeneous
patterns of radiotracer uptake in tumors.
3.4.1.1 Methods
Quantitative imaging characteristics of the MR-compatible PET (“PET/MRI”) scanner were eval-
uated with phantoms using calibration coefficients derived from a mouse-sized linearity phantom.
PET imaging performance was compared to a commercial small animal PET system (microPET R4)
and autoradiography in tumor-bearing mice. Pixel and structure-based similarity metrics were used
to evaluate image concordance among modalities. Feasibility of simultaneous PET/MRI functional
imaging of tumors was explored by following 64Cu-labeled antibody uptake in relation to diffusion
MRI using cooccurrence matrix analysis.
This section is published in the Journal of Nuclear Medicine: Thomas S.C. Ng, James R. Bading, Ryan Park, Hargun
Sohi, Daniel Procissi, David Colcher, Peter S. Conti, Simon R. Cherry, Andrew. A. Raubitschek, Russell E. Jacobs (2012)
Quantitative, simultaneous PET/MRI for intratumoral imaging with a MR-compatible PET scanner. Journal of Nuclear
Medicine , 53 (7).).
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myanenko, Desiree Crow, Alex Poznak, Sonia Collazo and Bita Alaghebandan for their technical assistance. Drs. Yibao
Wu and Scott Fraser gave helpful advice. The project was funded by NIBIB R01 EB000993, NCRR S10 RR015703, S10
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3.4.1.2 Results
The PET/MRI scanner showed stable and linear response. Activity concentration recovery val-
ues (measured/true activity concentration) calculated for 4 mm diameter rods within linearity and
uniform activity rod phantoms were near unity ((0.97±0.06) and (1.03±0.03) respectively). Intra–
tumoral uptake patterns for both 18F-FDG and a 64Cu-antibody acquired using the PET/MRI scan-
ner and microPET were highly correlated with autoradiography (r >0.99) and with each other (r =
0.97±0.01). Based on this, we performed a preliminary study comparing diffusion MRI and radiola-
beled antibody uptake patterns over time and visualized movement of antibodies from the vascular
space into the tumor mass.
3.4.1.3 Conclusions
The MR-compatible PET scanner provided tumor images that were quantitatively accurate and spa-
tially concordant with autoradiography and the microPET R4. Cooccurrence matrix approaches
enabled effective analysis of multimodal image sets. These observations confirm the ability of the
current simultaneous PET/MRI system to provide accurate observations of intratumoral function
and serve as a benchmark for future evaluations of hybrid instrumentation.
3.4.2 Introduction
The tumor microenvironment greatly impacts the efficacy of cancer treatment [1]. Factors such as
heterogeneous perfusion and subpopulations of cells within tumors affect tumor progression and
response to therapy. Investigations of these factors usually involve measurements at a whole tumor
level (e.g.size) and tissue sampling for histological or biochemical assays. noninvasive imaging
complements these studies by providing intact tissue information at multiple timepoints in the same
individual [12].
The utility of multimodal imaging is well demonstrated in cancer research [14]. Advances
in hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) systems [190]
show particular promise for understanding the heterogeneous nature of the tumor microenviron-
ment. When spatially and temporally matched, high-resolution anatomical and functional informa-
tion such as the perfusion status [191], cellular density [192] and metabolic status of specific tissue
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regions acquired with MRI can enhance the interpretation of functional data provided by PET (e.g.,
oxygenation [183], cellular proliferation [53] and receptor expression [193]) and vice versa.
Conventional PET image analysis focuses on regions of interest (ROIs) encompassing whole
tumors, with some studies omitting obvious “necrotic” regions during analysis [192]. Efforts to
improve the spatial resolution of reconstructed PET images [194] and availability of coregistered
PET and MRI have engendered interest in understanding the heterogeneity of radionuclide uptake
observed with PET. For example, a recent clinical study by Metz, et al., examined heterogeneity
of tumor perfusion using MRI and correlated it with PET studies of integrin expression and tumor
metabolism [195]. Similarly, Cho, et al., compared MRI measures of tumor perfusion with uptake
of the PET hypoxia tracer 18F-MISO within rat tumor xenografts [183].
Correct interpretation of PET images, especially within regions of heterogeneous tracer uptake,
requires that fidelity be verified between these images and actual tissue activity concentration pat-
terns. Characterization of PET instrumentation usually entails measuring a standard set of metrics
in a variety of phantoms [196], followed by gross in vivo verification. While this approach examines
the general performance of the scanner, simple geometric patterns of phantoms may be insufficient
to predict in vivo performance. To validate the heterogeneous spatial patterns seen in PET images,
one needs to compare these images with a “gold standard” such as (QAR) [197].
We have evaluated the image quality of a first-generation, MR-compatible PET scanner
(“PET/MRI scanner”) [160]. Previous reports used standard metrics to assess the performance
characteristics of the scanner [198] and its ability to function within the integrated PET/MRI en-
vironment [105]. Here, we examined the image fidelity of the PET/MRI scanner and its ability
to quantify heterogeneous uptake patterns in mice compared with QAR and a commercial small
animal PET system. Phantoms were used to evaluate the quantitative capability of the PET/MRI
scanner. Next, the three systems were used to image patterns of 18F-fluoro-deoxyglucose and 64Cu-
antibody uptake within mice tumor xenografts. Finally, a preliminary, simultaneous in vivo diffu-
sion MRI/radiolabeled antibody PET study was performed and a cooccurrence matrix method was
applied to analyze the bimodal dataset.
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3.4.3 Materials and Methods
3.4.3.1 MR-compatible PET Scanner
The PET/MRI scanner being evaluated has been described in detail [160]. The system fits in a
Bruker–Biospin 7 T MRI system run using PARAVISION4 (Bruker-Biospin). PET data were ac-
quired using custom software. PET/MRI data were collected with an energy window of 350–650
keV. No attenuation, random coincidence, scatter or dead-time corrections were applied to PET/MRI
datasets (All data were collected at count rates low enough to avoid significant effects from dead-
time). Images were reconstructed with a 3D maximum a posteriori (MAP) algorithm (30 iterations,
b = 1×10−5) [60]. Detector sensitivity normalization was incorporated into the forward model in
MAP reconstruction. The FOV of reconstructed PET/MRI scanner images is 35.4×35.4×12.8 mm3.
Image matrix dimensions were 128×128×17 and voxel size was 0.28×0.28×0.75 mm3. The average
spatial resolution of the scanner (mean of values measured at off-axis distances of 0, 5, 10 mm using
filtered back-projection reconstructed images) is 1.5 mm [198].
3.4.3.2 Phantom Studies
We measured the linearity and uniformity of reconstructed image intensities from the PET/MRI
scanner. A linearity phantom was constructed by evenly spacing four 1 mL syringes (Becton Dick-
inson, BD, inner diameter = 4 mm) on the inner surface of a 50 mL Falcon tube (diameter = 30 mm,
BD, figure 3.21). Syringes were filled with 18F-FDG at concentrations of 2.5, 1.3 , 0.63, and 0.31
MBq/mL, as measured by a well counter (CRC-15R, Capintec). The phantom was centered in the
PET FOV and imaged simultaneously with PET/MRI 9 times over 2 hours (PET: duration = 720 s;
MRI: FLASH TR/TE = 500/4 ms, FOV: 35.4 × 35.4 mm2, slice thickness = 0.75 mm, matrix size =
128 × 128, 40 slices).
The phantom was rotated 90° clockwise about the long axis of the system between each scan
to test for activity-dependent differences in response among different regions of the reconstructed
images. Response homogeneity within PET images was measured with a “hot rod” phantom con-
figured with the same geometry as the linearity phantom, except that all syringes contained 1.5
MBq/mL of 18F-FDG. The hot rod phantom was imaged 10 times over 2 hours (PET: 600 s) with a
90° clockwise rotation between consecutive scans. The first linearity phantom scan of the study ses-
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Figure 3.21: Phantoms used in this study. (A) Schematic of the linearity and hot rod phantoms
(syringe and gelatin) used in the study. (B)–(I) Images of gelatin linearity phantoms acquired across
modalities. Blue food dye was used to visualize rods (B,F), while MR (Prohance) and CT (Isovue
300) visible contrast agents were mixed with radioactivity to enable visualization in MRI and CT
respectively (C,G). A small crack is evident in a frozen test phantom prepared for CT imaging (G);
this phantom was not used in the studies. The physical properties of the gelatin phantom (E) enabled
sampling for gamma counting as well as thin, frozen sectioning for autoradiography (I). The orange
box in (E) outlines a rod that was sampled with a biopsy punch and transferred for weighing and
gamma counting.
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sion was used to derive regression coefficients with which other scans were calibrated; this method
incorporated phantom-specific compensation for attenuation, scatter and partial volume effects. De-
tailed description of the calibration procedure is given in section 3.4.7.1.
We also validated stability of the PET/MRI scanner over multiple imaging sessions. Linearity
phantoms were prepared and imaged as described above for 3 separate imaging sessions over 10
days. The coefficient of variation (CoV) of calibration coefficients across sessions were calculated.
3.4.3.3 Animal Studies
Animal studies were approved by the Animal Care and Use Committee at Caltech. Ten days prior
to imaging, TgCEA+C57BL/6 mice were implanted in the right flank with 8×105 MC38.CEA col-
orectal adenocarcinoma cells [199].
18F-FDG. A tumor-bearing mouse was fasted for 4 hours, injected intravenously (i.v.) with 37
MBq of 18F-FDG, then warmed and sedated with a 1.5% isoflurane/air mixture. The injected activity
was sufficient to allow imaging of the same mouse by PET/MRI, microPET and QAR in the same
study session. After 60 min, the mouse was euthanized and secured to a cardboard platform; mouse
and platform were placed on a custom-designed plastic holder. The mouse was positioned with its
long axis orthogonal to the transaxial imaging planes of the PET/MRI scanner and imaged unfrozen
with simultaneous PET/MRI (PET: 600 s; MRI: RARE TR/TE = 3500/4.5 ms, matrix size = 128
× 128, resolution = 0.28 × 0.28 mm2, slice thickness = 0.75 mm, 34 slices). Following the initial
PET/MRI scan, the mouse was frozen in a dry ice and isopropyl alcohol bath, repositioned into the
holder and reimaged (PET: 1200 s; MRI: same as above). Using recorded prompts count rate and
previous work relating prompts rate to true coincidence count rate for the PET/MRI scanner [198],
we estimated the true-to-prompt coincidence event ratio for our scans to be ~50–75%.
To facilitate a) shielded transport between the laboratories where PET/MRI and
microPET/autoradiography experiments were done; and b) cryosectioning for autoradiography, the
frozen mouse was cut to obtain a 3.5 cm long section axially-centered on the tumor. A laser guide
ensured that the cut face was orthogonal to the long axis of the mouse. The section was positioned
in an imaging holder parallel to the holder’s axis to ensure that the cut-face was orthogonal to the
long axis of the microPET R4 scanner (Concorde Microsystems) [200]. The mouse section was
73
then serially imaged with microPET and microCT (Siemens InveonCT) (PET: 1200 s, 350–650
keV energy window, 6 ns timing window, corrections made for detector normalization, dead-time
and random coincidence events, CT: 80kVp, 500 mA, 200 ms/step, 361 steps covering 360°, 2
axial bed positions with a 20% overlap, voxels binned × 4). Measured true-to-prompt event ratio
in all microPET scans were >99%. MicroCT images were reconstructed with the COBRA-3D
reconstruction algorithm (Exxim) to produce datasets with isotropic voxels (210 mm per side). Prior
to reconstruction, microPET list-mode data were truncated to contain the same number of prompt
coincidence events as in the PET/MRI frozen-state scan. This was done in order to make true count
densities at least roughly comparable in the PET/MRI and microPET scans. Images were then
reconstructed using 3D OSEM-MAP (3D OSEM: 4 iterations, 12 subsets, followed by MAP: 30
iterations, b = 0.33, optimized for uniform resolution).
After microPET imaging, the mouse section was embedded in a 4% carboxy-methyl-cellulose
(Sigma-Aldrich) water mixture within a custom-steel mold. The mold was placed in a dry ice and
isopropyl alcohol bath for 10 minutes and then into a –20°C freezer for 1 hour before mounting
onto a cryomicrotome (Bright 5030/WD/MR, Hacker Instruments). Slices were removed until tu-
mor tissue was apparent. After that, 50 mm thick transaxial frozen sections, spaced 250 mm apart,
were acquired for autoradiography until all tumor tissue had been sectioned, ensuring at least 3 au-
toradiography slices per PET/MRI image slice. During sectioning, the block face was photographed
(Nikon D70, Tamron 90 mm 1:2.8 Macro f55 lens). Sections were placed onto storage phosphor
screens (Super Resolution Screen, PerkinElmer). A 14C standard strip (Amersham) was placed on
each screen for calibration of screen sensitivity. Screens were exposed to collected sections for 3.5
days at –20°C and then read with a laser scanner (Packard Cyclone).
64Cu-labeled Antibody. Distribution of a radiolabeled antibody against CEA, 64Cu-DOTA-NHS-
M5A (9), was imaged in a tumor-bearing mouse. The antibody (5.6 MBq, specific activity = 0.37
MBq/mg) was injected i.v., and in vivo simultaneous PET/MRI imaging was performed at 4 and 20
hours post injection. The animal was kept at 35°C–37°C with a warm air flow. At each timepoint,
PET (3600 s); anatomical MRI (RARE, same parameters as above) and diffusion MRI images
(TR/TE=3000/25ms, matrix size = 128×128, resolution = 0.28 × 0.28 mm3, slice thickness = 0.75
mm, 10 slices, d/∆ = 7/14ms, b-values = 0, 300, 1000 s/mm3, 1 direction) were acquired. The mouse
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was sacrificed 24 hours post injection. Images were then acquired with the PET/MRI scanner,
microPET and autoradiography and processed as per the 18F-FDG experiment.
3.4.3.4 Image Analysis
Image Coregistration. PET/MRI scanner images were aligned with MRI as previously described
[201]. Images from non-frozen and frozen specimens were aligned using a rigid-body transfor-
mation obtained via landmarks along the anatomic contour. MicroPET and microCT images were
coregistered with a rigid-body transformation (Amira) using landmarks present on both images. Au-
toradiography images acquired from different phosphor screens during the same study session were
cross-calibrated using 14C standard strips. For animal studies, slices within each autoradiography
and photography image z-stacks were first aligned across the stack using the Fiji StackReg func-
tion (http://pacific.mpi-cbg.de/wiki/index.php/Fiji). The two stacks were then coregistered using a
rigid-body transformation derived from 12 landmarks per slice clearly seen on both stacks. Three
adjacent slices falling within a given PET slice were averaged to match the slice thickness of the
PET/MRI scanner. Prior to cross-modal registration, PET/MRI and autoradiography/photography
datasets were resliced to 1.2 mm thickness to match the slice thickness of reconstructed microPET
images. Finally, PET/MRI and microPET/microCT image stacks were aligned to the autoradiog-
raphy/photography stack using a landmark-based rigid-body algorithm implemented in MATLAB,
resulting in a coregistered combined dataset with voxel dimensions of 0.28 × 0.28 × 1.2 mm3.
Regions of Interest. For phantom images acquired in PET/MRI studies, cylindrical volumes of
interest (VOIs) were axially centered within images of rods (diameter = 40% of the rod, length
= 8.3 mm). Tumor and whole-animal VOIs were drawn on photographic stacks using MRIcro
(http://www.MRIcro.com) and applied to PET and autoradiography images.
PET/autoradiography Comparisons. Similarity metrics used to compare animal images are
summarized in table 3.10. Image intensities within VOIs were scaled to fall between 0 and 1 for
similarity analysis. We used scaled images because it was not feasible to perform autoradiography
of a linear calibration phantom during day-long animal imaging experiments. Scaling was valid
since phantom studies showed that the PET/MRI scanner, microPET and autoradiography response
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were linear (see section 3.4.7, figures 3.23 and 3.30).
Table 3.10: Image similarity metrics used to compare PET image quality with autoradiography
Metric Name Equation Description
Correlation
coefficient
E[(x−mx)(y−my)]
σxσy Voxel by voxel correlation
between two regions of interest.
x, y refer to the voxel value for
the first and second image
respectively, m and σ refer to the
mean and standard deviation of
the voxel values in images X
and Y. E denotes expectation
value.
Peak
signal-to-noise
ratio (PSNR)
10log10
Max−voxel−valuei×Max−voxel−value j
Mean−voxel−di f f erencei j Voxel by voxel measure of SNR
within a ROI between images i
and j [202].
Structural
similarity index
(SSIM)
SSIM(x,y) = l(x,y)αc(x,y)β s(x,y)γ , Similarity index comparing
local image structure. l, c, s
refer to the luminance, contrast
and structure of the image,
respectively. a, b, g are
adjustable parameters. (Default
settings from [202] were used.)
See reference for a detailed
description.
Complex wavelet
structural
similarity index
(CWSSIM)
Same as SSIM, but with wavelet
analysis incorporated [203].
In vivo PET/diffusion MRI. Aligned and calibrated (using a linearity phantom as described in
section 3.4.7) PET/MRI scanner images were converted to units of percent injected dose per gram
(% ID/g). (ADC) tumor maps were generated from diffusion MRI data [192]. Cooccurrence matrix
analysis was used to compare ADC and PET images while taking into account the resolution differ-
ences between imaging modalities. The cooccurrence matrix C was calculated using the following
equation:
C∆x∆y∆z(i, j)∑np=1∑
m
q=1∑
l
r=1 =
 1, if ADCr(p,q,r)=iandPETr(p+
∆x
a ,q+
∆y
b ,r+
∆z
c = j,
0, otherwise.
ADCrand PETr are ADC and PET images whose voxel values have been binned to one of 15
evenly spaced values lying within the intervals i ε [0, 1.5×10-3 mm2/s] and j ε [0.25d, 0.75d] (d is
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the maximum % ID/g value in the VOI), respectively. p, q and r are voxel coordinates along x, y
and z directions of the n × m × l image volume (defined by the VOI). a, b and c are the PET voxel
dimensions (0.28 × 0.28 × 0.75 mm3). The parameters |∆x|, |∆y| (≤1.5 mm) and |∆z| (≤2.1 mm)
were equated to the image resolution (average FWHM values) of the PET/MRI scanner [198].
Statistical Analysis Two-way ANOVA was used to compare image homogeneity and linearity
of PET/MRI scanner phantom data. Differences between rod intensities measured from different
quadrants of the image and individual rod intensities measured from separate images during the
study session were tested. Differences were considered significant when p-values were <0.05.
3.4.4 Results
3.4.4.1 PET/MRI Scanner Response
Activity Concentration Recovery. Activity concentration recovery (ACR = measured value/true
value, measured value obtained from images using calibration coefficients derived as described
in section 3.4.7.1) from PET/MRI scanner phantom images are shown in figure 3.22. Linearity
phantom images had ACRs close to unity (0.97±0.06) for all rods (diameter = 4 mm) across a 10-
fold range of activity concentrations. No significant difference in activity concentration recovery
among spatial locations (p = 0.3) or among different rod activity concentrations (p = 0.3) were
observed. However, reproducibility of the scanner-derived ACR was inversely related to rod activity
concentration (ACR standard deviation = 23% for the lowest activity concentration rod compared to
9% for the highest activity concentration rod). This is likely due to increased noise in reconstructed
images at lower activity concentrations. Hot rod phantom images also had ACRs (1.03±0.03) close
to unity for a range of activities. Again, no significant dependence of ACRs on spatial location (p =
0.5) or rod identity (p = 0.5) was seen.
Stability Across Imaging Sessions. Calibration curves and regression coefficients obtained with
linearity phantoms from 3 separate imaging sessions over 10 days are shown in figure 3.23. The
data show that the PET/MRI scanner has a temporally stable and linear response across a wide range
of activity concentrations when system parameters are kept constant.
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Figure 3.22: PET/MRI scanner accuracy and stability within an imaging session. Measurements
were made on syringe “rod” phantoms described in 3.4.3.2. (A) Activity concentration recovery
(ACR) for 18F-FDG linearity phantom images acquired over 2 hours, with ROIs drawn over rods
with varying activity concentrations. No significant dependence on spatial location (p = 0.3) or
activity concentration (p = 0.3) was observed. (B) Rod ACRs compared with actual rod activity
concentrations. (C) ACRs of 18F-FDG hot rod phantom images acquired over 2 hours, compared
with respect to spatial location (TL = top left of image FOV, TR = top right of image FOV, BR =
bottom right of image FOV, BL = bottom left of image FOV) and rod identity. No dependence on
spatial location (p = 0.5) or rod identity (p = 0.5) was observed. (D) Rod ACRs compared to actual
rod activities at the time of imaging. All hot rod syringes contained the same activity concentration.
Error bars denote SD.
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Figure 3.23: Linearity and stability of the PET/MRI scanner across multiple imaging sessions. Mea-
surements were made on syringe “rod” phantoms described in 3.4.3.2. (A) Linearity phantom rod
image intensities from 3 separate imaging sessions over the course of 10 days are plotted against
actual activity concentrations. Fitted linear regression lines used to determine the calibration coef-
ficients are also shown. (B) Slope and intercept calibration coefficients (mean and SD) across the 3
sessions. CoVs for the slope and intercept were 6.8% and 11% respectively.
3.4.4.2 Comparison of Image Intensity Patterns Across Modalities
Qualitative Assessments. Figure 3.24A shows coregistered images of a mouse injected with 18F-
FDG and imaged using PET/MRI, microPET/CT and autoradiography/photography. As expected,
FDG uptake in the tumor was elevated compared to surrounding tissues. The image intensity pattern
was heterogeneous within the tumor and approximately congruent among all 3 imaging systems.
Regions of high activity were present in lateral and medial lobes of the tumor, with a region of lower
activity in between. The central region had somewhat higher relative intensity in autoradiography
compared to PET images. Images acquired 24 hours after injection of 64Cu-DOTA-NHS-M5A
are shown in figure 3.24B. Expected tumor localization of the antibody is observed, along with
intratumoral heterogeneity. The multilobed intratumoral uptake pattern is similar across PET/MRI,
microPET and autoradiography.
Quantitative Evaluation. Image similarity between different pairs of radioactivity image sets
was quantified using several metrics. Comparisons of PET/MRI scanner and microPET R4 with
autoradiography are shown in figures 3.25 and 3.26. Pixel-based correlation coefficients for all PET
to autoradiography comparisons were moderate to high (>0.7) for both whole-mouse cross sections
and tumor ROIs (figure 3.25A–B). Not surprisingly, correlation increased when autoradiography
was blurred to match resolution to the PET/MRI scanner and microPET, and dropped nearly to zero
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Figure 3.24: Multimodal imaging of radiotracer uptake in tumors. Mice bearing MC38.CEA tumors
were injected either with (A) 18F-FDG or (B) anti-CEA 64Cu-DOTA-NHS-M5A antibody and sac-
rificed after an uptake period. Tumor regions were then imaged with the PET/MRI scanner, frozen,
reimaged with PET/MRI, imaged in the frozen state with microPET and microCT, cryosectioned
and imaged with autoradiography. Matched tumor slices show qualitatively similar uptake patterns.
PET/MRI scanner images of 18F-FDG show a hot spot (circle) not observed with other modalities.
Comparison with MRI showed the hot spot to be on the animal’s surface, indicating that it was
caused by urine residue that was removed prior to subsequent imaging (Scale bar = 10mm).
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when the autoradiography dataset was scrambled. An alternative pixel-based metric, peak signal-to-
noise ratio (PSNR), gave similar results except that values were higher for whole-body than tumor
ROIs and the drop in metric value was less pronounced for a randomly scrambled image (figure
3.25C–D).
Figure 3.25: Pixel-based similarity across PET/MRI scanner (frozen specimens), microPET and
autoradiography images. 18F-FDG and 64Cu-antibody coregistered datasets are compared at whole-
body and tumor ROI levels using correlation coefficients (A–B) and PSNR (C–D). Similarity be-
tween each PET dataset and autoradiography (with and without a Gaussian filter applied to autora-
diography) were calculated and plotted against each other. A control comparison between PET
datasets and a scrambled autoradiography volume showed large decreases for correlation coeffi-
cient but not PSNR. Pearson correlation coefficients comparing PET/MRI vs. autoradiography and
microPET vs. autoradiography metrics are shown. Similarity metrics are described in table 3.10.
Images were also analyzed with structure-based metrics (figure 3.26). Mean structural similarity
index (SSIM) and Complex wavelet structural similarity index (CWSSIM) analyses showed no
clear difference between PET/MRI and microPET R4 scanners. With both measures, comparison
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of PET images for tumor ROIs generally showed higher intermodal similarity than did whole-body
ROIs. When autoradiography dataset was scrambled, structure-based comparisons decreased to
nearly zero, confirming that the metrics do reflect image similarity. Similarity metrics obtained by
comparing PET/MRI and microPET images to autoradiography were highly correlated (r ≥0.9).
Figure 3.26: Structure-based similarity among PET/MRI scanner (frozen specimen), microPET
and autoradiography images. 18F-FDG and 64Cu-antibody coregistered datasets were compared
as in figure 3.25, except using SSIM (A–B) and CWSSIM (C–D). Pearson correlation coefficients
comparing PET/MRI vs. autoradiography and microPET vs. autoradiography metrics are shown.
Small differences shown by the metrics can be related to images. For example, comparison
of FDG data slightly favored the PET/MRI scanner over microPET. A possible explanation for
this can be seen in figure 3.24A, where PET/MRI of the frozen specimen and QAR images show
a more pronounced low activity region between the two main high activity lobes and relatively
flat dorsal tumor contours compared to the microPET image. Differences among modalities are
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less pronounced in the antibody images; this is seen in figures 3.25B, D and 3.26B, D, where on
average data points lie closer to the identity line than for FDG images. CWSSIM, a metric less
sensitive to geometric distortions compared to other metrics [203], attenuates these differences but
also indicates better structural agreement between microPET and blurred autoradiography images
of 64Cu in tumor compared with PET/MRI.
Simultaneous In Vivo PET/MRI. Tumor uptake of 64Cu-DOTA-NHS-M5A at 4 and 20 hours
post injection is compared to simultaneously acquired MR-ADC images in figure 3.27. At 4 hours
post injection, much of the antibody was still in blood, as shown by the high signal in the inferior
vena cava (figure 3.27A) and low uptake within the ventral portion of the tumor. At 20 hours, the
antibody signal was spread throughout the tumor parenchyma (figure 3.27B). cooccurrence matrix
analyses of the uptake pattern reflect these observations (figure 3.28). At 4 hours, regions of rela-
tively high antibody concentration within the tumor tended to be in regions with high ADC values,
suggesting that the antibodies were in the tumor’s intravascular and/or interstitial spaces (figure
3.28A). By 20 hours, this high uptake/high ADC cooccurrence disappeared, suggesting uniform
antibody distribution within the tumor (figure 3.28B).
3.4.5 Discussion
Feasibility of in vivo PET/MRI has been well demonstrated [190]. However, it remains to be shown
that PET images from such a scanner accurately depict activity distribution within the imaged tissue.
Here, we demonstrated the ability of a MR-compatible PET scanner [105] to produce quantifiable
intratumoral images that are stable, linear and concordant with images from a commercial small
animal PET scanner and autoradiography.
PET systems require a uniform and linear image intensity response. PET/MRI scanner-derived
images of linearity and hot rod phantoms showed the system to be stable and linear during a single
imaging session and across multiple sessions. The linearity phantom allowed us to demonstrate
the stability of the PET/MRI system for measuring multiple activity concentrations in the same
image across multiple time points within an imaging session. These characteristics are crucial for
successful dynamic simultaneous PET/MRI studies. Activity concentration recovery in this study
compares well with previous reports for small animal PET [204, 205].
83
Figure 3.27: In vivo simultaneous diffusion MRI/radiolabeled antibody PET reveals phases of an-
tibody uptake. PET/MRI of a mouse was obtained at 4 (A) and 20 (B) hours post injection. Slices
from the two time points were matched as closely as possible. Both PET and diffusion MRI show
intratumoral heterogeneity of uptake and ADC values respectively. A general accumulation of anti-
body was observed between 4 to 20 hours. Focal distribution of antibody was observed in the more
dorsal portion of the tumor at 4 hours post injection; by 20 hours, the distribution encompassed most
of the tumor mass. Spatial patterning of the ADC (shown only for the tumor) was similar at both
time points. PET images were calibrated using a linearity phantom as described in section 3.4.7.
Arrow points to the inferior vena cava (Scale bar = 10mm).
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Figure 3.28: Cooccurrence matrix analysis of functional PET and MRI data offers insight into
tumor antibody uptake. (A) cooccurrence matrix comparing antibody uptake and ADC values at 4
hours post injection. The uptake comparison window was adjusted to account for the lower spatial
resolution of PET (1.5 mm FWHM) compared to MRI. At 4 hours, a large fraction of the antibody
signal colocalized with regions of high ADC, (>0.0015 mm2/s) suggesting much of the antibody
was in vascular and/or interstitial spaces. (B) By 20 hours, that component had disappeared; the
antibody was spread more evenly across the tumor mass. This was not apparent with pixel-by-pixel
matching (figure 3.31).
To quantitatively interpret and compare PET and QAR images, image intensities for both modal-
ities need to be linearly related to object activity concentration. To demonstrate that PET and QAR
imaging systems used in this study are linear and to confirm that our intended strategy for animal
studies is valid, we developed a gelatin phantom that could be visualized by optical imaging, MRI,
CT, PET, QAR, and assayed for radioactivity concentration by gamma counting (figure 3.23). Fig-
ure 3.30 shows that image intensities derived from phantoms were linearly related to sample activity
concentration for all 3 imaging systems, enabling us to compare images from different systems with
confidence.
The ability to return images with intensity patterns reflecting actual in vivo activity distributions
was compared among the PET/MRI scanner, microPET and QAR. intratumoral activity distributions
for a metabolic marker (18F-FDG) and a targeted antibody were in good overall spatial concordance
among modalities. However, detailed examination of the images revealed some differences. Reso-
lution differences between autoradiography and PET can be seen by the presence of finer structures
in autoradiographs compared to their PET counterparts. For example, the antibody distribution in
figure 3.24B showed a small rim of relatively high activity in the ventral portion of the tumor au-
toradiographs not visible with PET. Christian et al., reported similar observations, attributing them
85
to differences in resolution between PET and autoradiography [206]. Application of a Gaussian
filter to autoradiography images acquired in this study support this assertion (figure 3.29). Lack
of attenuation and scatter correction in PET/MRI scanner images may also contribute to dispari-
ties. Attenuation of 511 keV photons can be as high as 15% with small animal-sized objects [207].
However, since tumors imaged in our experiments were superficial, we expect attenuation-related
differences between PET and autoradiography to be minimal. Regardless of the limitations of the
imaging techniques used in this study, the intratumoral patterns are qualitatively similar among the
PET/MRI scanner, microPET and QAR for both 18F-FDG and the 64Cu-antibody. Furthermore,
similarity metrics showed good overall correlation between both PET systems and QAR. Image
differences between the two PET systems may be due to resolution differences between the sys-
tems and, in case of the 18F-FDG study, high count rates during the PET/MRI scan compared to the
microPET.
Figure 3.29: Resolution differences between autoradiography and PET. Images from the antibody
study used for analysis. 2D Gaussian filters were applied to the autoradiography and PET insert
images to simulate the spatial resolution of the commercial microPET R4 (~1.8 mm). Image filtering
of the autoradiography and PET insert images improved correspondence to the microPET image.
This highlights the resolution differences between the three imaging systems.
The necessity and utility of detailed quantitative analyses are illustrated in figure 3.27. Having
demonstrated good spatial fidelity of PET/MRI scanner images, we hypothesized that biological
inferences can be made by comparing simultaneously acquired PET and MR images. Fidelity of the
PET images allowed us to conclude that there was a time dependent heterogeneous tumor accumu-
lation of antibody during a preliminary study (figures 3.27, 3.28).
86
Previously, two methods have been employed to compare multimodal intratumoral datasets.
Cho et al. performed a pixel-wise comparison of PET and DCE-MRI maps [183], while Metz et al.
used arbitrary thresholds to segment tumor subregions for comparison [195]. The former approach
neglects differences in resolution between the imaging modalities, while the latter requires multi-
ple PET datasets and is observer dependent. We accounted for differences in resolution between
PET and MRI by analyzing image sets with a cooccurrence matrix bin-offset equal to the mean
FWHM of the scanner. This analysis demonstrated spreading of antibody from a highly intravas-
cular/extracellular region throughout the tumor. There is recent interest in modeling tumor growth
kinetics using multimodal imaging datasets on a pixel-by-pixel basis [208]. The cooccurrence ma-
trix method can be incorporated into these analyses to account for resolution differences between
the different modalities. Further improvements can be made to this method. For instance, one can
vary the FWHM window to account for varying spatial resolution within the PET FOV. Further
considerations of the method is explored in appendix C.
To date, few studies have been published that evaluate PET image fidelity to actual in vivo
activity distributions. Christian et al. developed a Styrofoam holder surrounding a mouse to allow
coregistered PET and autoradiography [112]. Cho et al. developed a foam mold/plastic holder
for rat imaging [183]. The current PET/MRI scanner is not large enough to accommodate these
solutions. Instead, landmarks visible on all anatomical images (MRI, CT, photography) along with
laser-guided positioning of the mice allowed effective coregistration between PET and QAR.
It is remarkable that, despite limitations inherent in a first-generation prototype (e.g.low sen-
sitivity and lack of random coincidence or dead-time corrections), the current PET/MRI scanner,
operated simultaneously with MRI, provided PET images with essentially equivalent spatial pat-
terns as the well-established microPET R4. This demonstrates the ability of the MR-compatible
PET scanner to deliver useful in vivo information acquired simultaneously with MRI. Next gen-
eration systems will likely improve on the quantitative ability and image quality observed in the
current system. Methods developed here can be utilized as a benchmark to assess image qual-
ity of future systems. Further, availability of good fidelity, coregistered PET/MRI datasets and
their QAR/photography counterparts offers the opportunity to explore the biological implications of
complementary imaging information, and provide a test bed to develop and evaluate in vivo–relevant
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PET partial-volume, motion-correction and attenuation-correction algorithms.
3.4.6 Conclusions
We evaluated the ability of a MR-compatible PET scanner to generate spatially and quantitatively
accurate images. Images acquired from tumor-bearing mice using different radioisotopes showed
good correspondence among the PET/MRI scanner, microPET R4 and autoradiography. A cooc-
currence matrix method enabling effective comparison of complementary PET and MR images was
presented. This work provides a basis for pursuing biologically relevant simultaneous PET/MRI
studies. Progress in hybrid PET/MRI technology will provide improvements in image quality.
Methods from this study can be applied to evaluate such improvements.
3.4.7 Supplemental Data
3.4.7.1 Materials and Methods
Calibration of PET/MRI Scanner Images. PET/MRI scanner images of syringe phantoms were
decay corrected and normalized for scan duration prior to analysis. The first linearity phantom
image acquired during a given study session was used to convert image intensities to units of ab-
solute activity concentration (kBq/mL). Rod image intensities from the PET/MRI image, obtained
from cylindrical volumes of interest axially centered on each rod (diameter = 40% of the rod di-
ameter, length = 8.3 mm), were plotted against activity concentrations measured by well counting
of samples taken from the phantom. Plots were fitted by linear regression, taking into account the
random variability of both the measured independent and dependent variables [209]. The result-
ing regression coefficients were used to calculate activity concentrations for all images acquired
during the corresponding study session. This calibration procedure incorporates phantom-specific
compensation for attenuation, scatter and partial volume effects into the calibration coefficients.
Cross-comparison of PET/MRI Scanner and microPET Linearity with Autoradiography and
Direct Assay. To enable quantitative comparison of images across PET and QAR systems, it was
necessary to ensure that all three systems had a linear response. Two phantoms were used for this
purpose. A linearity phantom was made by solidifying a 10% gelatin solution (solid state density =
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1.01 g/mL) in a cylindrical mold made from a 50 mL Falcon tube (BD). While the gel was liquid,
4 rods, each 4 mm in diameter, were evenly spaced in the mold. Once the gel had set, the rods
were removed, and the holes were filled with gelatin mixed with 64CuCl2 solution (Washington
University School of Medicine) containing Prohance (Bracco; 0.1 mM) and Isovue 300 (Bracco;
1mM). Initial mixture activity concentrations were 3.7, 1.9, 0.93, and 0.56 MBq/mL. The 12.7 h
half-life of 64Cu enabled the phantom to be imaged on the same day with the PET/MRI scanner,
commercial small animal PET and QAR. A second “hot rod” gelatin phantom was made in the
same manner as the linearity phantom, except that the 4 rods each contained an initial activity
concentration of 1.9 MBq/mL. The rods were surrounded with gelatin containing 0.19 MBq/mL of
64Cu.
Phantoms were cut to 15 mm length to remove gelatin spillover at the ends. The removed
sections of the phantom were sampled with a biopsy punch (inner diameter = 2 mm, Miltex), and
the samples were placed in pretared Eppendorf tubes for gamma counting. Each region of interest
(background and rod regions) was sampled twice. The phantoms were imaged simultaneously with
PET/MRI (PET: 2700 s; MRI: FLASH TR/TE = 500/4ms, FOV: 35.4 × 35.4 mm3, slice thickness =
0.75 mm2 matrix size = 128 × 128, 40 slices). Immediately after imaging, the phantoms were placed
in a dry ice and isopropyl alcohol bath for 5 minutes. The phantoms were subsequently imaged on a
microPET R4 (Concorde Microsystems) for 20 minutes (350–650 keV energy window, 6 ns timing
window).
After microPET imaging, the phantoms were cut in half. One half was sampled for gamma
counting, while the other half was mounted onto a cryomicrotome (Bright 5030/WD/MR, Hacker
Instruments). Five 50 mm thick frozen transaxial sections, spaced 250 mm apart, were obtained
and transferred onto a chilled autoradiography cassette containing a storage phosphor screen (Super
Resolution Screen, PerkinElmer). The loaded cassette was stored for 1 day at –20°C. Screens were
read with a laser scanner (Packard Cyclone). Tubes containing phantom samples were assayed for
radioactivity using a calibrated gamma counter (Model 1480 Wizard 3°, Wallac Oy). Sampling of
the phantom was done at each stage of the imaging procedure (PET/MRI imaging, microPET R4
imaging and autoradiography) to account for diffusion of the radioactivity and contrast agent as
evident in figure 3.21.
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PET images were reconstructed and analyzed as described in section 3.4.3.4. Circular ROIs
(diameter = 80% of rod diameter) were used for rod analyses on autoradiography images. Back-
ground activity was analyzed with ROIs (diameter = 5.3 mm) placed at five different locations per
slice. Although variable slice thickness is a potential source of error in QAR, it was found to be
negligible in our study. The CoVs of activity concentrations measured across several slices of the
gelatin hot rod phantom (background = 0.19 MBq/mL, rods = 1.9 MBq/mL) were 3.0% and 3.2%
for background and hot rod regions respectively. These values are lower than observed by Christian
et al. (3.5%) after adjustment for differences in slice thickness [210].
Rod and background intensity values from gelatin phantom images were plotted against activity
concentrations measured by direct weighing and gamma counting of relevant samples. Plots were
fitted by linear regression. Pearson correlation coefficients compared to gamma counting were also
calculated.
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Figure 3.30: Linearity of PET/MR scanner, microPET R4 and autoradiography. Image intensities
acquired from the same gelatin-based linearity and hot rod phantoms were plotted against direct
assay measurements for (A) PET/MR scanner, (B) microPET R4 and (C) autoradiography. Linear
regression was performed for each dataset. Pearson correlation coefficients are shown for each
dataset. Software processing revealed that the linearity phantom rod with the highest activity was
overexposed on the autoradiography phosphor imaging plate (the * data point in C). That data point
was excluded from further analysis. (a.u. = arbitrary units)
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Figure 3.31: Scatter plot of simultaneous diffusion MRI and PET antibody measurements at two
different times after injection of 64Cu-labeled antibody. Quantitative pixel values from the tumor
ROIs shown in figure 3.27 show low correlation between antibody uptake and ADC values (r = 0.21
and –0.02 at 4 and 20 hours, respectively).
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3.5 Synchronization of PET/MRI Hardware
Simultaneous PET/MRI instrumentation enables PET and MRI images to be acquired in spatial
and temporal coregistration. The issue of spatial coregistration of PET and MRI information was
addressed in sections 3.2 and 3.3. Here, we address the issue of accurate temporal synchronization
of the PET insert and MRI. We describe a system to allow synchronous PET/MRI data acquisition.
A schematic showing how the workflow for synchronous PET/MRI acquisition is shown in
figure 3.32. Software modules were inserted into the PET acquisition program and MRI pulse
sequence to allow cross-communication of the two systems. The modules can either trigger the
process of synchroniation or wait for a signal from the other signal. The user can begin acquisition
via a PET or MRI trigger.
1. Start MRI 
sequence
3. PET so!ware starts PET scan 
4. PET begins PET acquisi"on
2. MRI wait 
for PET 
setup
5. MRI 
acquisi"on 
begins
MRI-triggered start
PET-triggered start
MRI instrument
PET instrument
Figure 3.32: Synchronous PET/MRI acquisition may be dictated by either PET or MRI acquis-
tion. Software modules embedded in the MRI and PET programs are written to allow cross–
communication between the two systems. PET acquisition can be started by a MRI trigger em-
bedded in an MRI pulse sequence or manually. The PET software then sends a sync signal back
to the MRI, allowing the pulse sequence to begin acquisition at a fixed time. Each arrow (except
between step 2 and 5) represents a synchronization signal.
Acknowledgment: Thanks to Martin Judenhofer for help with PET software coding. An updated version of the PET
software including the module can be obtained on request.
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3.5.1 Materials and Methods
3.5.1.1 PET setup
The current PET hardware utilizes the NIM standard, while the input/output of both the MRI system
and the PET computer system are based on TTL. A logic level translator (Phillips Scientific, NIM
model 726) was used to allow cross-communication between the NIM and TTL standards. The
current PET software [162] was modified to enable system cross-communication using TTL via
pins available on a standard parallel port.
3.5.1.2 MRI setup
Paravision 5.1 (Bruker, MA) software is used for MRI control. Communication with other systems
can be achieved via TTL ports on the MRI hardware console. A software module that can be inserted
at the beginning of any Bruker MRI pulse sequence was written to enable cross-communication with
the PET system.
The code for the pulse sequence modules, implemented here for a standard FLASH sequence,
is shown in appendix D.
3.5.2 Discussion
Temporal synchrony of PET and MRI data is an integral advantage of simultaneous PET/MRI sys-
tems. For many PET/MRI applications, the synchrony required are on the scale of the study session
(e.g.~minutes/hours). In these cases, temporally registered PET/MRI datasets can simply be ac-
quired separately in the same study session.
A need for a higher degree of synchrony (~seconds) arises when the physiological processes
being studied are transient (e.g.BOLD responses can change within seconds) and when the contrast
agents being imaged have fast kinetic properties (e.g.Gd-DTPA or 18F-FDG, section 3.33). Perfect
(within milliseconds) synchronization of PET and MRI in these cases facilitates the posthoc analysis
of the dual-dynamic datasets.
Further, the availability of temporally aligned data is also beneficial for improving the quan-
tification of PET images. Posthoc MR-guided correction of PET datasets, such with the use of
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MR-navigator echoes to reduce motion blurring in reconstructed PET images [100] require that the
MRI and PET data be synchronized.
In summary, a system was implemented to enable perfect synchrony of PET and MRI data
acquisition for the integrated small animal PET/MRI scanner. All or parts of the system can be
easily ported to future versions of the scanner.
Figure 3.33: Fast kinetics of small molecular agents necessitate synchronous PET/MRI. Time
curves of 18F-FDG uptake in the abdominal aorta (AIF) and tumor in a tumor-bearing mouse. The
ROI for the obtained time curves were defined by spatially coregistered MRI. Perfect temporal
synchrony of such datasets with DCE-MRI will facilitate kinetic modeling and comparisons of
multmodal datasets.
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3.6 MR Gradient Effects on the PET Insert
In section 3.4, we demonstrated that the PSAPD-based MR-compatible PET system show good
quantitative fidelity when used simultaneously with the MRI. However, initial studies with the cur-
rent PET insert did show a slight decrease (7%–10%) of count rates in the presence of MRI pulse
sequences [105]. It is important to understand the effect of such observations as next generation
hybrid PET/MRI systems are being developed. Peng [142] explored the effect of MR-gradient
switching using a single PET module. They found that count rate attenuation using a single PET
detector was related to the location of the detector in relation to the gradient being operated, the
magnitude of the gradient waveform and the ramp-time of the gradient. Here, we present results
further examining this effect using an intact PET system.
3.6.1 Materials and Methods
Studies were performed using the MR-compatible PET insert. A 68Ge cylindrical source (PET 2.5
C6/0.5, Sanders Medical) was placed in the center of the PET FOV inside a standard RF coil at the
center of the MRI FOV. The PET insert was powered as per the conditions described in 3.4. PET
data were acquired using in-house software [162]. Each dataset was acquired with a buffer size of
5 K and a duration of 300 s.
To examine the effects of individual MRI pulse sequence components on count rates, data ac-
quisition was performed during trapezoidal/sawtooth waveforms set along the Y gradient direction
(TR = 500 ms, no RF pulse was applied). By using electronic TTL gating signals programmed into
the pulse sequence, count rates during specific portions of the pulse sequence were examined (figure
3.34):
1. Gradient off
2. Data acquired during the whole sequence (“Combined”)
3. Gradient on (Set at 20% of the maximum magnitude)
4. During ramping (50 ms risetime)
5. During ramping (10 ms risetime)
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6. During ramping (1 ms risetime)
Decay and duration normalized counts were compared between portions. Three datasets were ac-
quired for each portion. The global coincidence counts as well as the coincidence counts per detec-
tor were recorded. ANOVA with Bonferroni correction was used to analyze the counts data. The
peaks and FWHM for energy spectra of each detector were analysed with Kruskal-Wallis test. No
thresholds were applied to the spectra.
Figure 3.34: MRI gradient effects on count rates. A schematic of different pulse sequences used
to probe gradient effects on PET insert count rates. PET data were acquired at different portions
of the gradient waveform. I. When the gradient was off, II. during the whole pulse sequence, III.
when the gradient is on (here set at 20% of maximum magnitude), during the gradient ramping with
a risetimes of IV. 50 ms, V. 10 ms and VI. 1 ms. Pulse sequences were set with a TR = 500 ms.
Acquistion windows were done within 50 ms (i.e.vertical bars were truncated to clarify the regions,
rather than reflecting the exact timing).
3.6.2 Results
Count rates across all portions are shown in figure 3.35. Consistent with previous results, count rates
were highest when the gradient was off. In the presence of gradient power, global coincident counts
were attentuated (p = 0.06) by 2%–8%. The greatest attenuation occured during rapid oscillation
of the gradient (1 ms risetime, ~8% decrease). Steady-state gradient powering and slower risetimes
showed similar attenuation (~2%–4%). Gradient effects on individual detector counts are shown in
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figure 3.36. Different count rates across detectors were observed due to the different amplification
gains for individual PSAPDs. Count attenuation due to different portions of the gradient waveform
on each detector reflects global observations, with the 1 ms risetime showing the greatest decrease.
In general, no statistically significant interaction between gradient portions and detector locations
was observed (p = 1). However, examination of the individual detectors counts versus gradient por-
tions data by one-way ANOVA revealed the detectors that showed significant or close to significant
decreases during gradient oscillations were those aligned along the Y gradient direction (quadrant
II and IV in figure 3.37, table 3.11). This is consistent with previous results obtained with a single
detector.
Figure 3.35: MRI gradient effects on count rates for the PET insert. Global coincident count rates
for the PET insert under different gradient conditions are shown. No significant differences were
observed. However, the presence of the gradient appears to attenuate the count rate slightly. Error
bars are SD.
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Figure 3.36: MRI gradient effects on count rates for individual detectors. Coincident counts mea-
sured from the PET insert were sorted to relevant detector pair (each count was thus counted twice)
for each gradient pulsing condition. The count variation across multiple detectors is due to the
different amplication gains of individual PSAPDs. The differences between different gradient con-
ditions were generally small (<10%). The greatest count attenuation were observed during rapid
risetimes (~1ms). This was most pronouced for detector 8. Error bars are SD.
Figure 3.37: Orientation of PET detector modules in MRI. The PET insert was orientated within the
MRI as shown for the gradient effect experiments. The axis shows the orientation of the x-y MRI
gradients. The location of each detector (numbered clockwise in Arabic numerals and shown by
slice wedges) is approximated by the wedges. The locations were split into for quadrants (numbered
in Roman numerals and colored) for analysis.
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Table 3.11: Count rate differences across different gradient conditions for individual detectors.
P-values from one-way ANOVA analysis across different gradient conditions are listed, with signif-
icantly different conditions (when applicable) from subsequent multiple comparison analyses.
Detector ID p-value from ANOVA analysis Descriptions of significantly different conditions
1 0.4 –
2 0.2 –
3 0.4 –
4 0.52 –
5 0.29 –
6 0.05 –
7 0.02 1 ms risetime was different to all others
8 <0.01 1 ms risetime was different to all others
9 0.9 –
10 0.01 1 ms risetime was different to all others
11 0.09 –
12 0.23 –
13 0.18 –
14 0.07 –
15 0.4 –
16 0.15 –
Energy spectra information at different gradient conditions for each detector are shown in figure
3.38. No significant differences for both the peak position and FWHM were observed between all
conditions.
3.6.3 Discussion
An important consideration in the design of hybrid imaging systems is the presence of interference
effects that may hinder each individual imaging modality’s performance. Previous studies showed
a decrease in count event rates from the PET insert in the presence of running MR-pulse sequences
(including gradient switching and RF pulsing) [106]. Further studies using a single PET detector
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(a) Energy spectra, peaks, for different gradient conditions (b) Energy spectra, FWHM, for different gradient condi-
tions.
(c) Energy spectra, for different gradient conditions.
Figure 3.38: Energy spectra for different gradient conditions. Error bars are SD.
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module inside the MRI highlighted the effects of gradient strength, switching rates and the location
of the detector in relation to the MR gradients toward this decrease [142]. Here, we extended those
observations by recording counts from different portions of the gradient waveform. This confirmed
that the presence of the MR gradient, whether in a switching or on state, does cause a small but
noticable count attenuation of PET data. Further, increased gradient oscillations showed greater
attenuation. These observations are consistent with the fact that greater count attenuation was seen
for RARE compared to SE [106] and the fact that sequences with longer TR (lower gradient duty
cycle) show less count atteunation.
The interference due to the gradient did not distort the energy spectra, suggesting that the mode
of interference is not pure electrical noise. A possible cause for the interference is the presence
of eddy currents [142, 211]. However, the exact mechanism of this effect remains unknown and
requires further investigation.
Similar investigations with the X and Z gradients, as well as higher (>20%) and longer gradient
on states were not pursued because of difficulties with the temperature control of the PET system in
these situations. Amplication gains of PSAPDs are temperature dependent [212]. While the MRI
and PET temperature controllers can maintain the system’s temperature for regular pulse sequences,
it is unable to maintain temperature stability for prolonged switching of the gradient. Future PET
systems should be more stable [213] and allow further investigations of gradient effects. A corollary
of this finding is that the gradient duty cycle for regular pulse sequences are usually low and thus
results in a small loss of events.
The findings from this and other studies [211] suggest that strategies can be developed to cor-
rect for gradient interference effects. PET data acquired simultaneously with MRI can be gated to
different portions of the pulse sequence corresponding to different gradient shapes. Data acquired
in the presence of the gradient pulse can either be removed or corrected for count attenuation post
acquisition.
RF effects on the PET system were not systematically studied. We observed that RF pulses can
cause low energy noise, saturate PET electronics but not affect count rates (consistent with [211]).
Prudent shielding and grounding of the cables connecting to the RF coil and leading out of the PET
insert, along with proper energy thresholding of PET data eliminated virtually all RF interference
102
effects. These precautions were adopted for all studies described herein.
In summary, we found that PET count attenuation during pulse sequences is directly related to
the presence of the MR gradient. Energy spectra are not degraded during gradient on states, sug-
gesting that counts acquired during these periods do provide useful data provided they are corrected
for attenuation effects.
103
3.7 PET/MRI Informatics Considerations
Multimodal imaging datasets are usually acquired sequentially and integrated posthoc manually.
We describe the database and image file generation system that was used ing all studies described
herein. The system enables almost-automatic integration and processing of multimodal datasets.
The setup allows facile analysis of multimodal imaging data individually or together.
3.7.1 Image Generation
MRI and PET images were reconstructed and processed using their native software. To faclitate
storage and analysis, images were subsequently converted to the open source NIFTI-1 image format
(http://nifti.nimh.nih.gov/nifti-1). Subject, timing and imaging parameter information are stored in
either the filename or the header file.
3.7.2 Storage
Images are stored on a linux server. The following directory heirarchy is defined:
• Subject
– Study day
* Study number
· Type of study (PET/ DCE-MRI/ DWI/ MRI anatomical scans etc...)
· Image files
A screenshot of this heirarchy is shown in figure 3.39.
3.7.3 Integration
The database heirarchy inherently allows different image files acquired from the same study to
be linked. However, this information will be lost if images are transferred to another location
separately. To account for this, we define a unique identifier that is stored in the NIFTI-1 extension
header which permanently links multimodal files from the same study.
The unique identifier is defined by 3 aspects:
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Figure 3.39: PET/MRI database setup. Individual image files (stored as NIFTI-1) are stored ac-
cording to the subject, date and type of data. An example heirarchy for a typical PET/MRI study
subject is shown here. The database is setup on a linux server and implemented using MATLAB.
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1. The native modality, which heads the start of the identifier.
2. Associated modalities, which are listed following the native modality information.
3. The time of image acquisition. The timestamp is defined at image acquisition and encoded
for all linked modalities during NIFTI-1 file generation.
Code to generate this unique idenifier using MATLAB is shown in appendix E.
3.7.4 Discussion
Automatic databasing and integration of multimodal datasets provide several advantages. Firstly,
human error during data processing is minimized. Secondly, the introduction of multimodal imaging
in recent years is now reaching a stage where complete datasets are now beginning to be sufficiently
complex, such that manual analyses are not feasible. Automatic databasing and integration is a step
toward approaches that are now commonplace in bioinformatics. The current database setup enables
the user to analyse simultaneous PET/MRI data easily in real-time, thus harnessing the advantages
offered by the instrumentation. Alternatively, the database also allows the user to analyse large
multimodal datasets easily post-acquistion, since the linkage information is already enocded in the
heirachical setup.
Although each imaging modality may have their own proprietary data format, we chose to adopt
the open source NIFTI-1 format. The format can be read by a number of free image viewers. The
image and header information are also stored as a single file, which is useful for storage and transfer.
A unique identifer to link multimodal images is a compromise between a fully external ap-
proach, whereby a spreadsheet is kept of all the data and an fully internal approach, where this
spreadsheet is kept inside the image header. The identifier is space efficient and contains all the
information that one needs to determine linkage between any two image datasets (type of modal-
ities involved and timing information). The identifier can be stored within the headers of existing
data formats and hence will not impede manipulation with current software. A simple plugin can be
developed on any software platform to read this identifier and link image datasets together during
post-hoc analysis.
In summary, we developed a database system to enable facile processing and integration of
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multimodal datasets. This facilitates the analysis of multi-subject, longitudinal imaging studies that
are being pursued with the PET/MRI system.
107
Chapter 4
Serial Diffusion MRI to Monitor and
Model Early Treatment Response to the
Targeted Nanotherapy CRLX101
4.1 Abstract
4.1.1 Purpose
Targeted cancer nanotherapies are being developed to enhance local tumor therapeutic response.
The nanotherapy CRLX101 (formerly IT-101), has been shown to be effective in preclinical models
and is currently in clinical trials. We evaluated the efficacy of diffusion-weighted magnetic reso-
nance imaging (diffusion MRI) to monitor early response of CRLX101 and to evaluate its potential
as a therapeutic response predictor using a mechanistic model of tumor cell proliferation.
4.1.2 Experimental design
Diffusion MRI was serially performed following CRLX101 administration in a murine lymphoma
model. Apparent diffusion coefficients (ADC) were extracted from the data and used as a treatment
response biomarker. Animals treated with irinotecan (CPT-11) and saline were imaged for com-
parison. ADC data were input into a mathematical model of tumor growth to evaluate its ability
This section is being prepared for publication: Thomas S.C. Ng, David Wert, Hargun Sohi, Daniel Procissi, David
Colcher, Andrew A. Raubitschek, Russell E. Jacobs. (2012) Serial diffusion MRI to monitor and model early treatment
response to the targeted nanotherapy CRLX101.
Acknowledgments: We thank Dr. Thomas Schluep of Calando Pharmaceuticals for providing the CRLX101 (for-
merly IT-101), Dr. Andrey Demyanenko, Desiree Crow, Bita Alaghebandan, and Sonia Collazo for their technical assis-
tance. Drs. Mark Davis, Yun Yen and Scott Fraser gave helpful advice and support. The project was funded by NIBIB
R01 EB000993, NIH R01 EB00194, NRSA T32GM07616, City of Hope Lymphoma SPORE Grant (P50 CA107399),
the Beckman Institute and the Caltech/City of Hope Biomedical Initiative.
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to predict therapeutic response. Histological analysis using cleaved-caspase 3, TUNEL, Ki-67 and
H&E were conducted on tumor samples for correlation with imaging results.
4.1.3 Results
Mean ADC changes for CRLX101 treated tumors at day 2, 4 and 7 post-treatment were 16 ± 9%,
24 ± 10% and 49 ± 17% respectively, which were statistically greater than the controls (p ≤ 0.02)
and noticeably greater than CPT-11 treated tumors (5 ± 5%, 14 ± 7% and 18 ± 6%). Model-derived
parameters for cell proliferation obtained using ADC data distinguished CRLX101 treated tumors
from controls.
4.1.4 Conclusions
Temporal changes in the functional imaging biomarker, ADC, specified early CRLX101 treatment
response and could be used to model image-derived cell proliferation rates following treatment.
Comparisons of different treatments (targeted and non-targeted) highlight the utility of noninvasive
imaging and modeling to evaluate, monitor and predict responses to targeted nanotherapeutics.
4.2 Translational Relevance
Targeted nanotherapies are being developed for cancer treatment. The advantage of these therapies
over conventional treatments lies in their ability to increase drug uptake in tumors while reduc-
ing treatment-related toxicity. The availability of clinically applicable biomarkers will facilitate
the clinical translation of nanotherapies. We evaluated the applicability of diffusion MRI to moni-
tor CRLX101 (a cyclodextrin-based polymer particle containing the DNA topoisomerase I inhibitor
camptothecin) efficacy in a preclinical model of malignant lymphoma. Diffusion MRI distinguished
animals treated with CRLX101 from controls as early as day 2 after treatment. Diffusion MRI also
demonstrated the reduced efficacy of irinotecan compared to CRLX101. Incorporating diffusion
MRI data into a mathematical model of tumor growth allowed prediction of the enhanced antipro-
liferative effect of CRLX101 as compared to the non-targeted agent. These results demonstrate
that serial imaging using diffusion MRI, combined with judicious modeling of imaging data, pro-
vides useful biomarkers to evaluate, monitor and predict the efficacy of targeted nanotherapies in
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the clinic.
4.3 Introduction
Targeted cancer nanotherapies are increasingly being explored as alternatives to conventional thera-
peutics. They have the potential to increase treatment efficacy and reduce treatment-related toxicity
(TRT) through improved tumor drug delivery [22]. Compared to conventional therapies, nanoscale
therapeutics show increased plasma half-life and can localize to the tumor mass via targeting mech-
anisms such as enhanced permeability and retention (EPR) [21, 214]. Recently, the EPR effect has
been coupled with surface functionalization of particles [31] to improve retention in the tumor and
target specific tumor cell subsets. Moreover, evidence exists that nanotherapies can also escape
multidrug resistance pathways since their mode of cellular uptake can bypass P-glycoprotein efflux
pumps that cause resistance to conventional drugs [214].
Nanotherapies may prove to be useful for the treatment of malignant lymphoma. Despite great
advances in lymphoma management, over half of the patient population diagnosed with aggressive
non-Hodgkin lymphoma, 30%–40% with advanced Hodgkin’s lymphoma, and many with indo-
lent lymphoma still develop resistance or relapse of the disease [215, 216, 217]. Several strate-
gies, including the single or combined application of multi-drug chemotherapy, immunotherapy
and radiation-based therapies, are currently being explored as salvage regimens [216, 217]. Impor-
tant considerations during the treatment selection process include the need to minimize TRT to the
patient as well as the need to avoid cross-resistance from first-line regimens [218, 217]. Thus, the
use of targeted nanotherapies offers an interesting therapeutic alternative.
The nanoparticle CRLX101 (formerly IT-101, Cerulean Pharma Inc.) is a conjugate of a b–
cyclodextrin-based polymer and 20(S)-campthothecin (CPT). CPT is a topoisomerase I inhibitor
with a broad activity spectrum. CRLX101 increases the solubility of CPT, keeps CPT in its ac-
tive lactone form, improves CPT tumor localization and minimizes CPT-associated TRT [24, 19].
Preclinical in vivo studies of CRLX101 demonstrated its efficacy in a broad range of solid tumors
[217, 17], including subcutaneous and disseminated xenograft lymphoma models [217]. CRLX101
is currently in phase I and phase II trials for a variety of solid tumors [219].
A major challenge for clinical translation of cancer nanotherapies is the effective evaluation of
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treatment response. Imaging technologies have been used to monitor responses to conventional ther-
apy [220]. Typical methods rely on changes in tumor size [11, 221]. Morphological imaging using
computerized tomography (CT), ultrasound and anatomical magnetic resonance imaging (MRI) can
assess changes in the appearance or growth of tumor masses. However, such changes often occur at
least several weeks after treatment, which may delay useful modifications of the treatment course.
A functional imaging technique, diffusion MRI [222], is being investigated to evaluate therapeutic
responses in animal models [223, 224] and human clinical studies [156, 225]. A quantitative metric
derived from these studies, the apparent diffusion coefficient (ADC), has been shown to be sensitive
to tumor therapy response. Although the diffusion of water within tumors is mediated by many
complex processes, ADC has been demonstrated to be related to tumor cellularity and extracellular
volume [226]. Increased ADC values over the course of a treatment time course are correlated with
tumor treatment response to small molecule chemotherapy [223, 224], adoptive immunotherapy
[227] and photodynamic therapy [33].
Mathematical models of cancer growth have been shown to predict tumor treatment response
on an individual basis. Modeling adds an extra dimension to clinical management by enabling
prospective, patient-specific adjustments of treatment regimens [228, 229]. noninvasive imaging
data have been applied successfully to models of tumor growth and treatment response in brain
[230, 132, 231, 232] and kidney [233] tumors. These studies demonstrate that incorporation of
imaging data into mathematical models of tumor growth can provide insights at the cellular scale
that may elude conventional measures of tumor progression, such as the RECIST criteria [234].
Furthermore, since the efficacy of nanotherapies is a complex function of the drug payload and the
carrier’s interaction with the tumor microenvironment [124], image-based modeling of treatment
response may also provide mechanistic insights into the functioning of nanotherapies in vivo.
The purpose of this study is to determine the feasibility of diffusion MRI to evaluate and pre-
dict early treatment efficacy of the nanotherapy CRLX101. Using a preclinical model of Burkitt’s
lymphoma, we compared the diffusion MRI response of low dose CRLX101 to a high dose adminis-
tration of a water-soluble CPT analog, irinotecan (CPT-11), and to controls. Further, serial diffusion
MRI data were incorporated into a mathematical model of tumor cell proliferation to evaluate its
ability to highlight and predict the antiproliferative activity of CRLX101 in vivo.
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4.4 Materials and Methods
4.4.1 Cell Culture, Animal Model, and Human Lymphoma Xenograft Models
Daudi cells (human Burkitt’s lymphoma line) were obtained from the American Type Culture Col-
lection. Cells were maintained in sterile culture media as previously described [235]. Six to eight
week old female athymic nu/nu mice (Charles River) were injected with 0.2 mL of 1:1: mixture of
tumor cell suspension in 1% human serum albumin in HBSS (Mediatech) and Matrigel (BD Bio-
sciences) subcutaneously into their right groin region. Approximately 3 × 106 cells were injected
for each mouse. Mouse care and experimental procedures were carried out in accordance with pro-
tocols approved by the Research Animal Care Committee at the City of Hope and the Animal Care
and Use Committee at Caltech.
4.4.2 In Vivo MRI Studies
A Biospec (Bruker-Biospin Inc. Billerica, MA) 7 T MRI scanner and a home-built birdcage coil
with an 8 cm axial field of view (FOV) were used for mouse MRI image acquisition. For all
imaging sessions, animals were anesthetized using 1.3%–1.75% isoflurane and body temperature
was maintained at 36°C–37°C with warmed air flowing through the bore. For anatomical imaging,
a rapid acquisition with relaxation enhancement (RARE) MRI sequence (TR/TE = 4000/23 ms;
RARE factor, 4; number of averages, 2; FOV, 35.4 × 35.4 mm2; image matrix, 128 × 128; slice
thickness, 0.754 mm) was used to collect 40 contiguous images across the mouse torso, allowing
tumor visualization.
For diffusion MRI, treatment and therapy monitoring began approximately 21 days post xenograft
inoculation, when tumors reached the size of 300–800 mm3. Tumor sizes were determined from re-
gion of interests (ROI) drawn from anatomical MRI images. On the day of treatment, mice were
either injected with: a) 0.9% saline intravenously (i.v), b) 100mg/kg CPT-11 intraperitoneally (i.p.)
or c) 5mg/kg CRLX101 (i.v.). Anatomical and diffusion MRI scans were acquired immediately
before treatment (day 0, baseline), 2, 4 and 7 days posttreatment. A total of 19 mice were imaged
for this study. Both CRLX101 and control groups contained 7 mice. Within those treatment groups,
N = 3 were imaged on days 0, 2 and 4 and N = 4 were imaged on days 0, 2, 4 and 7. All mice in the
112
CPT-11 group (N = 5) were imaged on days 0, 2, 4 and 7.
Diffusion MRI was acquired with a spin-echo diffusion MRI sequence [69] (TR/TE = 3000/25
ms ; D = 15 ms, d = 3 ms, with three b values = 0, 800, and 1,200 s/mm2 acquired in 3 orthogonal
directions; FOV, 35 × 25 mm2; image matrix, 175 × 125 (zero filled to 256 × 125 ; slice thickness,
0.754 mm). The number of slices acquired in each study was determined by the tumor size to ensure
full coverage of the tumor mass.
ADC tumor maps were generated using these trace diffusion images by fitting to the Stejskal-
Tanner equation [68] using MATLAB. TheS0 images derived from this analysis were used as tem-
plates to segment the tumor region. Segmentation was done manually using MRIcro (http://www.mricro.com).
4.4.3 Modeling Tumor Growth Using Diffusion MRI
A simplified logistic model of tumor growth, developed by Atuegwu et al. [230], was applied to
the dynamic diffusion MRI data in order to estimate tumor cell proliferation rates and tumor cell
numbers. Since it was not possible to spatially coregister tumor images from multiple time points
on a voxel-by-voxel basis, we only considered ROIs based on the whole tumor. Briefly, the model
is defined by
N(t) =
jN(t1)
N(t1)+(j−N(t1))e−kt , (4.1)
where N(t) is the number of cells per tumor voxel at time t, N(t1) is the number of cells present at
t = t1, the first time point in the calculation. k is the cell proliferative rate and j the cell carrying
capacity in the population, here assumed to be the maximum number of cells in the imaging voxel.
If a linear relationship between ADC and cellularity is assumed, ADC can be related to cell number
by
ADC(t)−ADCw
ADCmin−ADCw =
(
N(t1)
j
)
, (4.2)
and derive k and N(t) by combining (4.1) and (4.2) [229]:
ADC(t)−ADCw
ADCmin−ADCw =
(
ADC(t1)−ADCmin
ADC(t1)−ADCw
)
e−kt . (4.3)
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ADCwis the ADC of free water (~3 × 10-3 mm2/s) [236] and ADCmin is the minimum voxel ADC
value in a given tumor.
The ability of the model to calculate tumor growth was tested by calculating Ncalculated(4) and
Ncalculated(7), which were calculated with k values derived from day 0/2 and day 2/4 ADC data
respectively using equation 6. These were compared to Nestimated(4) and Nestimated(7), which were
measured from actual ADC data taken on day 4 and 7 and calculated using equation 5.
The cellular proliferation rate k using a combination of ADC data from different time points
(day 0/2, 0/4, 2/4, 4/7) were also calculated for each individual.
4.4.4 Histological Assessment
A separate group of animals with Daudi lymphoma tumors were prepared for histological compari-
son with noninvasive imaging (N = 24). Animals were divided into control, CPT-11 and CRLX101
groups. The animals were treated identically as those in the imaging studies. At days 0, 2, 4 and
7, animals (N = 2 per time point) from each treatment group were sacrificed by transcardiac perfu-
sion and tumors were excised. Tumors were placed in 4% paraformaldehyde overnight, dehydrated
in 70% ethanol and subsequently embedded in paraffin. Paraffin blocks were sectioned at a slice
thickness of 4 mm.
Paraffin sections were deparaffinized in xylene and rehydrated through a descending gradient of
alcohol (100%, 95%, 80%, 2 minutes at each concentration) and then water.
Antigen retrieval was achieved with 10mM Tris, 1mM EDTA, 0.05% Tween 20 pH9.0 for 20
minutes in a steamer and then cooled for 20 minutes. Individual sections from each treatment cohort
and time point were then incubated with primary antibodies to the cellular proliferation marker Ki-
67 (1:200, Neomarkers, RM-9106-SO) or the apoptotic marker cleaved caspase-3 (1:500, Invitro-
gen, 700182). Immunohistochemistry was performed on a DAKO Autostainer utilizing a peroxidase
DAB method (Leica, Novalink RE7150-K) followed by counterstaining with hematoxylin.
Staining for apoptosis was performed using a terminal nucleotidyl transferase-mediated nick end
labeling (TUNEL) assay (Roche, Insitu Cell Death Detection Kit) and visualized with a peroxidase
DAB method (Leica, Novalink), followed by counterstaining with hematoxylin. Corresponding
sections were also stained with H&E for overall tumor and cellular morphology.
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All slides were scanned on a Ventana Coreo slide scanner for visualization.
4.4.5 Statistical Analysis
Comparison of ADC, tumor size and cell proliferation data among the three treatment groups was
accomplished at each time point using a non-parametric Kruskal-Wallis test. Multiple comparison
tests were performed with Bonferroni correction after a Mann-Whitney test. N(t) data were com-
pared using Pearson’s (PCC) and concordance (CCC) correlation coefficients. A p-value of 0.05 or
smaller was considered to be statistically significant.
4.5 Results
4.5.1 Diffusion MRI is Sensitive to Early CRLX101 Treatment Response
Diffusion MRI was used to quantify the temporal response of the lymphoma microenvironment to
CRLX101, CPT-11, and control treatments in animals implanted with Daudi tumors. ADC maps of
representative tumor response to the various treatment groups are shown in figure 4.1. According to
figure 4.1, ADC values remain relatively constant for the control animal (top row) over the course
of 7 days, with most of the tumor volume having relatively low ADC values (green) at each time
point. A small pocket of high ADC can be seen by day 7, possibly due to spontaneous necrosis as
a result of increasing tumor size. The CPT-11 treated animal (bottom row) showed a similar ADC
map pattern throughout most of the tumor, with low ADC values over a substantial part of the tumor
volume across all time points. On day 2 after CPT-11 administration, clusters of high ADC values
(as indicated by red to orange pixels) can be seen around the edges of the tumor, suggesting CPT-11
response. By day 4 and day 7, small high ADC clusters still existed, but appeared to approximately
the same as were seen on day 2. The ADC map patterning remained similar between day 4 and day
7. Compared to the two other treatment cohorts, the CRLX101 treated tumor (middle row) showed
a steady increase in the ADC value throughout the whole tumor bulk. By day 2 posttreatment, the
whole tumor volume showed an increase in ADC. This trend continued onto day 4 and day 7. These
findings were also observed when visualized with one-dimensional histograms of ADC tumor voxel
distributions (figure 4.2).
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Figure 4.1: Diffusion MRI is sensitive to early CRLX101 response. Representative ADC map of
Daudi tumors are shown as color overlays on T2-weighted anatomic MRI images. diffusion MRI im-
ages were acquired on day 0 (pretreatment), day 2, day 4 and day 7 for control (top row), CRLX101
treated (middle row) and CPT-11 treated (bottom row). diffusion MRI clearly shows an increased
ADC response to CRLX101 throughout the whole tumor mass as early as day 2 posttreatment,
compared to CPT-11 treated and control animals (scale bar = 10 mm).
To compare the diffusion MRI response between treatment groups, the mean percentage change
of ADC values from baseline were calculated and graphed in figure 4.3. CRLX101 treated tumors
clearly exhibited increasing tumor ADC values over the course of 7 days compared to baseline (16
± 9%, 24 ± 10% and 49 ± 17% change from baseline on day 2, 4 and 7, respectively). CPT-11
treated tumors also showed a mean increase in ADC values over the week (5 ± 5%, 14 ± 7% and
18 ± 6%), while control tumors showed a slight decrease in ADC value compared to baseline (-4 ±
3%, -7 ± 3% and -9 ± 3%). Compared to the control group, the increases observed in the CRLX101
group were significant on all days (day 2: p = 0.02, day 4: p <0.01, day 7: p <0.01). This was not
the case for the CPT-11 group (day 2: p = 0.4, day 4: p = 0.05, day 7: p = 0.05).
4.5.2 Diffusion MRI Response Correlates with Traditional Measurements of Tumor
Growth
Drug efficacy is typically measured by analyzing tumor volumetric changes over time. Tumor
volume information was obtained from MRI scans concurrent with diffusion MRI studies. Volume
changes as sorted by treatment cohort are shown in figure 4.4. Control tumors steadily increased in
size during the week time course (25 ± 17%, 49 ± 15% and 130 ± 44% change from baseline on day
2, 4 and 7, respectively), while CRLX101 treated tumors steadily decreased in size (-5 ± 3%, -30 ±
4% and -45 ± 13%). As with the ADC values, size decrease in the CPT-11 treated group was less
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Figure 4.2: Histogram analysis of diffusion MRI. One dimensional histogram of ADC values from
animals treated with (A) saline, (B) CRLX101 and (C) CPT-11 over the course of 1 week are shown.
In a control animal (A), the distribution of ADC values within the tumor remained relatively stable
over the course of the week. In a CRLX101 treated animal (B), a gradual right shift of the ADC
value distribution toward higher values can be observed as early as day 2 and continuing onto day 4
and 7. In the CPT-11 treated animal, the ADC distribution showed a slight right shift toward higher
values by day 4. However, the magnitude of this shift was less than that of observed in (B). The day
7 distribution remained similar to the day 4 histogram. These observations are consistent with the
MR images (figure 4.1), and highlight the efficacy of CRLX101.
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Figure 4.3: ADC changes over treatment week show efficacy of CRLX101. Percentage change of
mean ADC values compared to baseline is graphed for the three different treatment groups over
one week posttreatment. Plots show a significant increase in ADC for CRLX101 treated animals
compared to CPT-11 and control (p <0.001). CPT-11 animals showed a slight increase (p >= 0.05)
in the ADC values over the week compared to baseline, while control animals showed a slight
decrease. CRLX101 treated animals showed an increase in ADC values at all time points, which
was significant on day 2 (p = 0.02), day 4 (p < 0.01) and day 7 (p < 0.01). Error bars denote standard
error.
drastic (-15 ± 5%, -22 ± 13% and -26 ± 8%) compared to the nanoparticle-treated group. The tumor
size decreases in the CRLX101 treated group were not significantly different to control on day 2 (p
= 0.08), but were significant by days 4 and 7 (both p <0.01). In comparison, CPT-11 group tumor
size changes were only significantly different to the control group on day 4 (p <0.01).
4.5.3 Logistic Model of Tumor Growth can be Applied to Diffusion MRI of Malig-
nant Lymphoma
Tumor cell number determined by incorporating diffusion MRI data into a model of tumor growth is
shown in figure 4.5. Ncalculated compared to Nestimatedfor days 4 and 7 are shown in figures 4.5A and
4.5B respectively. The PCC between Ncalculated(4) and Nestimated(4) is 0.92 (p <0.0001). The CCC
is 0.83. PCC and CCC between Ncalculated(7) and Nestimated(7) are 0.91 (p <0.0001) and 0.9. These
values demonstrate a strong relationship between the simulated and estimated data, demonstrating
that the logistic model is applicable to this lymphoma model.
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Figure 4.4: Tumor volume size changes over treatment week. Mean tumor sizes, as measured
from anatomical MRI images, are graphed for the three different treatment groups over one week
posttreatment. CRLX101 treated tumors decreased significantly compared to control tumors over
7 days (p <0.001) and significantly different to CPT-11 tumors on day 7 (p = 0.01). Compared to
baseline, CRLX101 tumor sizes significantly decreased on both day 4 and 7 (p <0.01). Error bars
denote standard error.
4.5.4 Modeling of Tumor Proliferation using Diffusion MRI show Antiproliferative
Activity of CRLX101
Model-derived mean cell proliferation rates (in units of 1/day) measured from different time points
across treatment groups are shown in figure 4.6. Corresponding boxplots are shown in figure 4.7.
CRLX101 treated animals showed negative tumor proliferation rates across all time points (-0.09 ±
0.05, -0.05 ± 0.03, -0.05 ± 0.01 and -0.11 ± 0.05 for day 0/2, 0/4, 2/4 and 4/7 respectively) and were
significantly different (p =0.02) to control tumors (0.03 ± 0.02, 0.02 ± 0.01, 0.02 ± 0.02 and 0.04 ±
0.04). CPT-11 animals (-0.04 ± 0.04, -0.02 ± 0.02, -0.06 ± 0.02 and 0.01 ± 0.01) showed negative
proliferation rates between day 0 and day 4. These were significantly different to controls for rates
calculated between day 2/4 (p = 0.03). Interestingly, proliferative rates in CPT-11 tumors calculated
between day 4 and 7 became positive.
4.5.5 Histological Assessment of CRLX101 Response
Treatment-induced changes observed by diffusion MRI were correlated with histological observa-
tions of tumor response. Tumor sections were stained for activated (cleaved) caspase-3 to moni-
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Figure 4.5: A logistic model of tumor growth can be applied to ADC data. (A) Ncalculated(4) (using
ADC data from day 0 and day 2) is compared to Nestimated(4). The linear fit (with 95% prediction
intervals) is also plotted. The Pearson’s correlation coefficient, r, is 0.92 (p = 0.0001) and the
concordance correlation coefficient, CCC, is 0.83. (B) Ncalculated(7) (using ADC data from day 2
and day 4) is compared to Nestimated(7). r = 0.91 (p = 0.0001) and CCC = 0.9.
120
Figure 4.6: Cellular proliferation rates for different treatment groups were calculated by applying
ADC data to a logistic model of tumor growth. Rates were calculated for (A) control, (B) CRLX101
and (C) CPT-11 animals between day 0/2, day 0/4, day 2/4, and day 4/7. Rates from CRLX101
animals were negative for all time periods and were significantly different to controls (p = 0.02).
Rates for CPT-11 animals were negative between day 0 to day 4, being significantly different to
controls between day 2/4 (p = 0.03). By day 4/7, CPT-11 proliferation rates became positive and
similar to controls. Error bars denote standard error.
Figure 4.7: Boxplots of cellular proliferation rates for different treatment groups calculated by
applying ADC data to a logistic model of tumor growth. Boxplots for (A) control, (B) CRLX101
and (C) CPT-11 animals between day 0/2, day 0/4, day 2/4, and day 4/7 are shown.
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tor apoptotic activity (figure 4.8A). Control tumors showed minimal staining for active caspase-3
throughout the week. In comparison, CRLX101 treated tumors showed a dramatic increase in
caspase-3 activation on day 2. Levels remained increased compared to time-matched control tu-
mors on day 4 and day 7, albeit lower than day 2 cleaved caspase-3 levels. CPT-11 treated animals
also showed a noticeable increase in active caspase-3 levels compared to control tumors on day 2.
CPT-11 active caspase-3 levels were indistinguishable to time matched controls by day 4 and day 7.
Analysis using a TUNEL assay (figure 4.8B) to stain for apoptotic cells by detecting 3´ DNA strand
breaks (a biochemical hallmark of apoptosis) showed similar results. CRLX101 treated tumors
showed an increase in apoptotic cells by day 2 of treatment, which persisted on day 4 and day 7.
CPT-11 treated tumors did not show a noticeable increase in apoptic cells on day 2 post-treatment,
but a number of apopotic cells were observed on day 4 and day 7. By comparison, control tumors
did not show an increase in apoptotic cell staining throughout the week.
Since the active ingredient of CRLX101 and CPT-11, camptothecin, inhibits cellular prolifer-
ation, we also stained tumors using the cellular proliferation marker Ki-67 (figure 4.8C). Control
tumors maintained high Ki-67 expression throughout the week. By comparison, both CRLX101 and
CPT-11 treated tumors showed decreased Ki-67 staining by day 2 of treatment. Ki-67 expression
in CRLX101 tumors decreased steadily throughout the week, while Ki-67 expression in CPT-11
treated tumors on day 4 remained similar to day 2 and were comparable to baseline by day 7.
H&E-stained sections from the control group showed a dense cellular pattern that remained con-
sistent from baseline to day 7 (figure 4.8D). By comparison, CRLX101 tumors showed a gradual
decrease in cellular density over 7 days. An increase in the number of amorphous cells can be ob-
served in day 4 and day 7 tumors. CPT-11 tumor sections show a slight decrease in cellular density
on day 2. By day 4 and day 7, the cellular patterns have reverted to baseline patterning. These
cell density pattern differences between treatment groups were also seen on the other hematoxylin-
stained sections (figure 4.8A–C).
4.6 Discussion
In the current study, diffusion MRI was used to follow the response of a preclinical model of malig-
nant lymphoma to a targeted nanotherapy (CRLX101) and its small molecule chemotherapy coun-
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Figure 4.8: Histological assessment of CRLX101 and CPT-11 response. Tumors treated with
CRLX101 (5 mg/kg), CPT-11 (100 mg/kg) or saline were harvested for histology on days 0, 2,
4, and 7. Tumor samples were subsequently sectioned and stained with (A) Cleaved caspase-3
(costained with hematoxylin), (B) TUNEL (costained with hematoxylin), (C) Ki-67 (costained with
hematoxylin) and (D) H&E (scale bar = 500 µm).
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terpart (CPT-11). As shown in figures 4.1 and 4.3, CRLX101 treatment led to quantifiable changes
in ADC as early as day 2. By comparison, CPT-11 treatment also resulted in detectable changes in
ADC, but was attenuated compared to the CRLX101 treatment. This correlated with tumor growth
kinetics, which indicated that CRLX101 treatment resulted in marked tumor regression while only
mild regression was seen with CPT-11 treatment (figure 4.4). Moreover, diffusion MRI results cor-
related with histology. CRLX101 and CPT-11 treated tumors showed increased apoptotic events by
day 2. Decreased cellularity was observed in both treatment cohorts compared to controls across
the week. A decrease in the proliferation marker Ki-67 was also observed in both treatment cohorts.
This reflects the fact that CPT inhibits cell proliferation and is concordant with previous studies
showing high topoisomerase I inhibition by CRLX101 and CPT-11 within 48 hours of administra-
tion [217]. Taken together, these results confirm the improved efficacy of CRLX101 compared to
small molecule chemotherapy. Furthermore, diffusion MRI was able to demonstrate this improved
efficacy at an early time point.
Other functional imaging techniques are being investigated to monitor early responses in lym-
phoma [221]. Many of these studies involve nuclear imaging, specifically PET. In particular,
18F-fluoro-2-deoxy-d-glucose (FDG-PET) [13, 237, 238] and 3’-18F-fluoro-3’-deoxy-L-thymidine
[239, 240, 107] are promising imaging biomarkers of lymphoma response. Interpretation of nuclear
imaging studies can be complex, as many different physiological processes can result in a positive
signal during treatment. For example, local inflammation following therapy can increase the FDG-
PET signal, masking treatment response [241]. Diffusion MRI readouts are less sensitive to such
inflammatory effects [192]. Concerns of ionizing radiation overexposure, especially in lymphoma
patients who may be exposed to serial imaging scans and/or radiation therapy [242] also necessarily
limits the number of nuclear imaging scans that can be obtained from a patient, especially at early
treatment time points.
Although ADC by itself is already a promising imaging biomarker to indicate tumor response to
CRLX101, the availability of ADC datasets from multiple time points enables mathematical mod-
eling of tumor growth. This potentially allows the prediction of future treatment response in an
individual patient. We applied a simple logistic model of tumor growth [229] to ADC data. The
model makes the simplifying assumption that each imaging voxel consist only of tumor cells and
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that ADC changes are entirely due to the reduction in cellularity; yet it still provides instructive
predictions using diffusion MRI datasets. This was shown by the strong correlation between sim-
ulated (using data from previous time points) and estimated (data from the time point of interest)
tumor cell number at both day 4 and day 7 (figure 4.5). Proliferation rates generated from this model
separated CRLX101-treated and control groups (figure 4.6) and highlighted the enhanced antiprolif-
erative effect of CRLX101 [217]. Analysis of proliferative rates across time points may add insights
to a treatment’s mode of action. For example, consideration of the CPT-11 ADC and tumor growth
data alone through day 7 would indicate that the tumor may still be responding to treatment, albeit
less than with the nanotherapy. However, analysis of the proliferation data indicated that between
day 4 and 7 CPT-11 tumors showed a trend toward positive proliferation rates, suggesting treatment
failure. The latter analysis is consistent with histology; by day 7 the Ki-67 staining in CPT-11 tu-
mors were similar to baseline and control. In contrast, CRLX101 proliferation rates were negative
between day 0 and day 2, increased slightly between days 2 and 4 before decreasing again from
day 4 to 7. This observation is consistent with CRLX101 Ki-67 staining, but is not immediately
apparent from looking at ADC changes alone. The reason for this fluctuation of proliferation rate
is unclear; tumor uptake and biochemical activity of CRLX101 have only been followed for up to
48 hours [217]. It has been suggested that CRLX101 may have antiangiogenic effects and enable
prolonged drug release via hydrolytic and enzymatic cleavage of the cyclodextrin-polymer [19].
Such effects may be synergistic and lead to the increased efficacy observed at later time points.
Techniques that can probe CRLX101’s dynamic antiangiogenic effects within the tumor, such as
dynamic contrast-enhanced MRI [131], may be able to elucidate this process.
Since it was difficult to spatially coregister individual tumor images across time points, imaging
data were only analyzed at a whole-tumor ROI level. Thus, the heterogeneity of the tumor mass,
which may also be an important determinant to treatment response, was neglected. This may be
addressed in future studies by prudent spatial coregistration across time points. Furthermore, the
current model can be integrated into more sophisticated models [208] of tumor growth by incorpo-
rating data acquired concurrently with other modalities (e.g.PET) [201].
In conclusion, we have demonstrated that diffusion MRI can monitor the early response to
CRLX101 treatment in a preclinical model of malignant lymphoma. Modeling of the ADC data
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emphasized the enhanced antiproliferative effect of CRLX101 compared to controls and CPT-11.
This demonstrates the utility of diffusion MRI for preclinical and clinical evaluation of targeted
nanotherapies such as CRLX101 and suggests that an image-driven modeling approach can provide
insights to their mechanism(s) of action in vivo.
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Chapter 5
Imaging the Tumor Response to the
Tumor-penetrating Peptide iRGD
Improvement of drug uptake into the tumor mass is highly desirable. Recently, a tumor-penetrating
peptide, iRGD, has been shown to improve the uptake of a number of different classes of drugs
into the tumor mass without seeming to alter the pharmacokinetics of the drugs in other tissues.
Translation of iRGD to the clinic would be facilitated by a noninvasive assay that can identify
patients sensitive to iRGD. Furthermore, a noninvasive assay may provide further insights into the
in vivo mechanism of iRGD. We hypothesize that iRGD can modulate the uptake of MRI and PET-
visible contrast agents by altering the perfusion characteristics of the tumor. We hypothesize that
this modulation would be visible by DCE-MRI, diffusion MRI and PET.
In this chapter, we present preliminary results of MRI and PET experiments probing the tumor
response to iRGD. The results show that DCE-MRI may be a potentially useful tool to visualize
iRGD response in the clinic. However, further investigations into the effects of iRGD in animal
models of cancer needs to be pursued to build on these results.
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5.1 Introduction
5.1.1 CendR Rule
Teesalu et al. identified a peptide motif (via phage display) which mediated uptake of labelled phage
into a variety of tumor cells [50]. The motif consists of RXXR. They found that this motif needs to
be at the C-terminus of the peptide chain (either endogenously or exposed by enzymatic cleavage)
to be active (thus the CendR rule). Furthermore, they discovered that the motif interacts with the
neuropilin-1 receptor, a mediator in the VEGF pathway [243, 244]. VEGF165A, a potent mediator
of vascular permability, contains the CendR motif. Incorporation of multimeric CendR peptides
increased vascular permeability and uptake of CendR-labelled phage into lung and subcutaneous
tissue. Interestingly, several viruses express the CendR sequence on their membrane and envelope
proteins.
5.1.2 iRGD
CendR peptides have no specific tissue homing ability. Sugahara et al. identified a class of CendR
peptides that contain the RGD motif [48]. The RGD motif has been well characterized to bind to
αv integrins receptors, which are often overexpressed in tumor blood vessels and have been used
to target agents to tumor blood vessels [245, 136]. CendR-containing, internalizing-RGD (iRGD)
peptides, when linked to nanoparticles, phage and micelles increased their tumor penetration signifi-
cantly. In a BT474 xenograft mouse model, iRGD-Abraxane concentration in tumors were increased
10-fold over Abraxane alone.
In a subsequent study, Sugahara et al. further demonstrated that iRGD effects can be mediated
without linkage of the peptide to the agent of interest [49]. Coadministration of iRGD was shown
to increase tumor penetration of a small-molecule doxorubicin, doxoruibin-containing liposomes,
and the antibody trastuzumab. iRGD’s in vivo mechanism of action remains unclear. It is postu-
lated that the RGD motif allows tumor homing. An as yet unknown protease is responsible for the
peptide cleavage, exposing the CendR motif. Interaction of the CendR motif with the neuropilin-1
receptor results in both increased vascular permeability and increased tumor cell uptake of agents.
The contribution of both mechanisms to effective drug uptake remains unknown. Indeed, the ac-
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tion of neuropilin-1 expression in tumors is complex and remains unclear [246, 247]. The exact
timing of uptake efficacy is also unknown, although significant uptake increases of coadministered
agents have been shown within a 30 minute to 3 hour time window post iRGD injection (private
communication, K.S.).
5.1.3 Noninvasive Measures of Vascular Permeability with MRI
DCE-MRI is a commonly used method to evaluate vascular permeability in tumors (see section
2.3.2.2). The majority of DCE-MRI studies focus on either differentiating tumor grades or studying
the vascular modulation as a result of antiangiogenic therapies. Angiogenic factors within tumors
are often dysregulated, favoring neovascularization rather than vessel maturation [248, 249]. As
a result, tumor blood vessels are often tortuous and leaky. The basis behind this is incompletely
understood. However, many studies have shown that increased tumor leakiness, measured by DCE-
MRI, correlates with tumor grade and malignant potential [250, 251, 252]. Permeability has also
been correlated with other tumor microenvironmental factors, such as hypoxia [253].
Folkman hypothesized that cutting off the tumor blood supply is a viable anti-tumor strategy
[254]. This has led to the development of several antiangiogenic and vascular disruptive therapies
for cancer. DCE-MRI has shown potential to monitor the effects of these therapies [255, 221].
Decreases in permeability parameters (e.g.Ktrans) has been demonstrated as a positive biomarker of
antiangiogenic treatment efficacy [256, 131, 257].
For both tumor phenotyping and treatment response scenarios, tumor vascular changes usually
occur over days to months. We hypothesize that iRGD increases the uptake of MRI-visible contrast
agents via an increase in vascular permeability and that this occurs within a short timescale (<30
minutes). Few studies have explored the use of DCE-MRI to measure drug-modulated increases
in vascular permeability, expecially at such a short timescale. Su et al. observed pharmacoki-
netic changes of Gd-DTPA uptake immediately after the intravenous application of angiotensin II,
hydralazine and histamine [258]. Tumor enhancement was decreased in the presence of all three
modulators. Only the vasodilator histamine delayed Gd-DTPA washout. Wang et al. investigated
the hydralazine response using Gd-DTPA-Albumin, observing a decrease in the tumor blood volume
fraction occupied by the contrast agent [259].
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The effect of localized angiogenic stimuli has also been monitored by DCE-MRI. Dafni et al.
observed increased dermal permeability to Gd-DTPA-Albumin in response to intradermal injection
of VEGF165 within 30 minutes of administration [260]. In a separate study, they also showed
that VEGF165 attenuation in tumors decrease Gd-DTPA-Albumin within 48 hours in a C6 cell line
with tetracycline-inducible VEGF expression [261]. Recently, Cartwright et al. also showed in-
creased permeability and vascular changes of urinary bladder tissue in the presence of a VEGF121-
containing graft-matrix over a 3-week period using Gd-DTPA [262]. These results suggest that
tumor permeability increases mediated by iRGD may be probed by DCE-MRI.
5.2 Materials and Methods
5.2.1 Preparation of compounds
iRGD’s structure is described elsewhere [48]. iRGD was synthesized commercially (Bachem) and
lyophilized for long term storage. Aliquots of iRGD for individual studies were made up in 1 × PBS
and stored at –80°C until use. Tests on this material demonstated that iRGD was stable at 4°C for
at least 2 weeks (private communication, A.R.).
Platelet-activating factor (PAF, Sigma-Aldrich, P4904) was diluted with 1 × PBS, aliquoted and
stored at –20°C until use.
5.2.2 Cells and Tumor Models
The HER2-expressing BT474 human breast cancer cell line was cultured in SFM4MAB medium
with 10% fetal bovine serum and penicillin/streptomycin. 17β -estradiol pellets (Innovative Re-
search of America) were implanted subcutaneously into the back of the athymic BALB/c nude mice
one day prior to orthotopic innoculation (6th and 9th mammary fat pad) of 5 × 106cells in matrigel
(BD Biosciences). Tumors were ~2–300 mm3at the time of imaging. Mouse care and experimental
procedures were carried out in accordance with protocols approved by the Research Animal Care
Committees at the Sanford Burham Institute, City of Hope and Caltech.
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5.2.3 MRI-only Studies
A timeline for MRI-only studies is shown in figure 5.1. Before each imaging session, each mouse
is catheterized with a 30G needle attached to PE10 tubing in the tail vein for contrast agent and
peptide administration inside the MRI. Baseline and treatment imaging sessions were separated by
~3 hours to allow adequate washout of CA from the first scan (Gd-DTPA, Magnevist, Bayer, plasma
half-life = 12 minutes in mice).
5.2.3.1 Anatomical MRI
A Biospec (Bruker-Biospin Inc., Billerica, MA) 7 T MRI scanner and a home-built birdcage coil
with an 8 cm axial field of view (FOV) were used for mouse MRI image acquisition. For all imaging
sessions, animals were anesthetized using a 1.3%–1.5% isoflurane/air mixture and body temperature
was maintained at 36°C–37°C with warmed air flowing through the bore. For anatomical imaging,
a RARE sequence (TR/TE = 4000/23 ms; RARE factor = 4; number of averages = 2; FOV = 35.4 ×
35.4 mm2; image matrix = 128 × 128; slice thickness = 0.754 mm) was used to collect 40 contiguous
images across the mouse torso, allowing tumor visualization.
5.2.3.2 T1 mapping
A variable flip angle method outlined in section 3.1.1.3 was used to generate T1 maps. Gradient
echo images (FLASH, FA = 12°, 24°, 36°, 48°, 60°, matrix size = 140 × 80, voxel size = 0.25 ×
0.25 mm2, slice thickness = 1 mm, TR/TE = 200/2 ms) centered on the tumor (3 slices) and the left
ventricle (1 slice) were acquired.
5.2.3.3 DCE-MRI
After T1 maps were acquired, 0.9% saline, 10 nmol/kg PAF or 0.2 mg/mouse iRGD in a volume
of 0.1 mL was injected into the mouse, followed by a 0.1 mL saline chase to clear the catheter.
12 minutes was allowed to elapse prior to starting the DCE-MRI scan. The DCE-MRI time series
were acquired using a gradient echo sequence (FLASH, FA = 35°, TR/TE = 25/2 ms, geometry the
same as the T1 maps, time resolution = 2 s, duration = 22 minutes). After a baseline of 2.5 minutes,
Gd-DTPA (0.1 mmol/kg per DCE-MRI scan) was injected intravenously via the catheter using a
131
powered-injector (New Era Inc., Farmingdale N.Y.) at 0.5 mL/min.
To retain good spatial coregistration between baseline and treatment scans, mice were secured
in the animal holder between the two imaging sessions obtained on the same day. The holder was
placed on a warm electric blanket outside the MRI to keep the mice warm during this period (~3.5
hours, to allow for CA washout). A motorized stage enabled exact repositioning of the holder in
the MRI. Mice were kept lightly anesthesized using ~0.5%–0.7% isofluorane. Lactate Ringer’s
solution (0.15 mL per mouse) was injected subcutaneously halfway through the intersession period
to reduce metabolic acidosis. Mice were kept in their home cage at all other times. All the MRI
scans described above were performed for both baseline and treatment scan sessions. A total of 10
mice were used in this study. Half (N = 5) were treated on the first day with PAF, while the other
half (N = 5) were treated with iRGD on the first day. Treatments were reversed on day 3.
Figure 5.1: Study design for iRGD MRI. Each BT474-bearing mouse was imaged on three con-
secutive days. Each day consisted of two DCE-MRI scan sessions. PAF or iRGD was injected
intravenously 15 minutes before the second DCE-MRI scan on day 1. The alternative treatment was
administered on day 3. Saline was administered on day 2. 3 hours were allow to elapse between
baseline and treatment scans to allow adequate CA washout.
5.2.3.4 Image Analysis
DCE-MRI data were analyzed with the extended Kety model [82]. The model incorporates the
exchange of CA between the extracellular vascular space (plasma) and the tissue extracellular space
(figure 2.3). The influx rate of CA moving from the plasma to tissue space is denoted Ktrans. The
efflux rate from the tissue back to the plasma is related to the extracellular volume fraction ve by
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Ktrans
ve
. Assuming instantaneous homogeneous distribution of CA in both compartments, the model
can be described by
d
dt
Ct(t) = KtransCp(t)− (Ktransve )Ct(t). (5.1)
Ct(t) and Cp(t) are the concentrations of CA in tissue and plasma respectively. The solution to this
equation is
Ct(t) = Ktrans
∫ t
0
Cp(u)e
−(Ktransve )(t−u)du. (5.2)
This equation neglects the vascular volume in the tissue, which may be invalid in pathological
tissues. The model can be extended to include a vascular fraction component vp:
Ct(t) = Ktrans
∫ t
0
Cp(u)e
−(Ktransve )(t−u)du+ vpCp(t). (5.3)
Ct(t) and Cp(t) are obtained from the dynamic time series. ROIs drawn over the tumor and left
ventricle (LV) were used forCt(t) andCp(t) respectively. Signal intensity for each voxel in the ROIs
was first converted to R1 = 1/T1:
R1(t) =
1
TR
ln
(
(S0 sinαe−TE/T
∗
2 )−S(t)cosα
(S0 sinαe−TE/T
∗
2 )−S(t)
)
. (5.4)
R1, TR, TE described previously, α is the flip angle, T ∗2 >> TE , S(t) is the signal intensity
time course and:
S0 = SSS
(1− e−TR/T1cosα)
(1− e−TR/T1)sinαe−TE/T ∗2 . (5.5)
SSS is the steady state average signal intensity before CA administration. R1(t) is converted to
C(t) using the fast exchange limit assumption:
R1 = r1(1−h)C+R10. (5.6)
r1is the relaxivity of Gd-DTPA at 7 T (4.71 s-1 mM-1), h is the hematocrit of a mouse (h = 0.45
based on literature values) and R10 is derived from the T1 map.
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Calculation of Cp(t), the arterial input function (AIF) is a subject of intense investigation. For
this study, we adopted an image-based method similar to Loveless et al. [263]. For our studies,
voxels with SNR <5 at all time points in the LV ROI on each individual dataset were first removed.
Next, each voxel in the ROI was visualized individually. Voxels that do not show a time curve
reflecting plasma uptake (i.e.fast uptake, rapid washout) were further excluded. The remaining
voxels were averaged together to represent the individual AIF for the particular study (AIFind).
Each AIFind was fitted to a model derived by MacGrath et al. [264], described as a mixture of a
Gaussian and an exponential modulated by a sigmoid:
Cp(t) =

0 , t ≤ t0,
∑Nn=1
An
σn
√
2pi e
(
−(t−Tn−t0)2
2σ2n
)
+ αe
−β (t−t0)
(1+e(−s(t−τ−t0))
, t ≥ t0,
(5.7)
where N = 1, An, Tn and σn are the scaling constants, centers and widths of the nth Gaussian; α and
β are the amplitude and decay constant of the exponential; s and τ are the width and center of the
sigmoid respectively. t0 marks the start time of CA injection. The Gaussian constants are related
to the speed of injection and the shape and concentration of the bolus, while the other constants
are related to the decay of the CA in the plasma. We chose this model as opposed to other models
described in the literature because it gave the best visual fit among all the AIFs considered in this
study. Most AIFs showed a maximum peak concentration of approximately 2.5–3 mM, peaking
at approximately 15 seconds post CA injection. The AIFs measured for one mouse on a single
imaging day had peaks at ~1 mM. This resulted in vascular parameters which were, on average,
twice as high as parameters from other datasets. Thus, for consistency, we replaced these AIFs with
an AIF generated from the same animal on the preceding day. Parameters generated from either
AIF did not signifcantly affect subsequent cohort analysis.
The fitted AIF was applied to equation (5.3) to derive Ktrans, ve and vp. Values were fitted for
the averaged whole ROI time curve (global ROI) and voxel-by-voxel using a Levenberg-Marquardt
nonlinear algorithm implemented in MATLAB. For voxel fitting, voxels that did not converge to a
realistic fit (r2 <0, Ktrans ≥ 5, 0 < ve < 1 and 0 < vp < 1), were removed from further analysis.
The second DCE-MRI dataset on each day was compared to the baseline dataset acquired earlier
in the same day.
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A sample AIF and tumor curves from a single dataset (with associated model fits) are shown in
Figure 5.2.
(a) AIF time curve. Raw data in red, model fit in
blue.
(b) Tumor time curve from ROI drawn over the
whole tumor (global ROI). Raw data shown in red,
extended Kety model fit shown in blue. Model fit
used the AIF shown in a)
(c) Sample voxel fits from the same tumor as b). Raw data shown in blue, red line denotes Kety model fit. Data
was fitted with data from the first 10 minutes, but the fit is shown across 12.5 minutes.
Figure 5.2: AIF, tumor time curves and model fits from Magnevist injection.
A semiquantitative metric, the area under the curve (AUC), was also calculated for each global
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ROI and voxel concentration vs. time curve. AUC was calculated using the trapezoidal rule over
the course of 8 minutes post CA injection.
5.2.4 PET/MRI studies
A timeline for the PET/MRI studies is shown in figure 5.3. Mice were setup as per the MRI-only
studies.
Figure 5.3: Study design for Diffusion MRI/PET. Each BT474-bearing mouse was imaged over
the course of 20 hours. Saline or iRGD was injected intravenously 10 minutes before the injection
of 64Cu-DOTA-NHS-Herceptin. Simultaneous PET/ diffusion MRI was performed 3 and 20 hours
after antibody injection.
5.2.4.1 Anatomical MRI
Anatomical MRI was obtained as per section 5.2.3.1.
5.2.4.2 In Vivo PET/MRI
Simultaneous diffusion MRI/ PET was performed with and without iRGD administration. Saline
(N = 3) or iRGD (0.5 mg/mouse, N = 3) at a volume of 0.1 mL was injected i.v. , followed by64Cu-
DOTA-NHS-Herceptin (3–4 MBq/mouse, i.v.) 10 minutes later. 64Cu-DOTA-NHS-Herceptin was
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synthesized as per previous studies [115].
Combined diffusion MRI and PET was obtained 3 and 20 hours post radiolabelled antibody
injection. Anatomical MRI was first done to position the tumor in the center of the PET FOV.
Diffusion MRI was obtained with a spin-echo sequence (TR/TE=3000/23ms, matrix size = 140 ×
80, resolution = 0.25 × 0.25 mm3, slice thickness = 1 mm, 10 slices, d/∆ = 3/15ms, b-values = 0,
300, 1000 s/mm3, 1 direction) and processed as described in section 3.4.3.4. PET was obtained with
a duration of 1200s at the 3 hour time point and 1800s at the 20 hour time point.
An additional 6 mice (N = 3 per cohort) were also imaged with anatomical MRI/PET. Images
were acquired at 1 and 20 hours after antibody injection. PET was obtained with a duration of 600
and 1800 s at the 1- and 20-hour time points respectively.
5.2.4.3 Image Analysis
PET images were processed and calibrated as described in section 3.4.3. PET and anatomical MRI
images were aligned to ADC datasets using the method described in Section 3.2.3.2. Tumor ROIs
were drawn on the anatomical MRI images in order to extract tumor ADC and PET uptake values
(in units of % ID/g). Due to a hardware malfunction during one of the study days, 20-hour time
points PET images were not obtained for 2 saline and 1 iRGD-treated mice. Diffusion MRI were
obtained for those animals.
5.2.5 Histological Assessment
iRGD effects on the uptake of Herceptin were assessed by histology. Mice bearing BT474 tumors
were injected with saline or iRGD (0.5 mg/ mouse) intravenously. This was immediately followed
by an injection of Alexa 633-conjugated Herceptin (0.1 mg, i,v.). Tumor samples were obtained at
1, 3 and 20 hours post Herceptin injection (N = 2 per time point, per treatment). 20 minutes prior
to tumor extraction, FITC-labelled Lycopersicon esculentum lectin (0.15 mg per mouse i.v., Vector
Laboratories) were injected to visualize perfused vessels. Mice were sacrificed by transcardiac
perfusion and tumors were excised. Tumors were placed in 4% paraformaldehyde overnight and
then cryoprotected in a sucrose gradient (10%–30%) over three days. Tumors were then embedded
in OCT (Sakura) and 20 µm cryosections were obtained.
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All tumor slices were stained with DAPI and then visualized using either a 5x/0.15 Ph1 (Plan-
Neofluar) objective on a Zeiss LSM 5 Exciter confocal microscope. Five random FOVs were imaged
from slides containing slices from each tumor to evaluate antibody uptake.
5.2.6 Statistical Analysis
Two-sided paired t-tests were used to compare iRGD or PAF cohorts to the control cohort. A p-value
of 0.05 or smaller was considered to be statistically significant.
5.3 Results
5.3.1 MRI-only Studies
Uptake curves in the tumor were highly heterogeneous (figure 5.4). Thus, we analyzed the tumor
both using global ROI-generated parameter values and on a voxel-by-voxel basis. Voxel-by-voxel
parametric maps for a mouse treated with saline, iRGD and PAF are shown in figure 5.5.
Figure 5.4: Heterogeniety of tumor CA uptake. Curves taken from 3 different ROIs within the tumor
shown in figure 5.2 show that different regions of the tumor (outlined in yellow) show different
uptake kinetics (scale bar = 5 mm).
Mean Ktrans, ve and vpvalues derived from global and whole (mean from voxels fits obtained for
the whole tumor) ROIs are shown in table 5.1. No signifcant differences were observed between
baseline values for all treatment cohorts across Days 1–3, suggesting that administration of PAF or
iRGD on Day 1 of the study did not have dramatic long term (>12 hours) effects on tumor vascular
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(a) Ktrans maps for an individual mouse due to different treatments. An increase in Ktrans was observed after both iRGD
and PAF treatment, mostly around the medial side of the tumor (yellow arrows). In contrast, no dramatic increase was
seen after saline treatment (scale bar = 5 mm).
(b) ve maps for an individual mouse due to different treatments. An increase in ve was observed after PAF treatment
throughout the tumor slice. In contrast, no dramatic increase was seen after saline or iRGD treatment (scale bar = 5
mm).
Figure 5.5: Vascular parametric maps for a single mouse over multiple days.
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parameters and justified the study design.
Table 5.1: Mean vascular parameters for different treatment cohorts for global ROI and whole
ROI (voxels). Standard errors of the mean are shown. All global fits had a r2 value greater than
0.98. Although in both ROIs increases in Ktrans and ve were observed, these were not statistically
significant (p > 0.05).
Ktrans(1/min) ve vp Ktrans(1/min) ve vp
saline 0.1±0.02 0.19±0.03 0.01±0.002 0.1±0.02 0.18±0.02 0.01±0.003
iRGD 0.08±0.01 0.16±0.02 0.01±0.002 0.17±0.06 0.24±0.08 0.01±0.002
PAF 0.08±0.01 0.18±0.03 0.01±0.004 0.17±0.06 0.38±0.17 0.02±0.007
Baseline (AM) 12 minutes posttreatment (PM)
Global ROI
saline 0.13±0.02 0.23±0.02 0.01±0.002 0.12±0.01 0.21±0.01 0.01±0.003
iRGD 0.1±0.01 0.2±0.02 0.01±0.001 0.17±0.04 0.21±0.03 0.01±0.001
PAF 0.11±0.02 0.22±0.03 0.01±0.003 0.2±0.05 0.26±0.03 0.02±0.003
Baseline (AM) 12 minutes posttreatment (PM)
Whole ROI, from voxels
Table 5.1 shows that both iRGD and PAF caused an increase in both Ktrans and ve calculated
from a global ROI and also voxels from the whole tumor (whole ROI). However, neither cohort was
statistically significantly different from the saline cohort. To account for the intersubject variability
of tumor vascular parameters, we calculated the percentage change from baseline of each parameter
for each subject and compared these values. These are tabulated in table 5.2. Again, both iRGD
and PAF cohorts showed increased percentage changes from baseline values for both Ktrans and ve
compared to the saline treated cohort. The PAF cohort showed statistically significant increases in
Ktrans (for both global, p <=0.01 and whole ROI, p <=0.01) and ve (whole ROI, p = 0.02) compared
to the control cohort.
Table 5.2: Mean percentage change from baseline of vascular parameters for both global ROI and
whole ROI (voxels). SEMs are shown. * and ** denote significant differences with the saline cohort
(p <= 0.01 and p = 0.02 respectively).
% change from baseline Ktrans ve vp Ktrans ve vp
saline 14±20 3.7±8.9 78±40 10±16 -1.9±7.4 36±21
iRGD 94±63 32±33 45±20 56±28 4.5±9.4 6.7±9.4
PAF 105±32 * 77±38 137±78 80±25 * 23±10 ** 73±32
Global ROI Whole ROI, from voxels
Heterogeniety of treatment response was probed further by segmenting the tumor. Two seg-
mentation criteria were examined. First, voxels from each tumor were sorted into percentile bins
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according to Ktrans values (e.g.top 10% Ktrans values, top 10%–20% Ktrans values etc.). Percent-
age changes from baseline of both Ktrans and ve for each percentile bin were compared between
treatment cohorts. These comparisons are shown in figure 5.6. Ktrans values after PAF treatment
generally increased across all Ktrans percentile bins. In contrast, Ktrans increases after iRGD treat-
ment were greater for highly enhancing voxels (higher Ktrans bins) compared to the lower enhancing
voxels (low Ktrans bins). Ve increases due to PAF were greater for highly enhancing voxels compared
to lower enhancing voxels, while ve did not change from the baseline for the iRGD cohort.
(a) Ktrans percentage change. (b) ve percentage change.
Figure 5.6: Mean percentage change from baseline, sorted by tumor Ktrans value. Stars (*) denote
that PAF treatment was significantly different to the saline control (p <0.04). Error bars denote
SEM.
Next, voxels from each tumor were sorted based on their distance from the tumor edge, which
was determined based on the ROI mask. Percentage changes from baseline of both Ktrans and ve
as a function of distance from the tumor edge were compared between treatment cohorts. These
comparisons are shown in Figure 5.7. Ktrans increases from the baseline were consistent regardless
of the distance from the edge of the tumor for both PAF and iRGD cohorts. This was also the case
for ve increases observed in the PAF treated cohort.
AUC parameters calculated for the global ROI and the whole ROI are shown in table 5.3 and
table 5.4. While not statistically significant, AUC results showed similar trends to compartmental
modeling results, showing an increase in CA uptake post iRGD and PAF treatment compared to the
saline controls.
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(a) Ktrans percentage change. (b) ve percentage change.
Figure 5.7: Mean percentage change from baseline, sorted by distance from the tumor edge. Stars
(*) denote that PAF treatment was significantly different to the saline control (p <0.04). Error bars
denote SEM.
Table 5.3: Mean AUC calculated over 8 minutes post CA injection for different treatment cohorts
for global ROI and whole ROI (voxels). Standard errors of the mean are shown. Although both
iRGD and PAF cohorts showed increases in AUC, these were not statistically significant (p >0.05).
AUC had units of mM min.
AUCpre AUCpost AUCpre AUCpre
saline 0.16±0.02 0.16±0.02 0.17±0.02 0.16±0.02
iRGD 0.14±0.02 0.21±0.07 0.14±0.02 0.22±0.07
PAF 0.15±0.03 0.32±0.13 0.16±0.03 0.33±0.13
Global ROI Whole ROI, from voxels
Table 5.4: Mean percentage change from baseline of AUCs for both global ROI and whole ROI
(voxels). SEMs are shown. AUC had units of mM min.
% change from baseline AUCGlobal ROI AUCwholeROI
saline 6±10 5±10
iRGD 40±37 42±37
PAF 78±32 77±31
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5.3.2 PET/MRI Studies
PET/MRI images acquired at different time points for saline-treated and iRGD mice are shown in
figures 5.8 and 5.9. A general trend from low to high antibody uptake over time was observed
regardless of treatment. For the particular mice shown, higher antibody uptake in the tumor was
observed at all time points when treated with iRGD. Interestingly, the spatially matched diffusion
MRI images showed that high ADC values were present in the iRGD-treated tumor. Lower ADC
values were present in the time matched saline-treated control.
Figure 5.8: PET/MRI of radiolabelled-Herceptin uptake 1 hour post saline/iRGD treatment and
antibody injection. At 1 hour, most of the antibody was still in the systemic circulation, as demon-
strated by the high activity in the torso. A small but significant increase in antibody uptake within
the iRGD-treated (most of the tumor contained activity at the image threshold level) tumor com-
pared to saline-treated control (half the tumor does not show any activity at the image threshold
level) was observed. Arrow points at the tumor (scale bar = 5 mm).
Mean ADC and antibody uptake values across both treatment cohorts are shown in tables 5.5
and 5.6. Maximum antibody uptake values are shown in table 5.7. No significant difference in mean
ADC values were observed between treatment cohorts at all time points. A 50% increase in mean
antibody uptake in iRGD-treated animals compared to the control animals 1 hour after treatment
and antibody injection (p <0.02) was observed. However, by 3 and 20 hours, no difference was seen
between the two cohorts. No significant difference in the maximum tumor PET uptake value was
observed between the two cohorts at all time points.
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(a) 3 hours posttreatment/ antibody injection in a saline control and iRGD-treated mouse. This particular iRGD-treated
mouse showed high antibody uptake in the tumor compared to the saline control. Correspondingly, the tumor ADC values
were also higher in this mouse compared to the saline control (scale bar = 5 mm).
(b) 20 hours posttreatment/ antibody injection in a saline control and iRGD-treated mouse. This particular iRGD-treated
mouse showed high antibody uptake in the tumor compared to the saline control. Correspondingly, the tumor ADC values
were remained higher in this mouse compared to the saline control.
Figure 5.9: PET/ Diffusion MRI of radiolabelled-Herceptin uptake 3 and 20 hours post saline/iRGD
treatment and antibody injection. This particular iRGD-treated mouse showed high antibody uptake.
However, no significant differences of ADC or PET uptake were observed between the iRGD and
saline cohorts.
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Table 5.5: Mean tumor ADC values at 3 and 20 hours post iRGD treatment. No significant differ-
ences between cohorts were observed. Errors denote SEM.
x10-3mm2/s 3 hours 20 hours
saline 1.27±0.1 1.18±0.1
iRGD 1.22±0.2 1.23±0.2
Table 5.6: Mean tumor PET uptake values at 3 and 20 hours post iRGD treatment. Mean antibody
uptake in iRGD treated animals was significantly higher than controls at the 1 hour time point (*, p
<0.02). Errors denote SEM.
% ID/g 1 hour 3 hours 20 hours
saline 1.62±0.1 6.76±0.1 20.9±2.5
iRGD 2.55±0.2* 7±1.8 18.8±5.7
Table 5.7: Maximum tumor PET uptake values at 3 and 20 hours post iRGD treatment. Errors
denote SEM.
% ID/g 1 hour 3 hours 20 hours
saline 4.25±0.3 8.50±1.5 53.5±8.8
iRGD 6.90±1.1 15.1±7.7 56.6±20.5
5.3.3 Histological Assessment
Sample immunofluoresence images of optically labelled Herceptin antibody are shown in figures
5.10 and 5.11. Qualitatively, iRGD-treated tumors showed higher antibody uptake compared to the
saline cohorts across all time points. However, high antibody uptake was also observed in certain
saline-treated tumors. intratumoral antibody distribution patterns can be also be variable (figure
5.12).
5.4 Discussion
The ability to identify iRGD-responsive patients prior to treatment will facilitate iRGD’s path to
translation and maximize its patient impact. Several approaches can be used for this process. A
tumor biopsy can identify the presence of the putative targets of iRGD, αv integrin and neuropilin-1
receptors. However, information about the heterogeneous spatial expression of these markers, an
important determinant for efficacy [265, 266], may not be available with this technique. More-
over, biopsies cannot be obtained with sufficient time resolution to gauge the efficacy of the iRGD
response (~hours).
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DAPI Antibody
Control
Saline
20 hours
Saline
20 hours
Saline
3 hours
Saline
3 hours
Saline
1 hours
Saline
1 hours
Figure 5.10: Immunofluoresence of antibody uptake with saline. Alexa-633 Herceptin antibody
injected into saline-treated BT474 mice over the course of 20 hours. Tumors were harvested at
various time points post injection. Images were all acquired using the same laser and aperture
settings. Images with the highest antibody signal from each slide are shown on the left. Regions
with lower uptake from the same slide are shown on the right. Some saline-treated tumors did
show high antibody uptake (seen here especially at the 3 hour time point). A control tumor with no
antibody injected is presented. Lycopersicon esculentum lectin signal was variable across all tumors
and thus is not presented (scale bars = 0.2 mm).
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Figure 5.11: Immunofluoresence of antibody uptake with iRGD. Alexa-633 labeled Herceptin anti-
body was injected into BT474 mice with iRGD over the course of 20 hours. Tumors were harvested
at various time points post injection. Images were all acquired using the same laser and aperture
settings. Images with the highest antibody signal from each slide are shown on the left. In general,
an increased uptake of antibody was observed over the course of 20 hours, with more uptake visible
in iRGD-treated animals compared to saline controls. A control tumor with no antibody injected
is presented. Lycopersicon esculentum lectin signal was variable across all tumors and thus is not
presented (scale bars = 0.2 mm).
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Figure 5.12: Tiled images of a BT474 tumor treated with iRGD and Alexa-633 labelled Herceptin
antibody and harvested 3 hours post injection. Distribution of antibodies (red) vary greatly across
the tumor, with several concentrated regions of antibody uptake (blue: DAPI, green: lycopersicon
esculentum lectin, orange: matrigel plug, scale bar = 0.2 mm).
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Noninvasive imaging represents an interesting alternative approach to monitor iRGD efficacy.
In particular, MRI can provide high-resolution images of tumor tissue with no ionizing radation.
Further, dynamic MRI can monitor physiological changes in the tumor in real time.
5.4.1 DCE-MRI
We designed the DCE-MRI protocol used in this study with consideration for its direct clinical ap-
plicability. Gd-DTPA is a clinically approved CA which is widely used to quantitatively evaluate tu-
mor vascular permeability preclinically and clinically and has a short plasma half-life (<12 minutes
in murine models). Since iRGD was shown to improve the uptake of small molecule doxorubicin
[49], we hypothesized that it would also increase the uptake of Gd-DTPA. Pre- and posttreatment
DCE-MRI scans were obtained in the same animal to account for the tumor response variability
between subjects; a critical factor for patient studies. This variablity also motivated the need to treat
the same tumor with all three different conditions. A key assumption made here is that PAF and
iRGD have short acting time windows (<12 hours). We believe that this was reasonable based on
previous reports showing that both PAF and iRGD have high activity within 3 hours of adminis-
tration [267, 49]. Other classes of small molecule vasoactive agents also have short time windows
of action (<3 hours) [258]. Furthermore, the plasma half-life of iRGD in mice is less than 10 min-
utes (private communication, A.R.), suggesting that very little, if any, peptide will be in circulation
more than 12 hours post administration. The fact that baseline DCE-MRI parameters for different
treatments, which were obtained on separate days, did not differ significantly from each other also
supported this assumption. Baseline scans were also obtained to account for intrasubject variabilty
of DCE-MRI parameters over time, since this may change relatively quickly (~days) during the
natural progression of preclinical tumor models [268].
Preliminary DCE-MRI results presented here suggest that DCE-MRI can monitor systemic ad-
minstration of a potent vascular permeability modulating agent. Significant increases in vascular
permeability (Ktrans ) and tumor extracellular volume (ve) compared to saline control were observed
in PAF-treated mice (table 5.2). PAF was chosen as the positive control in this study based on
previous reports describing the ability of localized [269, 270] and systemically adminstered PAF
[271, 267] to increase vascular permeability in a variety of tissues [272, 273]. Moreover, VEGF
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pathway activation has been implicated as a factor for this increase [272, 273]. The neuropilin-1
receptor, which interacts with the cleaved-iRGD product, is also involved in the VEGF pathway
[274, 243, 275, 244], specifically by increasing tissue vascular permeability [276, 277, 246]. We
chose to deliver PAF systemically to mimic the administration of iRGD; the dose was chosen based
on previous reports [271, 267] and preliminary toxicity studies. Increases in both Ktrans and ve are
consistent with PAF’s ability to increase tissue vessel permeability and to cause localized inflam-
mation which would lead to delayed CA washout.
On average, iRGD-treated tumors showed a slight increase in Ktrans above baseline compared
to saline treatment, but this increase was not significantly different. This suggested that a vascular
permeability effect is present, but is lower than that effected by PAF. No observable ve deviations
from baseline was seen. The latter observation suggests that the extracellular space in the tumor
does not expand due to iRGD, suggesting that the CA may be taken up by cells.
Since vascular permeability parameters (and changes compared to baseline) were heterogeneous
throughout the tumor (figure 5.5), we stratified tumor voxels according to the presence of viable
vessels (defined by Ktrans) and distance from the tumor edge. PAF caused a signficant increase in
all Ktrans values across the whole tumor, highlighting its potency. In contrast, Ktrans increases were
greater in iRGD-treated tumors as a function of voxel Ktrans status. Tumor voxels with higher Ktrans
values most likely contain higher density of viable vessels. Thus, increases in vascular permeability
should be most visible in these regions. Ve did not change at the lowest Ktrans voxels, corresponding
to poorly enhancing regions. Ve increases observed for PAF-treated tumors are consistent across
other Ktrans values. We did not observe any trends in Ktrans or ve values as a function of distance
from the tumor edge. Voxels were analyzed only if a reasonable parameters were able to be fitted.
Thus, the matrigel plug and obvious central necrotic regions that are visible in certain tumors were
excluded from analysis.
A semiquantitative metric, AUC, showed similar trends between cohorts as the pharmacokinetic
model parameters. Along with the good model curve fits (figure 5.2), this suggests that pharmacoki-
netic modeling can be applied to the current dataset.
Quantitative DCE-MRI, especially in small animals, is challenging. Several factors can af-
fect the output parameter values. To keep relatively good spatial coregistration between pre and
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posttreatment DCE-MRI data, mice were kept lightly anesthetized in the animal holder between
imaging sessions. Isofluorane is a vasodilator and increases vascular permeability via caveolae
transport [278]. Studies with Gd-DTPA-Albumin showed that anesthesia induction with isofluorane
can cause increased CA extravasation from vessels [279]. A study with a similar protocol as our
study (maintainance of anesthesia using 2% isofluorane for 4–5 hours) did not show a demonstrat-
able Ktrans increases between the two imaging sessions [280]. Caveolae are not necesary for the
hyperpermeable tumor vascular phenotype [281], but their role in iRGD activity remains unknown.
Another confound is the acquisition of the AIF. Image-derived AIF can be corrupted by flow and
motion artifacts. AIFs used in this study were comparable to literature [264, 263]. A population-
based AIF or the use of a reference region based DCE-MRI analysis method [84] can be used to
verify the consistency of these results. The small size and contrast generating mechanism of Gd-
DTPA may also have confounded results. Since tumor vasculature is hyperpermeable, Gd-DTPA
may leak through the tumor vessels regardless of the presence of iRGD. Although not clinically ap-
proved, larger-sized CA such as Gd-DTPA-Albumin may be more sensitive to permeability changes
[282]. Further, the long half-life of such agents may enable the pharmacodynamics of iRGD to be
visualized. Previous results suggest that iRGD may mediate uptake of agents by tumor cells [48].
The lack of obeservable ve increase supports this. Signal intensity changes caused by intracelluar
Gd-agents are significantly attenuated compared to their extracellular counterparts, since the wa-
ter compartment within organelles and the cytoplasm are small and water exchange with external
compartments can be slow [283]. An alternative method of MRI visualization that is less affected
by these issues is the use of R∗2 -agents such as iron oxide particles [284, 78]. Studies using these
different types of agents are being pursued in the lab.
5.4.2 PET/MRI
Sugahara et al. showed that iRGD increased Herceptin uptake in BT474 tumors [49]. Thus, we
hypothesized that this uptake could be observed with PET, coregistered with diffusion MRI. The
DCE-MRI protocol in the MRI-only study was not used here because its MRI gradient requirements
made temperature control of the PET difficult. Diffusion MRI can be sensitive to sudden changes
in vascular permeability [285]. We hypothesized that this technique may also be sensitive to iRGD
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effects.
While certain animals treated with iRGD did show increases in both ADC values and radio-
labelled antibody uptake (figures 5.8 and 5.9), no significant differences were observed for either
biomarker between saline and iRGD-treated cohorts overall. An increase in antibody uptake for
iRGD-treated animals compared to control was present 1 hour post injection, but the difference
was not prolonged into later time points. Unfortunately, no ADC images were acquired with the 1
hour PET images; so no intratumoral structural information was available to guide our PET image
interpretation.
Histological results were variable. Visual inspection of random tumor regions suggested that
slightly higher antibody uptake was present overall in iRGD-treated tumors. Yet there were some
saline-treated tumors that also exhibited high antibody uptake. Antibody distribution showed high
intratumoral variability. A method that allows histological visualization of large tumor volumes,
such as the VIBRA-SSIM technology (D. Koos, S. Fraser, Caltech), would complement current
imaging studies by providing a complete picture of tumor microstructure and intratumoral antibody
uptake.
5.4.3 Conclusions
Preliminary results outlined in this chapter did not show dramatic changes in vascular permeability
(using DCE-MRI) nor antibody uptake (using PET and optical imaging) due to iRGD. Concur-
rent studies using the same mouse tumor model, using luciferase, different radiolabelled agents
(e.g.minibodies) and treatment response as alternative readouts of iRGD reported similar variable
results (private communication, A.R.). Several issues need to be considered when evaluating these
results apart from those discussed above. Firstly, PET and MRI may be too insensitive to the changes
caused by iRGD. If the changes occur in concentrated regions within the tumor, then partial vol-
ume effects may average out the iRGD effects. The heterogeniety of tumor iRGD response, as
observed in the DCE-MRI results presented here, is an important factor that needs to be considered
and may explain the variability of the histology and the results from the communicated treatment
response studies. Secondly, the current iRGD is monovalent. This may not efficiently activate the
neuropilin-1 receptor, since its signalling requires dimerization or multimerization [50]. A mul-
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timeric form of iRGD may interact with neuropilin-1 better than monomeric iRGD and result in
enhanced downstream effects. Another consideration is the applicability of the mouse tumor model
for these studies. Tumor growth in mice are much faster than in humans. Thus, one would expect
the angiogenic process to be quite different to human tumors too. BT474 was chosen as the model
system based on previous reports showing the good neuropilin-1 receptor expression in this cell
line [48] and good iRGD response [49]. However, other investigators reported that BT474 actually
show low neuropilin-1 expression in their hands [286]. Others have also reported that αvβ3 integrin
expression are low in BT474 tumors [287]. This suggests that the development of suitable cancer
mouse models for certain applications remains very challenging. Human tumor pathology and treat-
ment response may be significantly different to their animal counterparts. Of course, our discussion
assumes that the proposed mechanism of action of iRGD is accurate. In light of these results, it will
be important to elucidate and verify iRGD’s mode of action in more basic studies.
Ultimately, the clinical efficacy of iRGD and the applicability of noninvasive imaging to monitor
iRGD effects may only be determined by pursuing human studies. Imaging and analysis techniques
developed in this chapter will be directly applicable to these pursuits.
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Chapter 6
Summary and Future Work
6.1 Summary
Three major contributions were made in this work:
• A small animal simultaneous PET/MRI system was developed to enable robust intratumoral
imaging in vivo.
– We developed image coregistration techniques that align simultaneously acquired PET
and MRI images to subvoxel accuracy.
– We characterized the interference effects between the PET and MRI instrumentation
in the hybrid system. We showed that quantitative, dynamic PET/MRI studies can be
performed with the hybrid PET/MRI system with minimal distortions to either the PET
or MRI images.
– A method was developed to enable the precise spatial coregistration of PET/MRI and
DWBA images obtained from the same animal subject. This method was used to demon-
strate that the hybrid PET/MRI system returns tumor images that are commensurate with
intratumoral activity distributions in the underlying tissue.
• The diffusion MRI technique was adapted to monitor the response of the cancer nanotherapy
CRLX101
– We showed that diffusion MRI is sensitive to CRLX101 response within 2 days of treat-
ment and before significant tumor size changes were observed.
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– Model-based analysis of the diffusion MRI data was able to predict the antiprolierative
effects of CRLX101 and the reduced antiprolierative effect of CPT-11 by comparison.
• PET and MRI techniques were developed to monitor the effects of the tumor-penetrating
peptide iRGD
– DCE-MRI was able to visualize increased vascular permeability and extracellular vol-
ume due to PAF-administration.
– DCE-MRI did not show significant differences in vascular permeability and extracellu-
lar volume due to iRGD-administration.
– PET/MRI studies showed that iRGD responses can be variable and may be tumor growth-
dependent.
6.2 Future Work
6.2.1 Next Steps for Hybrid PET/MRI
Catana and Peng outlined a road map for the potential of hybrid PET/MRI [106, 142]. Since their
discussions, the field of hybrid PET/MRI has grown substantially. In light of the current work, we
elaborate on some of the points they raised and add to the PET/MRI roadmap .
6.2.1.1 Hardware
The major motivation for our work in sections 3.2 and 3.4 is the belief that the availabilty of high-
resolution PET information to synergize with high-resolution information provided by anatomical
and functional MRI will be an important motivator for the adoption of PET/MRI technology. Hard-
ware for next-generation systems will be driven partly by this motivation. Increasing the number
of detectors in the system and incorporating DOI capability to each PET detector will improve the
sensitivity of the system, reduce parallax errors and enlarge the axial FOV. DOI can be implemented
by placing PSAPD detectors on both ends of the scintillation crystal array. Decreasing the scintil-
lation crystal size from 1.5 × 1.5 mm2 to 1 × 1 mm2 can improve the spatial resolution to close to
1 mm at the center of the FOV. The number of detector rings can be increased from 1 to 4. These
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modifications can extend the axial FOV up to 6 cm (sufficient for whole body mouse scans) and
improve the sensitivity of the system to 20%–30% [213]. The enlarged FOV will improve the time
efficiency of small animal PET/MRI studies, as the animal can remain static during the whole study.
Increased sensitivity of the PET system will be very important for combined dynamic PET/MRI
studies since each time bin for these studies will contain low activity counts.
A major challenge towards this goal is to design PET detectors, and a system that house these
detectors, that will fit within the confined space imposed by the MRI system. An obvious solution
is to miniaturize all the parts that are found in the current system. However, the presence of more
electronics in the same volume may amplify the shielding and temperature challenges (e.g.section
3.6) that underlie the current technology. These challenges can only be explored and met as the
next system is being built. Methods developed in this and previous works will aid in evaluating new
systems at each stage of development.
6.2.1.2 Software
Concurrent PET and MRI datasets can be used to improve the data quality of each separate dataset.
Some active avenues of research in this area were outlined in section 2.3.3. One important line of
research is the development of partial volume correction techniques for reconstructed PET images
using MRI information. Current studies are restricted to phantom explorations and/or lack gold
standard verification [288, 289]. The availability of datasets such as those in section 3.4) will be
useful to verify these techniques in in vivo situations.
6.2.1.3 Applications
Widespread adoption of PET/MRI technology will be dependent on the utility of its applications.
There is no doubt that PET and MRI information are synergistic, but as mentioned in section 2.3.3,
it will be the necessity of near-simultaneous PET/MRI data acquisition that will drive hybrid system
development.
Verification of Image-based Models. We used a diffusion MRI-based model of tumor growth to
understand treatment response of a cancer nanotherapy. The model can be improved by introducing
more measurable parameters, which PET/MRI can provide. For example, tumor glycolytic and pro-
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liferation information from 18F-FDG and 18F-FLT images can be fed as the proliferative parameter
in the logistic model [208]. Conversely, the robustness of parameters derived from a unimodal-
ity model (e.g.diffusion MRI only) can be verified with information obtained from the alternative
modality (figure 6.1).
Control 
Treated
Figure 6.1: Simultaneous PET/MRI data can analyzed with image-based models. Availability of
simultaneous PET/MRI data, such as the FDG-PET/diffusion MRI data shown here, can be inte-
grated into multimodal models of tumor growth or be used to verify unimodal models. FDG-PET/
diffusion MRI images were acquired in mice treated with cyclophospamide or saline and followed
over the course of a week. (Scale bar = 10 mm).
Improved PET and MRI quantification. Quantification of PET is challenging and is the sub-
ject of numerous investigations. In section 3.4 we showed that PET images from a small animal
PET/MRI scanner return good quantitative images. This was aided by the fact that attenuation ef-
fects of tissue and bone in small animals on 511 keV photons are minimal. Robust quantiation
of PET images in larger animals and patients requires good attenuation correction. Availability
of temporally and spatially coregistered PET/MRI images will provide accurate anatomical maps
(from MRI) that can be used to correct PET datasets. However, since MRI does not provide direct
measures of photon attenuation, it will be important to determine optimal ways to convert the MRI
data into attenuation maps.
Similarly, quantification of MRI signals can be complex. MRI image intensities can be mod-
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ulated by several mechanisms, ranging from the intrinsic relaxation properties of the underlying
tissue, the type of pulse sequence being used, to the presence of CA. In particular, quantification of
“smart” MRI CAs that are sensitive to physiological changes in vivo would benefit from the avail-
ability of concurrent PET data. The PET data aids the interpretation of the MRI signal changes.
An example of this concept has been shown by Frullano et al., who developed a bimodal PET/MRI
probe that is sensitive to pH [90]. PET imaging of this probe provided its concentration. This
concentration information was then used to normalize the MRI relaxation information to determine
pH.
In chapter 5, we demonstrated the utility of quantitative pharmacokinetic modeling to study
physiological processes. Most kinetic models require an AIF to derive quantitative parameters.
Spatially coregistered MRI images can guide ROI delineation for imaged-derived AIFs for PET
(figure 5.2, [290]). Alternatively, bimodal CAs can be used in conjunction with the hybrid instru-
mentation to allow the AIF to be obtained using one modality (optimized to collect AIF data) while
tissue information can be obtained with the other modality (optimized to collect information from
the tissue).
Real time PET/MRI-guided imaging. The availability of near-perfect spatially coregistered PET/MRI
images will allow one modality to guide image acquisition by the other modality in real-time. For
example, rapid location of tumor metastases by PET can inform the choice of the specialized func-
tional or anatomical MRI imaging sequence, which can vary depending of the location being im-
aged, to pursue in the same study session. Another area of study where real-time analysis of simul-
taneous PET/MRI can have a big impact is in the area of cardiology and peripheral vascular disease.
PET or PET/MRI visible probes targeted to vascular inflammation or early atherosclerotic plaque
formation can be located by PET, followed by high-resolution MRI of the anatomy around the high-
lighted region [186]. These types of studies are not only time efficient, but the combined imaging
technique can be potentially more sensitive and specific than the single modality tests currently
available.
Multimodal studies of uptake and response. The current work developed a PET/MRI strategy
to follow the uptake and response of cancer nanotherapy where simultaneity of image acquisition
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is important. Future studies can build upon the initial results presented here. In particular, PET
insert-compatible DCE-MRI in combination of radiolabelled nanotherapies will allow us to further
understand the interactions between tumor structure and drug uptake. Another realm of inquiry
where multimodal PET/MRI will be useful is the monitoring of immunotherapy. Multimodal im-
munotherapy, such as the combination of in vivo cell and cytokine therapies, act synergistically in
short time scales. Near-simultaneous PET/MRI will be useful here to monitor real-time biodistribu-
tion and interactions between these therapies at an organ-level scale.
6.2.2 Translational Considerations
In this work, we developed noninvasive imaging techniques to understand cancer nanotherapy up-
take and response in the preclinical setting. Unimodal or multimodal preclinical imaging provide
important links between basic biological studies and their clinical application. Ultimately, the
success of these preclinical studies will be gauged by whether they can positively impact patient
care. Simultaneous PET/MRI systems are being introduced in the clinic; the methods and imag-
ing approaches developed here are directly applicable for use in these systems. The diffusion and
DCE-MRI protocols described herein are currently being adopted for clinical trials. It will be very
important in future studies to verify the applicability of these protocols in human patients. Concur-
rently, methods developed in this thesis can be used to match imaging information to volumetric
microscale data (DWBA/histology) and to infer mechanistic insights (via image-based modeling),
both of which can inform the basic development of next-generation therapies.
It is hoped that the techniques and advances described herein will contribute in some way to-
wards the collective effort against cancer.
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Appendix A
A Study of the Timing Properties of
Position-sensitive Avalanche
Photodiodes
This paper describes work done in collaboration with Simon Cherry’s group at the University of
California, Davis. The timing of scintillation signals emanating from different areas of the PSAPD
surface were found to be related to the distance from readout pins. An algorithm was developed
to normalize for this effect for PSAPD detector-based PET systems. I was involved in the setup of
the experimental apparatus to characterize the PSAPD timing properties and contributed software
towards the implementation of the algorithm.
This section is published in Physics in Medicine and Biology: Yibao Wu, Thomas S. C. Ng, Yongfeng Yang, Kanai
Shah, Richard Farrell, and Simon R. Cherry (2009) A study of the timing properties of position-sensitive avalanche
photodiodes. Physics in Medicine and Biology, 54 (17). pp. 5155-5172.
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Abstract
In this paper we study position-dependent timing shifts and timing resolution in position sensitive
avalanche photodiodes (PSAPDs) and their effect on the coincidence window used in positron
emission tomography (PET) systems using these devices. There is a delay in PSAPD signals that
increases as the excitation position moves from the corner to the center of the device and the timing
resolution concurrently worsens. The difference in timing between the center and corner can be up
to 30.7 ns for a 14×14 mm2 area PSAPD. This means that a PSAPD-based PET system could require
a very wide coincidence timing window (>60 ns) if this effect is not corrected, although the individual
crystal pairs still have full-width half-maximum (FWHM) timing resolutions better than 7.4 ns. In
addition to characterizing the timing properties of PSAPDs, two correction methods were developed
and applied to data from a pair of PSAPD detectors. These two timing offset corrections reduced the
timing shift of a crystal pair from 52.4 ns to 9.7 ns or 1.3 ns, improved FWHM timing resolution of
the detector pair from 24.6 ns to 9.5 ns or 6.0 ns and reduced the timing window (sufficient to cover
at least twice the FWHM for all crystal pairs) from 65.1 ns to 22.0 ns or 15.2 ns respectively. A two-
step timing alignment method is proposed for a PET system consisting of multiple PSAPDs. Lastly,
the effect of PSAPD size on the timing performance was also evaluated.
Keywords
photodiodes; photodetectors; instrumentation; PET
1 Introduction
The use of position sensitive avalanche photodiodes (PSAPDs) is emerging as an interesting
alternative to traditional photodetector technology such as photomultiplier tubes (PMT) for
positron emission tomography (PET) detector development (Shah et al., 2004; Catana et al.,
2006; Zhang et al., 2007; Yang et al., 2008). The small size of PSAPD-based detectors
compared to more bulky PMT-based types may be advantageous for use in confined
geometries. Compact detector designs possible with PSAPDs allow for scanner configurations
with increased sensitivity and high and uniform spatial resolution. PSAPDs also have high
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quantum efficiency, a wide spectral response and are insensitive to magnetic fields (Pichler et
al., 2006). Thus, PSAPD-based PET detectors have been adapted for applications such as
depth-of-interaction (DOI)-encoding (Yang et al., 2008) and MR-compatible PET systems
(Catana et al., 2008). Although one of the main advantages of using PSAPDs compared to
conventional avalanche photodiodes (APDs) is the significant reduction in the number of
electronic readout channels, this technology also presents challenges compared to APD- and
PMT-based detectors. The most obvious, though most easily addressed, challenge is the pin-
cushion distortion of spatial positional readout information due to the non-linear fashion in
which charge is shared among the four corner anodes (Shah et al., 2004). Several groups have
proposed both software (Despres et al., 2007; Zhang et al., 2007; Chaudhari et al., 2008) and
hardware (Grazioso et al., 2002; Shah et al., 2002) solutions to correct or account for this
distortion for flood map histogram discrimination. One other notable effect that our group has
observed is the apparent time shift between signals originating from the center of the PSAPD
versus those from the edges or corners. Previous studies have noted a timing shift of up to 25
ns (Catana et al., 2006). This has been attributed to the resistive readout present on PSAPDs.
In order to maintain the high spatial resolution offered by a crystal array setup while capturing
all coincidence events, a wide timing coincidence window of 80 ns is currently used in our
PSAPD-based detectors. Here, we further characterize the time difference of signals originating
from different positions on the PSAPD and explore their dependence on the size of the PSAPD.
Using this information, we propose an approach to correct the timing signal after signal read
out from the detector to the data processing portion of the system. The ability to correct for
this timing shift will improve the timing resolution of a crystal array/PSAPD-based detector
and reduce sensitivity to random events via much tighter coincidence windowing.
2 Materials & Methods
2.1 Timing shift and timing resolution at various locations on PSAPD surface
To determine the timing shift and timing resolution at different locations on the surface of a
PSAPD, an experimental setup was built as shown in Figure 1. A 14×14 mm2 PSAPD was
coupled to three individual LSO crystals each of size 1.43×1.43×6 mm3. The crystals were
polished on all sides and wrapped with teflon tape on five sides except the one coupled to the
PSAPD. The three crystals were placed at three representative locations, corner, edge and
center, using a positioning guide made of teflon. Optical coupling between the LSO crystals
and PSAPD was accomplished using optical grease (BC-630, Saint-Gobain Ceramics &
Plastics, Inc., Newbury, OH). A PMT (R580, Hamamatsu, Hamamatsu City, Japan) coupled
to a single LSO crystal with size of 1.5×1.5×20 mm3 was used as the timing reference. The
separation between the front surfaces of the two detectors was 60 mm. A 22Na point-like source
with activity 23 µCi was placed at the center of the setup.
The signal from the PMT was buffered with a fan-out unit (740, Philips Scientific, Mahwah,
NJ); one output was fed to an ORTEC 584 constant fraction discriminator (CFD) (Advanced
Measurement Technology, Inc., Oak Ridge, TN) and the generated trigger was used for PMT
timing. The delay for the CFD was ~3 ns. Another fan-out output was shaped with a shaping
amplifier (N568B, CAEN Technologies, Staten Island, NY) and fed to a data acquisition
(DAQ) board (PD2-MFS-2M/14, United Electronic Industries, Inc., Walpole, MA). The
shaping time was 1 µs.
Signals from the PSAPD were first amplified with 5 CR-110 charge sensitive pre-amplifiers
(Cremat, Watertown, MA). The cathode signal from the PSAPD was then shaped using a fast
filter amplifier (ORTEC 579) with a differentiation and integration time of 10 ns and fed to a
CFD to generate the timing signal for the PSAPD. The shaped signal from the corner was
observed to have a rise time of 55 ns and fall time of 110 ns and the signal from the center had
a rise time of 80 ns and fall time of 160 ns. The delay for the CFD was ~45 ns. The 4 anode
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signals from the PSAPD were shaped using the N568B shaping amplifier with a shaping time
of 1 µs and recorded by the data acquisition system.
A coincidence trigger was made from the timing signals obtained from the PMT and PSAPD
using a coincidence unit (Philips Scientific 756). The trigger was then delayed and width-
extended using a delay and gate generator (ORTEC 416A) before being sent to the DAQ system
as the trigger. The coincidence timing window 2τ was set to 88 ns where τ was the width of
the trigger signals from the PMT and PSAPD. To ensure correct timing for coincidence
processing, a delay of 72 ns was introduced to the PMT timing signal before being passed to
the coincidence unit to account for the intrinsic timing delay between PMT and PSAPD signals.
The position-dependent timing difference between the PMT and PSAPD was measured with
a time-to-analog convertor (TAC) unit (ORTEC 566). The PMT timing signal was used as the
start signal and the PSAPD timing signal was used as the stop signal. The output was recorded
by the DAQ system. In-house developed DAQ software was used to store the raw data
(Judenhofer et al., 2005).
The timing spectrum for each crystal was generated and analyzed. The centroid of the timing
spectra (with respect to an arbitrary reference time) and the full-width at half-maximum
(FWHM) of the timing spectra (corresponding to the timing resolution) were calculated for
each crystal. The timing shift is defined as the difference in the centroid locations for events
occurring in two different crystals. The CFD thresholds were set just above the noise (~60 keV)
and no software energy windows were applied, either for the PMT or PSAPD signals.
2.2 Timing shift and timing resolution of a crystal array on a PSAPD
A setup similar to Figure 1 was used to measure the timing shift and timing resolution of a
complete LSO crystal array on a PSAPD. The individual crystals on the PSAPD were replaced
with an array consisting of 8×8 crystal elements, where the size of each element was
1.43×1.43×6 mm3. The dimension of the whole array was 12×12×6 mm3 thus it covered 73%
of the area of the PSAPD. The array was centered on the PSAPD with a positioning guide made
of teflon. The single crystal on the PMT was replaced with an LSO crystal array. The crystal
array was composed of 12×12 individual crystals with size of 1.51×1.51×10 mm3 and the size
of array was 19.2×19.2×10 mm3. An LSO array was used on the PMT because it is impractical
to perform the experiment using the movable stage with a point source. The 22Na source was
replaced with a cylindrical 68Ge source and placed at the center of setup. The cylindrical source
had a diameter of 25 mm and a length of 50 mm, and its activity was 71 µCi. A cylindrical
source was chosen to avoid constrained solid angles that might bias the results. The separation
between the front surfaces of the two detectors was 120 mm and the source was placed at the
center of the setup.
The digitized timing and energy data were acquired, and the flood histogram was generated
with the energy data and segmented with a method modified from (Chaudhari et al., 2008).
The timing data were assigned to each crystal based on the crystal lookup table (LUT). Timing
spectra were generated and the shift of the centroid of the timing spectrum and the timing
resolution of each crystal measured. The spectra of the three selected locations closest to the
ones described in Section 2.1 were compared to the results obtained with the individual crystals.
2.3 Timing shift and resolution between a pair of crystal array-PSAPD detectors
The experimental setup shown in Figure 2 was used to measure the timing shift and timing
resolution between two PSAPD detectors. The same 8×8 LSO arrays described in Section 2.2
were centered on the PSAPDs with positioning guides made of teflon. Coincidences were
determined directly from the two detector triggers. The timing window 2τ was 88 ns. A delay
of 64 ns was added to the timing signal of one PSAPD, which was then used as the stop signal
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for TAC. This PSAPD detector is denoted PSAPD1. The other PSAPD detector is used as the
start signal for the TAC and is denoted PSAPD2. The separation between the front surfaces of
the two detectors was 120 mm and the same 68Ge source was placed at the center of setup.
To collect sufficient information for timing alignment, a cylindrical source was chosen which
was large enough to cover coincidence events between all individual crystal pairs. This
measurement does not require that all pairs have exactly the same number of events. If a point
source had been used, the overall timing spectrum might be artificially narrow because only a
few LORs are intersecting the source.
Flood histograms and crystal LUTs were generated from the data acquired. Each event was
assigned to a pair of crystals based on crystal LUTs. The timing spectrum for each pair of
crystals was created and the shift of the timing centroid and the FWHM timing resolution of
each pair calculated. In addition, a corner crystal on PSAPD2 was chosen as a reference crystal
and the shift in the timing centroid and the FWHM timing resolution of all the crystals in the
PSAPD1 detector with respect to this crystal were calculated.
2.4 Timing alignment using PMT-based detector as a reference (Method 1)
To improve the timing resolution of the pair of detectors and therefore reduce the coincidence
timing window required, the timing shift differences between individual crystal pairs need to
be corrected by applying a calibration offset to each pair. All PET systems generate coincidence
events from single events in a coincidence unit, either in hardware or software, either
centralized or distributed. A direct time alignment approach can be implemented in the
coincidence processing unit, during coincidence processing, where the timing shifts of all
crystal pairs are aligned by applying an offset to each crystal pair. However, this approach is
not practical for two reasons. Firstly, the offset lookup table required is large, on the order of
N2, where N is the total number of crystals in the whole system. Secondly, it requires complex
coincidence logic; a wide coincidence window is still needed initially to find all possible
coincidence events. The offset would then need to be applied from the offset LUT. Only at this
point can coincidence events within a narrower coincidence window be selected. In contrast,
a component-based approach can be implemented in either the coincidence or single event
processing units. The difference here from the direct method is that the offset is applied to each
single event using the offset value for the corresponding crystal before forming a coincidence
event.
For the component-based approach, there are two ways to generate the offset LUT. One is to
use a PMT-based detector as a reference, i.e. use the timing offset table derived from the timing
data from a crystal array/PSAPD detector with a PMT-based detector. This would use the data
generated in Section 2.2, and will be called Method 1. Method 2 uses offset tables derived from
timing data obtained from a pair of PSAPD detectors, and is discussed in the next section.
For Method 1, each PSAPD can use either the same timing offset LUT (assumes timing shifts
are invariant across different PSAPDs of the same size) or LUTs can be obtained for each
detector separately (not studied here) in reference to a PMT-based detector. Although each
individual offset LUT includes a fixed value which incorporates the intrinsic timing delay
between the PMT and PSAPD signals, this cancels out if the same offset LUT is used for the
two PSAPDs. A difference between the two fixed values will be included if different offset
LUTs are used. However, this is not an issue for alignment correction because these timing
differences only change the mean value of final timing spectra. This mean value can be
subtracted. Implementation of this is further discussed in Section 4.2.
In a PET system, individual time alignment LUTs can be acquired if the detectors can be
removed for individual measurement or the system has spare readout channels to insert a timing
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probe (Moses and Thompson, 2006) to determine multiple LUTs simultaneously. Here, we
compare the use of a single, common offset LUT applied to both PSAPD detectors (Method
1) versus the use of a unique LUT for each detector (Method 2). The hypothesis is that if the
timing differences are dominated by effects intrinsic to the PSAPD design, then a single
common offset LUT may be sufficient for accurate time alignment. In this case, the two
methods should give similar improvements in timing resolution. All offset tables were applied
with a step-size of 0.3125 ns to mimic the resolution of typical commercial PET electronic
systems (Musrock et al., 2003).
The timing spectra after offset correction were calculated and compared with the results
obtained before correction. A coincidence timing window was calculated that would be
sufficient to cover at least twice the FWHM for all crystal pairs. To calculate the overall timing
window, the left (TWleft,i,j) and right (TWright,i,j) boundaries of the individual timing window
were first calculated for each crystal pair using Equations 1 and 2, where TSi,j is the timing
shift between crystal i from PSAPD1 and crystal j from PSAPD2 forming this pair and
FWHMi,j is the timing resolution. The overall timing window width TWWoverall was then
calculated with Equation 3. For calculating the overall timing window after correction with
Method 1, the timing shift TSi,j was replaced by the timing shift after correction TSi,j−
(TSi,PMT−TSj,PMT).
(1)
(2)
(3)
2.5 Timing alignment using a pair of PSAPD-detectors (Method 2)
Method 2 generates two different LUTs, one for each PSAPD-detector in a pair. This may help
improve the resultant timing spectra because the relative location of the crystal array coupled
to the PSAPD can be slightly different for every detector and the arrays may also have slightly
different characteristics, not to mention the potential timing delay differences between each
PSAPD in the system. Moreover, Method 2 can be implemented without the need to remove
the detectors from a system and without the use of additional electronics channels to attach
external probes.
Two timing offset LUTs were generated from the data obtained with a pair of LSO array-
PSAPD detectors. MTS, the mean value of the timing shifts was first calculated using Equation
4 where TSi,j is the timing shift between crystal i from PSAPD1 and crystal j from PSAPD2
and N is the total number of crystal elements in one detector (here it was 64). The timing offset
values for each crystal i from PSAPD1 (TO1,i) and crystal j from PSAPD2 (TO2,j) were
calculated with Equations 5 and 6. To compare with the results obtained with Method 1, the
offset LUTs were manually shifted to have the same mean value MTS,PMT as Method 1
calculated using Equation 7. As per Method 1, these timing offset LUTs include an arbitrary
fixed mean value MTS,PMT, but this can be subtracted. For each pair, the offset TOPi,j was
calculated using Equation 8 and applied to the timing data.
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(4)
(5)
(6)
(7)
(8)
The timing shifts and coincidence timing window (same definition as in Section 2.4) after
timing alignment correction were calculated and compared with those obtained with no timing
alignment in Section 2.3. For calculating the overall timing window after correction with
Method 2, the timing shift TSi,j was replaced by the timing shift after correction TSi,j−TOPi,j.
2.6 PSAPD size effect on timing
With larger area PSAPDs, more detector elements can be decoded with one photodetector and
less electronics channels are needed per unit detector area. Due to the finite deadspace of the
packaging around PSAPDs, this also increases the packing fraction, potentially increasing the
sensitivity that is of significance for PET applications. However, the timing shift is mainly
caused by the capacitance of the PSAPD and the resistive readout on the anode side that
provides spatial location information. Increasing the size of the PSAPD should increase the
capacitance and cause greater timing shifts between different regions of the PSAPD. To explore
this, we compared the timing shifts measured from a 20×20 mm2 PSAPD to those from a 14×14
mm2 PSAPD, using the methods described in Section 2.1. The signal from a corner crystal had
similar rise time and fall time to those observed with the 14×14 mm2 PSAPD. As the signal
from the center of a 20×20 mm2 PSAPD was very slow (rise time of ~150ns and fall time of
~300ns), the timing shift was studied at two different CFD delays of 45 and 125 ns.
3 Results
3.1 Timing shift and timing resolution at various locations on PSAPD surface
Figure 3 shows the timing spectra at three representative locations on a PSAPD. The timing is
measured relative to the PMT signal, so each centroid includes a fixed value corresponding to
the timing delay between the PMT and PSAPD. The corner position had the fastest signal and
the best timing resolution of 2.3 ns while the center position had the slowest signal and worst
timing resolution of 3.9 ns. The timing shift between the corner and the center crystals was
30.7 ns. Because of this shift, current PET systems using PSAPD technology need a wide
timing window to accept coincident events from all locations across the surface of the PSAPDs.
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This necessarily increases the random events detected as well, decreasing the noise equivalent
count rate (NECR), especially at high count rates.
3.2 Timing shift and timing resolution of a crystal array on a PSAPD
The timing characteristics for each crystal of an LSO array/PSAPD detector in coincidence
with a PMT-based detector are plotted as a spatial distribution map in Figures 4a and 4b. The
timing centroids had a standard deviation of 6.8 ns and the maximum timing shift was 26.9 ns.
For timing resolutions, mean values of 3.4 ns with a standard deviation of 0.3 ns were observed
with a maximum value of 3.9 ns and a minimum of 2.5 ns. The timing spectra for three crystal
locations, corner, edge and close to the center are shown in Figure 4c. In agreement with the
single crystal data, the results showed that corner locations had the fastest signal and best timing
resolution of 2.8 ns and the central locations had slower signals and a worse timing resolution
of 3.5 ns. The timing shift from the corner to center was 23.6 ns. The reduction in timing shift
compared with the single crystal data of Section 3.1 is presumably due to some light sharing
between crystals, which results in a greater spread of the scintillation light once it reaches the
PSAPD surface.
3.3 Timing shift and resolution between a pair of crystal array-PSAPD detectors
The map of the centroids of the timing spectra is shown for each pair of crystals in Figure 5a
and the histogram of these centroid locations is shown in Figure 5b. The 64 crystals in the array
in Figure 5a are numbered horizontally with 1 corresponding to the top left corner, 8 to the top
right corner and 64 to the bottom right corner of the array. The timing centroids had a standard
deviation of 9.5 ns and the maximum timing shift was 52.4 ns. The timing resolution map and
the corresponding timing resolution histogram for each pair of crystals are shown in Figures
5c and 5d respectively. A mean FWHM timing resolution of 5.2 ns with a standard deviation
of 0.6 ns was measured, with a maximum value of 7.4 ns of and a minimum value of 3.0 ns.
The centroid of the timing spectra and the timing resolutions for the crystals in PSAPD1 in
coincidence with one corner crystal of PSAPD2 (opposing to the corner crystal on PSAPD1)
are plotted in Figures 6a and 6b. Three representative locations were chosen and the timing
spectra are plotted in Figure 6c. The results showed that the corner crystal had the fastest signal
and timing resolution of 4.0 ns while the center had the slowest signal and worst timing
resolution of 5.3 ns. The timing shift difference from the corner to the center was 23.8 ns.
3.4 Timing alignment using PMT-based detector as a reference (Method 1)
The timing offset LUT derived from Section 3.2 was applied to both PSAPDs. A map of the
timing centroid for all crystal pairs after offset correction is plotted in Figure 7a (same scale
as Figure 5a) and in Figure 7b (expanded scale). The histogram of the timing centroids is plotted
in Figure 7c. The timing centroids had a standard deviation of 2.3 ns and the maximum timing
shift was 9.7 ns. The measured averaged timing spectra of the pair of arrays before correction
(red line) and after correction using Method 1 (green line) are plotted in Figure 10. The FWHM
timing resolutions of the pair of arrays were 24.6 and 9.5 ns before and after correction
respectively. The required timing window improved from 65.1 ns to 22.0 ns after correction.
From Figures 7a and 7b, it is apparent that using the same offset LUT to correct both PSAPDs
does not align all crystal pairs evenly. The maximum residual timing shift of 9.7 ns is still
greater than the worst FWHM timing resolution of 7.4 ns measured between crystal pairs, thus
these residual timing shifts still are the primary determinant of the timing window. This
suggests that using one LUT is not likely the optimal method for time alignment.
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3.5 Timing alignment using a pair of PSAPD-detectors (Method 2)
The timing offset LUTs generated from the two individual PSAPDs are shown in Figure 8.
PSAPD1 which was used in the LSO array-PSAPD versus PMT measurements had almost the
same offset table as measured previously (Figure 4a) while PSAPD2 had slightly different
behavior (difference up to 4.5 ns), although overall metrics were similar. The timing offset
table of PSAPD1 had a mean value of 89.7 ns, standard deviation of 6.8 ns, a maximum value
of 100.6 ns and a minimum value of 73.8 ns. The timing offset table of PASPD2 had a mean
value of 89.7 ns, standard deviation of 6.7 ns, maximum of 100.3 ns and minimum of 74.8 ns.
A map of the timing centroids for all crystal pairs after correction is shown in Figure 9a (same
scale as Figure 5a) and in Figure 9b with expanded scale. The histogram of these centroids is
plotted in Figure 9c. The timing centroids had a standard deviation of 0.2 ns and the maximum
timing shift was reduced to just 1.3 ns. Compared to the results in Figure 7, no obvious
correction bias to any particular crystal pair was observed in the map. A narrower timing
centroid distribution was also seen. The measured averaged timing spectrum of the pair of
arrays after this timing correction was applied is plotted in Figure 10 (blue line) and the FWHM
timing resolution was measured to be 6.0 ns. The timing window necessary to cover twice the
FWHM timing resolution for all crystal pairs was 15.2 ns.
The results without correction and with the two time alignment correction methods are
summarized in Table 1. The timing resolutions of individual crystal pairs were the same with
and without correction. The difference between the maximum and minimum of the timing
centroids after correction was significantly reduced from 52.4 ns to 9.7 ns or 1.3 ns respectively,
and the FWHM timing resolution was improved from 24.6 ns to 9.5 ns or 6.0 ns respectively.
The timing windows that could be applied were reduced from 65.1 ns to 22.0 ns or 15.2 ns
respectively. The correction with one offset table for each PSAPD (Method 2) gave better
results than one offset table for all PSAPDs (Method 1).
3.6 PSAPD size effect on timing
Using a 45 ns CFD delay, the results from a larger 20×20 mm2 PSAPD are plotted in Figure
11a. The center and edge crystals had very broad and asymmetric timing spectra with a FWHM
of up to 13.9 ns. The left bump observed in the timing spectra of the center crystal in Figure
11a is probably caused by triggering on noise and the right bump is likely due to energy-
dependent walk when the CFD operates as a leading-edge discriminator for low energy events.
With a 125 ns CFD delay (Figure 11b), all three crystals had narrow timing spectral peaks and
had timing centroids of 145.4, 196.5 and 224.7 ns and FWHM of 3.3, 9.0 and 10.7 ns
respectively. Compared to the 14×14 mm2 PSAPD, the 20×20 mm2 PSAPD had a similar
timing shift effect but the magnitude of both the offset of the centroids and the FWHM were
greater. These results suggest that a 45 ns CFD delay was not enough to resolve signals arising
from the crystal at the center of the 20×20 mm2 PSAPD. This signal required a longer CFD
delay for proper peak resolution.
4 Discussion
4.1 Comparison of timing shift and timing resolution in different experimental setups
Moving from individual crystals (Figure 3) to crystal arrays (Figure 4c), the timing shift was
reduced, from 30.7 ns to 23.6 ns, and the timing resolution degraded slightly for a crystal located
at the corner (from 2.3 ns to 2.8 ns), while there was a small improvement in timing resolution
for crystals located on the edge or at the center (from 3.7 ns to 3.5 ns and 3.9 ns to 3.5 ns
respectively). This is presumably due to effects of light sharing within the crystal array that
results in a greater spread of the scintillation light once it reaches the PSAPD surface. The
exact positioning of the crystal with respect to the PSAPD surface may also contribute to the
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small differences in timing resolution. Comparing the timing resolution obtained using a PMT
reference (Figure 4c) to that obtained using one corner crystal on PSAPD2 as a reference
(Figure 6c), the timing resolution became worse due to the lower timing resolution of the
reference crystal (2~3 ns) and possible scattering (causing event mispositioning) in the crystal
array on PSAPD1. The timing shift however remained almost the same, 23.6 ns and 23.8 ns
respectively.
4.2 Implementation of timing alignment in an intact detector system
Timing alignment methods have been reported by several groups to improve timing resolution
in detectors (Lenox et al., 2007) or systems (Lenox et al., 2006; Moses and Thompson,
2006). Because of the large timing shift in the PSAPD and potential integration with a MR
system, these methods cannot be directly implemented in a PSAPD-based system. The timing
correction/alignment described in Method 2 can however be implemented in a system with
multiple PSAPDs in two steps: the first step is to determine the offset LUT for each PSAPD
detector; this is followed by an alignment between the LUTs for all the detectors in the ring.
The first step is shown in Figure 12a and can be performed in sequential pairs. In the single-
ring configuration shown, there are 16 PSAPDs that are divided into 8 directly opposing pairs.
The method described in Section 2.5 can be applied to each pair of PSAPDs. The mean value
of each LUT can be subtracted to generate individual offset tables.
The second step is to time align the offset LUTs between all the detectors in the ring. As shown
in Figure 12b, this can be achieved by choosing one PSAPD detector as the reference. In the
figure, PSAPD #1 is selected as the reference and the residual offset of PSAPD #2 compared
to PSAPD #1 can be calculated by acquiring coincidences between detectors 1 and 2 after
applying their individual offset tables. The offset of PSAPD #3 can be obtained by using #2
as reference, and so on. The source should be placed at the center as precisely as possible to
minimize measurement error. After all 16 offsets are obtained, the mean value of these 16
offsets can be subtracted to generate a unique residual offset value for each PSAPD in the ring.
By adding this residual offset value of PSAPD to the offset table of each PSAPD, the final
offset table for the system calibration can be achieved. The second step can be easily extended
to apply to multiple-ring systems.
4.3 PSAPD size effect
Using a long CFD delay (125 ns) gave reasonable timing resolution across the surface of 20×20
mm2 PSAPD, but it also caused energy thresholding problems, as shown in Figure 13a and
13b. For a CFD delay of 45 ns, the effective energy threshold for the corner was slightly higher
than the edge and center, albeit still sufficient for adequate thresholding for a PET system. For
a delay of 125 ns however, the effective threshold for the corner is much higher than the center
despite having similar photopeak energies. The reason is that the constant fraction (CF) signal
comes later than the duration of the thresholded signal for low energy events and therefore it
is not triggered. This non-uniform response across the surface of PSAPD may cause
normalization and/or random subtraction problems. The higher effective threshold associated
with the longer CFD delay forces the PSAPD to work at very low threshold level, increasing
the count rate and false triggers which have effects on dead time. Thus using larger PSAPDs,
there is a challenge in simultaneously obtaining good energy and timing resolution because it
is hard to find a CFD delay that is good for both measures. The proper functioning of a CFD
relies on pulses varying only in amplitude, not in shape. But this is not the case in PSAPDs. A
short delay did not provide good timing resolution because of the high noise associated with
the signal. We are therefore exploring other techniques, including non-cable delay CFD
(Binkley et al., 2002) and other signal processing techniques, for these large-area PSAPDs.
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Another effect that can be seen from Figure 13 is the shift of photopeak and this is due to the
sampling in the DAQ. The DAQ digitizes only one peak value for each signal per event and
the sampling position is determined by the DAQ trigger which is a delayed version of the
coincidence trigger. A shift in the trigger location caused the shift in energy photopeak,
however this is not an issue as each individual crystal is calibrated using its own photopeak.
In Figure 13a, the relatively small fraction of events that exhibit energy-dependent walk and
the relatively small magnitude (up to 30 ns) of that walk does not have a significant effect on
energy spectra in our studies because of the long shaping time used (1 µs).
5 Conclusions & Future Work
The position-dependent timing shift and timing resolution of PSAPDs were studied and two
methods to correct these phenomena were described. Moving from the corner to the center of
a PSAPD, the rise time of the signal becomes slower and the timing resolution worsened. Larger
area PSAPDs magnified this effect. Correction of this effect using one offset lookup table
derived from events acquired between an LSO array/PSAPD detector and a PMT reduced the
timing shift and improved the timing resolution, thus allowing the coincidence timing window
to be tightened. Using individual offset tables derived for each individual PSAPD the shift was
further reduced. This additional improvement was probably because of the other contributions
to the timing shift in addition to the intrinsic effect of PSAPD design, such as positioning of
crystal array or unique characteristics of each crystal array. The timing correction methods
described in this study can be applied to whole detector systems with multiple PSAPDs using
a two-step algorithm. Future studies will involve applying these correction methods in novel
PSAPDs detector systems. Further work is needed to determine the optimal detection
electronics for larger area PSAPDs where the changes in signal shape across the face of the
PSAPD make it hard to simultaneously achieve good timing and energy resolution.
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Figure 1.
Experimental setup for timing measurements of a PSAPD-based LSO detector in coincidence
with a PMT-based LSO detector.
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Figure 2.
Experimental setup for timing measurements of two PSAPD-based LSO detectors in
coincidence.
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Figure 3.
Timing shift and resolution at three locations on the surface of a PSAPD.
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Figure 4.
Spatial map of (a) the centroids of timing spectra (ns) and (b) the timing resolution (ns) for the
whole array and timing spectra (c) for crystals at three representative locations on the PSAPD
(comparable to the locations in Figure 3).
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Figure 5.
Crystal-crystal map of (a) centroids of timing spectra, (b) histogram of centroids, (c) map of
timing resolution and (d) histogram of timing resolution for all crystal pairs.
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Figure 6.
Spatial map of (a) centroids of timing spectra (ns), (b) timing resolution (ns) of crystals in
PSAPD1 with respect to corner crystal in PSAPD2 and (c) timing spectra for three
representative locations.
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Figure 7.
Crystal-crystal map of timing centroids plotted (a) on same scale as Figure 5a and (b) on
expanded scale, and (c) histogram of timing centroids after time alignment correction with
Method 1.
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Figure 8.
Timing offset LUTs of (a) PSAPD1 and (b) PSAPD2 used for correction Method 2.
Wu et al. Page 19
Phys Med Biol. Author manuscript; available in PMC 2010 September 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
178
Figure 9.
Crystal-crystal map of timing centroids plotted (a) on same scale as Figure 5a and (b) on
expanded scale, and (c) histogram of timing centroids after time alignment correction with
Method 2.
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Figure 10.
Measured averaged timing spectra (over all crystal pairs) without (red line) and with timing
offset correction Method 1 (green line) and Method 2 (blue line).
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Figure 11.
Timing spectra obtained from 20 × 20 mm2 PSAPD with CFD delay of (a) 45 ns and (b) 125
ns.
Wu et al. Page 22
Phys Med Biol. Author manuscript; available in PMC 2010 September 7.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
181
Figure 12.
Timing alignment scheme: to generate offset map for each individual PSAPD (a) and between
PSAPDs (b). The cylinders in (a) and (b) represent the sources. The rectangles in (a) represent
the regions covered by the opposing detector pairs. The lines with arrows in (b) show the
calibration sequence, starting from PSAPD #1 and ending at #16. The lines from #5 to #15 are
omitted for clarity.
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Figure 13.
Energy spectra obtained from 20×20 mm2 PSAPD with CFD delay of (a) 45 ns and (b) 125
ns.
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Appendix B
Receptor-targeted Iron Oxide
Nanoparticles for Molecular MR
Imaging of Inflamed Atherosclerotic
Plaques
This paper describes work done in collaboration with Angelique Louie’s group at the University
of California, Davis. The work involved the development of a novel iron-oxide based nanoparticle
that targets macrophages in vulnerable atherosclerotic plaques. Improved chemistry and functional-
ization (via sulfation) of the particle surface enabled improved plaque targeting compared to a first
generation particle. I was responsible for the design, acquisition and analysis of the in vivo studies.
This section is published in Biomaterials: Chuqiao Tu, Thomas S. C. Ng, Hargun Sohi, Heather A. Palko, Adrian
House, Russell E. Jacobs, and Angelique Y. Louie (2011) Receptor-targeted iron oxide nanoparticles for molecular MR
imaging of inflamed atherosclerotic plaques. Biomaterials, 32 (29). pp. 7209-7216.
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In a number of literature reports iron oxide nanoparticles have been investigated for use in imaging
atherosclerotic plaques and found to accumulate in plaques via uptake by macrophages, which are
critical in the process of atheroma initiation, propagation, and rupture. However, the uptake of these
agents is non-specific; thus the labeling efficiency for plaques in vivo is not ideal. We have developed
targeted agents to improve the efficiency for labeling macrophage-laden plaques. These probes are based
on iron oxide nanoparticles coated with dextran sulfate, a ligand of macrophage scavenger receptor type
A (SR-A). We have sulfated dextran-coated iron oxide nanoparticles (DIO) with sulfur trioxide, thereby
targeting our nanoparticle imaging agents to SR-A. The sulfated DIO (SDIO) remained mono-dispersed
and had an average hydrodynamic diameter of 62 nm, an r1 relaxivity of 18.1 mM1 s1, and an r2
relaxivity of 95.8 mM1 s1 (37 C, 1.4 T). Cell studies confirmed that these nanoparticles were nontoxic
and specifically targeted to macrophages. In vivo MRI after intravenous injection of the contrast agent
into an atherosclerotic mouse injury model showed substantial signal loss on the injured carotid at 4 and
24 h post-injection of SDIO. No discernable signal decrease was seen at the control carotid and only mild
signal loss was observed for the injured carotid post-injection of non-sulfated DIO, indicating preferential
uptake of the SDIO particles at the site of atherosclerotic plaque. These results indicate that SDIO can
facilitate MRI detection and diagnosis of vulnerable plaques in atherosclerosis.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death in the
western world and its prevalence is expected to increase further
during the next 3 decades [1]. Increasing evidence indicates that it is
atherosclerotic plaque rupture rather than the severity of vessel
occlusion that leads to major adverse events, such as stroke and
myocardial infarction [2,3]. Early detection of unstable plaques
would be of great value to guide treatment decisions, with the aim to
decreasemorbidity/mortality in affected patients. There is an intense
focus in the field to identify specific biomarkers that indicate a pla-
que’s risk for rupture and develop noninvasive methods to detect
those markers [1,4,5]. Magnetic resonance imaging (MRI) has played
a prominent role in anatomical and functional examinations of the
major vessels; however, without signal enhancement, the technique
lacks sufficient sensitivity to directly detect and identify biomarkers
of interest [6,7]
Recent advances in the development of MRI contrast agents
(CAs), which specifically target relevant biomarkers and enhance
images to generate sufficient contrast in tissues and organs of
interest, allow MRI to visualize molecules and molecular events
occurring at a cellular level [6,8]. However, the amount of
biomarkers in the cardiovascular system is usually expressed in the
low nanomolar range (109 mol/g of tissue), which is below the
detection sensitivity of routinely used gadolinium chelates
(107 mol/g of tissue). Particle-based technologies provide an
effective method to concentrate signal-generating materials into
a relatively small entity, which can greatly improve their detect-
ability (1010 - 1011 mol/g of tissue) in vivo [7,9,10]. Moreover, the
particle CAs have a large surface areas, allowing them to display
more targeting ligands, further enriching the CAs at the region of
interest (ROI).
Non-toxic and biocompatible iron oxide nanoparticles (IO NPs)
have been widely used as MRI CAs in the clinic [11]. IO NPs,
* Corresponding author. Tel.: þ1 530 7527134; fax: þ1 530 7527156.
E-mail address: aylouie@ucdavis.edu (A.Y. Louie).
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however, are generally non-specific; they show a differential
distribution in the body based primarily on relative tissue perme-
ability. We are interested in the development of IO NP CAs that
target biomarkers of atherosclerotic plaques. In the search for
markers to identify high-risk plaque, macrophages have been found
to correlate with plaque stability — plaques with high macrophage
content tend to be more unstable, and the distribution pattern for
the macrophages can be indicative of degree of stability [12,13]. IO
NPs have been used for MRI detection of plaques in pre-clinical
experiments using different animal models of atherosclerosis, and
the results showed that these particles accumulate in plaque
macrophages [14]. However, the uptake of IO NPs by macrophages
is non-specific through phagocytosis. This is an inefficient process
that provides relatively weak contrast between the plaque and
surrounding tissues [15]
We have previously developed CAs based on the scavenger
receptor type A (SR-A) targeting ligands maleylated BSA and
dextran sulfate [16e18]. SR-A is highly expressed on activated
macrophages and not found on normal vessel walls [19]. These
probes labeled atherosclerotic plaques with improved efficiency
over non-targeted probes. However, it was difficult to obtainmono-
dispersed IO NPs by synthesizing them using either dextran sulfate,
or a combination of dextran sulfate and dextran, as a starting
materials to form the coating [20]. In this work, we introduce a new
synthetic method in which we coated IO NPs with dextran (DIO),
then sulfated the dextran coating of the particles to make dextran
sulfate coated IO NPs (SDIO). The ability of SDIO to target macro-
phages in vitro and to detect and access macrophages in athero-
sclerotic plaque in vivo was evaluated by MRI.
2. Materials and methods
2.1. Materials
Materials were obtained from commercial suppliers and used directly, unless
otherwise noted. Dextran (from leuconostoc, average mol. wt. 9000e11,000) and
ferric chloride hexahydrate (FeCl3$6H2O, Fw 270.29 g/mol) were purchased from
Sigma-Aldrich. Ferrous chloride tetrahydrate (FeCl2$4H2O, Fw 198.81 g/mol) and
dextran sulfate (sodium salt, prepared from dextran from leuconostoc SSP., average
mol. wt. 5000) were acquired from Fluka. Ammonium hydroxide (28e30%), sodium
bicarbonate and sodium hydroxide were provided by Fisher Scientific. Sulfur
trioxide (SO3) pyridine complex, sulfur trioxide DMF complex and 2-methyl-2-
butene (2M2B) were purchased from Acros. Anhydrous formamide was purchased
from MP, Biomedicals, LLC. Spectra/por dialysis membrane (mol. wt. cut-off
50,000) was purchased from Spectrum Laboratories, Inc. P388D1 cells and RPMI-
1640 medium were obtained from American Type Culture Collection (ATCC). Fetal
bovine serum (FBS), L-glutamine, PBS (1X) and C12 e Resazurin were provided by
GIBCO. Lipoprotein deficient bovine serum (LPDS) was obtained from Biomedical
Technologies, Inc. (Stoughton, MA). Water was purified using a Millipore Milli-Q
Synthesis purifier (18.0 MU cm, Barnstead).
2.2. Synthesis of dextran sulfate coated iron oxide nanoparticles
Dextran coated iron oxide nanoparticles (DIO) were synthesized as previously
reported [20]. The DIO (200 mg) was dissolved in 10 mL of dry formamide. After
complete dissolution, 2-methyl-2-butene (2M2B) (1.6 mL, 15 mmol) was slowly
added to the flask under argon atmosphere and magnetic stirring. A SO3pyridine
complex (0.32 g, 2 mmol) was rapidly added, and the reactionmixture was stirred at
30 C under argon atmosphere for 2 h. The reactionwas quenched by slowly pouring
it into 7 mL of saturated sodium bicarbonate solution. After the final product was
concentrated, the residuewas dissolved inwater andwas dialyzed against deionized
water in a dialysis bag with molecular weight (MW) cut-off of 50,000 Da for 72 h
(8e10 changes of water). The solution was lyophilized to give a brown solid.
2.3. Characterization of SDIO
The iron oxide core size of SDIO and DIO were measured by transmission
electron microscopy (TEM) on a Philips CM-12, operating at 80 kV. The average
hydrodynamic particle size and size distribution of SDIO and DIO were measured
using dynamic light scattering (DLS) with a Nanotrac 150 particle size analyzer
(Microtrac, Inc., Montgomeryville, PA). The zeta potential (z) values of SDIO and DIO
were measured by determining the electrophoretic mobility using a NICOMP 380
ZLS device (Particle Sizing Systems, Inc., Santa Barbara, CA, USA) in deionized water
at room temperature. Elemental analysis was performed by Columbia Analytical
Services of Tucson, Arizona. FT-IR spectra were collected on a Shimadzu IR Prestige
21 spectrophotometer.
Longitudinal (T1) and transverse (T2) relaxation times were measured at 60 MHz
(1.4 T) and 37 C on a Bruker Minispec mq60 (Bruker, Billerica, MA). Three stock
solutions of SDIO were prepared by dissolving appropriate amounts of particles in
pH 7.0 deionized water. The concentration of iron was determined by ICP-MS. The
stock solutions were diluted to give three series of aqueous solutions with
decreasing iron concentration (0.3 mL each). All solutions were prepared by weight.
Iron concentrations were calculated based on the concentration of the stock solution
and appropriate dilution factors. T1 values were measured using an inversion
recovery sequence with 10e15 data points and T2 values were measured using
a CarrePurcelleMeiboomeGill (CPMG) sequencewith s¼ 1ms, and 200 data points.
Each solution was incubated at 37 C for 10 min before measurement. The longi-
tudinal (r1) and transverse (r2) relaxivity were determined as the slope of the line for
plots of 1/T1 or 1/T2, respectively, against increasing iron concentration with
a correlation coefficient greater than 0.99 [21]. The relaxivity of DIO was measured
by the same procedure. The T1 and T2 relaxation times of cell lysates containing SDIO
or DIO were also measured with the method described above.
2.4. Cell experiments
2.4.1. Cell culture
The P388D1 cells were maintained in tissue culture flasks (75 cm2) in media
(RPMI-1640 with 1% L-glutamine and 10% fetal bovine serum (FBS)) at 37 C in
a humidified environment of 5% CO2 atmosphere. When the cells reached 80e90%
confluence, the medium was removed. The cells were scraped down with a rubber
policeman and used for either sub-culture or in vitro cell studies. All experiments
were performed on cells that were passaged an equal number of times.
2.4.2. In vitro cellular uptake of SDIO and DIO
The P388D1 cells were plated to 60mm diameter tissue culture dishes at 1106
cells/mL of RPMI-1640 with 1% L-glutamine and 10% lipoprotein deficient bovine
serum (LPDS) (2 mL per dish). The cells were maintained in media at 37 C in
a humidified environment of 5% CO2 atmosphere overnight which allowed cells to
adhere to the bottom of dishes.
Three stock solutions of SDIO or DIO were prepared by dissolving appropriate
amount of particles in RPMI-1640 with 1% L-glutamine and 10% LPDS. The concen-
tration of ironwas determined by ICP-MS. The stock solutionswere dilutedwithmedia
to give series of three solutions with decreasing iron concentration. All solutions were
prepared by weight and iron concentrations were calculated based on the concen-
tration of the stock solution and appropriate dilution factors. The resultant media
solutions of SDIO or DIO were incubated in 37 C water bath for 20 min before use.
After removal of maintenance media, the SDIO or DIO medium solutions were intro-
duced to the cells and incubated at 37 C in 5% CO2 atmosphere for 2 h. After removal of
the media, cells werewashedwith 1X PBS (37 C) (3 2mL for each dish,w 2min for
each washing). Deionized water was added in dishes (1.2 mL for each dish), and the
freeze-thaw (30/20min)methodwas repeated twice to lyse cells. The cell lysateswere
put into 1.5 mL conical tubes and lyophilized. Deionized water was added to the
residue (0.3 mL each) to generate solutions for relaxation time measurement.
2.4.3. Specificity of uptake
To verify that cellular uptake was receptor-specific, competition experiments
were conducted and characterized by relaxation times. The P388D1 cells were
incubated with SDIO ([Fe] ¼ 5.0  105 M) in the presence of competing dextran
sulfate or non-competing dextran as control in 0, 0.02, 0.1, 0.4, 1, and 10-fold excess
concentrations. Cells were incubated at 37 C in a 5% CO2 atmosphere for 2 h and
then prepared for relaxation time measurement as described previously.
2.4.4. Cytotoxicity
Cytotoxicity of SDIO was evaluated with P388D1 cells using the C12 - Resazurin
viability assays. P388D1 cells in RPMI-1640 were plated in 96-well dishes at
a concentration of 1.1 104 cells per well. This places the cells at a density for linear
growth rate which is optimal for the assay. After overnight incubation in 5% CO2
atmosphere at 37 C, the existing RPMI-1640 was replaced with fresh media con-
taining varying amounts of SDIO. Cells were incubatedwith SDIO for either 4 or 24 h.
The media were removed and cells were washed with 1X PBS three times, then
media containing C12 - Resazurin (5 mM) was added. After incubation for 15 min for
reduction of the compound, fluorescence was measured using a Safire2 mono-
chromator microplate reader (Tecan Austria G.M.B.H., Austria) with excitation of
563 nm and an emission of 587 nm. Samples were performed in triplicate to provide
statistical significance.
2.5. Animal studies
2.5.1. Animal model
All animal experiments were performed under protocols approved by the
Animal Care and Use Committee of the University of California, Davis and the
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California Institute of Technology. Apo E/ mice (12 weeks old, Jax West Labora-
tories, West Sacramento, CA) were used for the experiments. Either the right or left
carotid artery of each mouse was ligated two weeks before imaging. Subsequent to
ligation, mice were placed on a high fat diet (TD.88137, Harlan Laboratories Inc.,
Madison, WI). To perform the ligation a medial incision was made between the
mandible and clavicle, exposing the glands and vessels of the neck. The carotid
artery was singled out from the surrounding tissue, with much attention given to
protecting and excluding the parallel-running vagus nerve. A 6/0 silk suture was
threaded under the dorsal side of the carotid artery and was tied off to cause injury
to the site. The procedure was concluded with five to six discontinuous 4/0 ethilon
sutures to reconnect the skin of the original ventral incision. The mice were moni-
tored twice a day for approximately four days to check for irritation and to
administer analgesics when appropriate.
2.5.2. In vivo MRI
All images were acquired on a 7T (Bruker Biospec) small animal magnet using
a home-built birdcage coil. For all time points, the animal was anesthetized with an
1.5% isofluorane:air mixture, kept at 35e37 C with warm air flowing through the
bore and the respirationwas monitored (MP150, Biopac, Goleta, CA). After localizing
the ROI around the neck using a RARE spin echo sequence (TR/TE ¼ 4000/22 ms,
matrix size¼ 128 128, FOV¼ 35.35 35.35mm2, slice thickness¼ 0.754mm), the
common carotid arteries were located with a time-of-flight angiography sequence
with venous saturation (FL2D_ANGIO method, Paravision 4.0: TR/TE ¼ 13.7/3.5 ms,
matrix size ¼ 150  100; zero-filled to 256  100, FOV ¼ 30  20 mm2, slice
thickness ¼ 0.754 mm). A gradient echo sequence was then utilized to visualize the
uptake of SDIO/DIO particles (TR/TE ¼ 1000/5 ms, F.A. ¼ 35 , matrix
size ¼ 200  200; zero-filled to 256  200, FOV ¼ 35.35  35.35 mm2, slice
thickness ¼ 0.754 mm) at the region of the common carotid arteries. A set of pre-
injection images was acquired one day prior to injection. For particle injection,
30 mg/kg Fe content of SDIO (n ¼ 3) or DIO (n ¼ 2) particles dissolved in saline were
injected via the tail vein. The imaging protocol was then repeated at 4 h and 24 h
post-injection.
2.5.3. MR images analysis
To analyze the acquired images, all gradient echo images were first recon-
structed such that the intensity scaling and offset of all images for each mouse were
equivalent. To compare particle uptake between timepoints and subjects, we define
a contrast ratio (CR) metric as:
CR ¼


Iligated
 Ibrain


Icontrol
 Ibrain

i

Iligated
 Ibrain


Icontrol
 Ibrain

prescan
(1)
Where Iligated is the mean intensity of the region of interest (ROI) drawn around
the ligated carotid artery, Icontrol is the mean intensity of the ROI drawn around the
contra-lateral carotid. Ibrain is the mean intensity of the ROI drawn in the spinal cord
at the same image slice as the other ROIs and i is either 4 or 24 h post-injection
timepoints.
ROIs were drawn manually at slice levels approximately located at the common
carotid arteries. These were matched between timepoints. Angiography images
were used to guide ROI delineation around the carotid arteries. Because previous
reports noted that the carotid vessels along with the wall are w1 mm in diameter
[22], all arterial ROIs had diameters of 1.5 mm. CR for SDIO injected mice and DIO
injected mice were compared using a two-sided t-test in Microsoft Excel.
3. Results and discussion
3.1. Synthesis of SDIO
The DIO were synthesized according to our previously reported
procedure [20]. The sulfation of polysaccharides hasbeen reported via
both heterogeneous and homogeneous synthesis pathways. Hetero-
geneous sulfation reactions with chlorosulfonic acid are subject to
major drawbacks such as multiple and non-reproducible side reac-
tions, presence of hazardous andnon-reproducible sulfation rates and
patterns, and backbone degradation. Homogeneous sulfation of
dextran with nitrogen base complexes of sulfur trioxide in aprotic
solvents are the preferredmethod; however, homogeneous reactions
are still accompanied by some non-reproducible side reactions such
as cleavage of labile functional groups and backbonedegradation [23].
Our first effort to sulfate DIO followed literature methods, which
performed sulfation of dextranwith sulfur trioxide pyridine complex
in dry formamide at room temperature [24]. However, the resultant
particles showed 2 size peaks with an average hydrodynamic diam-
eter of 122  97 nm. The sulfation reaction was reassessed under
different synthetic conditions including varying temperatures, using
sulfur trioxide DMF complex as sulfating agent, or using DMF as
reaction solvent, yielding similar results. This indicates that although
sulfation of dextranwith nitrogen base complexes of sulfur trioxide is
well-known [23], successful translation to a dextran coat on a nano-
particle is not trivial. The larger-sized peak may have been due to the
depolymerization of dextran followed by aggregation of incompletely
coated iron oxide nanoparticles.
Sulfur trioxide pyridine complex is made by dripping chlorine
sulfate acid into dry pyridine at 15 C [24]. However, the pres-
ence of pyridine may only partially limit the highly acidic char-
acter of chlorosulfonic acid, which is known to be responsible for
multiple, undesirable, and non-reproducible side reactions such
as cleavage of acid labile functional groups and partial depoly-
merization [25]. We therefore introduced an acid scavenger of
a neutral nature, 2-methyl-2-butene (2M2B), into the reaction
before the addition of sulfation agent, hypothesizing that this
would clear the free acid produced in the system in a timely
fashion and lead to a more efficient reaction, with diminished
side reactions in the sulfation of dextran coat on IO NPs (Scheme 1)
[25,26]. The purified, sulfated DIO were turned out to be mono-
dispersed nanoparticles.
3.2. Characterization of SDIO
3.2.1. SDIO formation verification
Successful sulfation was verified by infrared spectroscopy and
elemental analysis of the purified particles. Compared to the infrared
spectrum of DIO, new absorptions of S¼O groups at 1234 cm1
(asymmetrical stretch), 1011 cm1 (symmetrical stretch), and
826 cm1 (symmetrical CeOeS stretch) were observed, while the
absorptions at 3426 cm1 (O-H stretch) and 1026 cm1 (C-O stretch)
were decreased in the infrared spectrum of SDIO [24]. The emer-
gence of sulfur (9.74%) and decrease of iron content (from 17.7% in
DIO to 11.34% in SDIO) in SDIO further verified successful sulfation of
DIO. The results from elemental analysis of sulfur content also
showed that a 2 h reaction time was sufficient for the sulfation of
DIO; longer reaction time did not appear to increase sulfation.
3.2.2. SDIO size, relaxivity and surface charge
SDIO has an average core size of 7e8 nm (Fig. 1a) and an average
hydrodynamic diameter of 62.4 nm (Fig. 1b), an r1 relaxivity of
18.1 mM1 s1, and an r2 relaxivity of 95.8 mM1 s1 (37 C, 1.4 T) in
pH 7.0 deionized water. The r2 to r1 ratio was 5.3, indicating that
SDIO could be used, preferably, as a T2-weighted MRI contrast
agent.
The measured zeta potential (z) values were e 14.90 mV and e
40.05 mV for DIO and SDIO, respectively. Typically the z value
reflects the electric charge on the particle surface and indicates the
physical stability of dispersions and emulsions in a colloidal system
[27]. Double layers with high z values would create powerful
electrostatic repulsion and, consequently, prevent aggregation
resulting from collisions caused by Brownian motion. In compar-
isonwith DIO, the z value of SDIO decreased by 25.15mV, indicating
a more stable dispersion and emulsification of SDIO in water. In
practice, we found SDIO to be very stable, with a long shelf life in
aqueous solution. We have not observed any properties to change
(e.g. aggregation, size, and magnetic property) after benchtop
storage for over a year at room temperature.
Dextran in DIO is coated on the surface of iron oxide core. Due to
decreased access for hydroxyl groups that lay deeper in the poly-
mer layer, we estimate that the degree of sulfation of outer polymer
layer is greater than that of the inner polymer layer. This should be
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ideal because themaximum sulfation of surface dextran can greatly
increase the targeting ability of the nanoparticles to macrophages
with less charge repulsion at the inner polymer layers that can
affect size and MRI properties. Particle size was somewhat larger in
comparison with that of non-sulfated DIO. This is likely due to the
repulsion of negatively charged sulfate groups on the surface of
SDIO. The r1 and r2 relaxivity values of SDIO were similar to those of
DIO. This is not unexpected as the size of the iron oxide cores was
similar for DIO and SDIO. Reproducibility of our method was vali-
dated by repeating the same reaction; running the reaction with
a different scale of DIO; and using sulfur trioxide DMF complex as
sulfation agent instead of sulfur trioxide pyridine complex. All of
these reactions gave similar products, indicating that our sulfation
procedure is reproducible and robust.
3.3. Cell experiments
3.3.1. SDIO targeting to macrophages P388D1
We selected SR-A as the target for our particles because it is
highly expressed on activated macrophages in atheromas. SR-A
recognizes and binds a number of polyanionic molecules, such as
oxidized LDL, that contribute to the involvement of macrophages in
the formation of plaques [28]. For example, experiments conducted
on Apo E knockout (Apo E/) mice demonstrated that knocking
out SR-A resulted in a significant decrease in atherosclerotic plaque
size [29]. To demonstrate targeting of SDIO to macrophages, we
performed in vitro studies using P388D1 murine macrophage cells.
Uptake of DIO was also performed as a control for comparison; the
properties of the DIO particles were similar to those of the
commercially available MRI CA Sinerem (Table 1) [30].
The T2 values of the lysates of macrophages incubated with
increasing concentrations of SDIO or DIO for 2 h are shown in Fig. 2.
In comparison with DIO, the mean T2 values were significantly
lower for cell lysates incubated with SDIO at all concentrations. In
comparison with the lysates of blank macrophages, SDIO at
5.0 105 M Fe significantly decreased T2 by 70% (p value¼ 0.002),
compared to a 20% T2 decrease (p value ¼ 0.03) for the same iron
concentration of DIO, indicating that there was limited uptake of
DIO compared to SDIO under the same conditions. This resultwas as
expected because DIO is not a ligand of SR-A so it is not recognized
Fig. 1. (a) TEM, and (b) DLS of dextran sulfate coated iron oxide nanoparticles (SDIO).
Scheme 1. Sulfation of dextran coated iron oxide nanoparticles.
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by the receptor. Our results demonstrate that sulfation of DIO
facilitates SR-A targeting, and greatly improves accumulation of the
particles in macrophages over the non-targeted, dextran coated
particles.
3.3.2. Receptor-mediated uptake of SDIO by macrophages P388D1
Specificity for the cellular uptake of SDIO was confirmed by
competition studies in which cells were incubated with a fixed
concentration of SDIO and increasing excess of unlabeled dextran
sulfate (ligand of SR-A) or dextran (not a ligand of SR-A). If uptake of
the agents was receptor-mediated, the excess unlabeled ligand
should compete for binding to the receptors. Nonspecific uptake is
strictly concentration-dependent and would not be affected by
additional ligands in the solution [16,31]. Receptor-mediated
uptake of SDIO was confirmed by the results seen in Fig. 3:
increasing amounts of competitor, from 0.02 to 10-fold excess,
strongly reduce uptake, while increasing amounts of excess dextran
had little influence on the uptake, indicating that the uptake of
SDIO by SR-A is a receptor-mediated process. To exclude the
possibility that the reduced uptake of SDIO in the presence of
dextran sulfate is caused by toxicity or any other influence of
dextran sulfate on the cells themselves, dextran sulfate alone, at the
same concentrations, was applied to P388D1 cells in culture and
the cell viability was evaluated by the C12 - Resazurin viability assay
[32]. The average cell viability was above 96% after either 4 h or 24 h
incubation of cells with the concentration of dextran sulfate
varying from 0.04 to 10  103 M, indicating that the dextran
sulfate is not toxic to mammalian cells (Supplementary Figure 1).
3.3.3. Cytotoxicity of SDIO to mammalian cells
As a preliminary assessment of SDIO’s toxicity to cells, SDIO
were applied to P388D1 cells in culture and the cell viability was
evaluated by the C12 - Resazurin viability assay [32]. Untreated cells
served as negative control. The average cell viability is above 96% or
94% after 4 h or 24 h incubationwith the particles varying from 0.02
to 5  103 M iron, respectively (Fig. 4). The result showed that
SDIO at concentrations relevant for biological imaging do not have
observable toxicity to mammalian cells. This is similar to the results
for most of the in vitro cytotoxicity studies on iron oxide nano-
particles reported in the literature [33e36].
A major concern that limits the use of nanomaterials in clinic is
the potential toxicity. The iron oxide nanoparticles have been used
in the clinic due to their biocompatiblity. After injection the IO NPs
are taken up in the liver and spleenwhere they aremetabolized and
broken down slowly to release free iron ions. The released iron ions
are added to the body’s iron stores and eventually incorporated by
erythrocytes as hemoglobin [37]. Free iron ions could potentially be
cytotoxic because of the catalytic function of iron in the production
of reactive oxygen species (ROS), which in turn can cause lipid
peroxidation, protein oxidation, and DNA damage. However, the
body has the ability to process these released iron ions as indicated
by iron’s large median lethal dose (LD50) of 450 mg/kg for oral
ingestion in the rat model [10,14]. In fact, iron oxide nanoparticle
MRI contrast agents have maintained an excellent safety record
since they were approved for clinical use [37,38].
3.4. Animal studies
The Apo E/ mouse is a widely accepted model for athero-
sclerosis. In practice, we found that ligation of carotid arteries was
an effective method to generate macrophage-laden plaques [18].
The carotid artery is relatively superficial and more amenable to
surgical procedures than the coronary artery. Therefore, to evaluate
the preliminary in vivo capabilities of SDIO we utilized a carotid
ligationmodel. A single carotid artery in the Apo E/mouse (n¼ 5)
was ligated two weeks prior to the imaging study to induce
atherosclerotic plaques. A T2*-weighted MRI with gradient echo
sequence was utilized to visualize the uptake of SDIO and DIO
Fig. 2. Mean T2 values of cell lysates incubated for 2 h with SDIO (A) or DIO (-) of
different iron concentrations.
Table 1
Characteristics of dextran sulfate coated iron oxide nanoparticles (SDIO), in comparisonwith dextran coated iron oxide nanoparticles (DIO) and commercially available dextran
coated iron oxide nanoparticles (Sinerem).
Nanoparticles Core
size (nm)
Average
hydrodynamic
diameter (nm)
Relaxivity (mM1 s1)
(1.4 T, 37 C)
% iron z (mV)
r1 r2
SDIO 7e8 62.4 18.1 95.8 11.34 40.05
DIO 7e8 42.4 15.7 89.2 17.7 14.90
Sinerem N/A <50 nm 19.5a 87.6a N/A N/A
a 1.5 T, 37 C.
Fig. 3. Competitive uptake of SDIO ([Fe] ¼ 5.0  105 M) and dextran sulfate (-), or
dextran (A) by P388D1 cells.
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particles. Image slices from a representative mouse, matched at the
same slice level of the mouse common carotid arteries over a 24-h
time course are shown in Fig. 5a.
Because SDIO is a negative contrast agent, regions taking up
SDIO produce a T2* susceptibility effect, appearing darker than areas
without SDIO. The MR images displayed a sizeable decrease in the
signal of the ligated carotid artery at 4 and 24 h compared to the
pre-injection image. The result parallels that from the in vitro
particle incubation time study that showed that T2 values of the
lysates of macrophages incubated with SDIO decreased substan-
tially after a 4 h incubation time with little subsequent change
(Supplementary Figure 2). No discernable signal decrease was seen
on the control carotid artery. This suggests preferential uptake of
the SDIO particles at the sites of atherosclerotic plaque. Image slices
from a representative mouse injected with DIO particles is shown
in Fig. 5b. Compared to SDIO injected animals, less signal intensity
decrease was seen over time for the DIO injected subjects. Visual-
ization of the volume regions above and below each slice depicted
in Fig. 5, shown in Supplementary Videos 1-6, confirmed that the
signal decreases observed were due to localization of contrast
agent, and not in homogenities in endogenous signal between
slices.
Supplementary video related to this article can be found at
doi:10.1016.j.qdypi.2009.12.006.
To compare the relative uptake between SDIO and DIO particles
in a more quantitative manner, we define a contrast ratio (CR)
metric to measure the magnitude of signal decrease at the arterial
site. As seen in Fig. 6, the CR of SDIO injected mice were signifi-
cantly higher than those of the DIO injected mice by 4 h post-
injection (p value ¼ 0.03). This suggests that at the same injected
iron dose, SDIO accumulated preferentially compared to DIO
particles at the site of atherosclerotic plaque. It should be noted that
the ROIs delineated included the signal contribution of particles in
the blood. We normalize for this effect by comparing between the
left and right carotids, which factors out the signal contribution due
to blood borne particles.
Iron oxide nanoparticle-enhanced MRI has been reported to be
able to identify atherosclerotic plaques in both in vivo animal and
human studies [14]. However, the non-specific contrast agents are
taken up by activated macrophages in vulnerable plaques via
phagocytosis, pinocytosis or fluid-phase transport, which are
inefficient processes [15]. As a result, direct visualization of
atherosclerotic plaques often required relatively large amounts of
nanoparticles [14,39]. A tissue-specific contrast agent would allow
for an improved identification of these lesions [38,40]. Active tar-
geting of nanoparticles can be achieved by decorating them with
a ligand against a knownmarker associatedwith lesions. Our in vivo
MRI images revealed that at 4 h post-injection, targeted SDIO
Fig. 5. Signal change in MRI over time after SDIO (a) or DIO (b) injection. The ligated carotid artery is denoted by the yellow arrow and the control carotid artery is denoted by the
red arrow. Circles indicate the ROI measures used to derive the contrast ratio (CR) metric. To facilitate comparison, the magnified images in carotid areas were first rotated in plane
so all timepoints in the orientation. They were then zero-filled by a factor of 2 and then smoothed with a 2  2 Gaussian filter. (Scale bar ¼ 10 mm, both scale bar and intensity bar
apply to the whole animal images only. L ¼ left, R ¼ right, green box shows magnification area, white arrow denotes the trachea). (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
Fig. 6. Contrast Ratio between SDIO and DIO particle accumulation in vivo.
Fig. 4. Cell viability of P388D1 after 4- (A), or 24 h (-) incubation with different
concentrations of SDIO.
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provided a 4-fold increase in the contrast ratio compared to non-
targeted DIO. The contrast ratio metric was used to account for
differences in anatomy and physiology between subjects.
Comparing the signal decrease between the ligated and control
artery region normalizes the metric and allows cross comparisons
over timepoints and between subjects. It should be noted that the
ROIs delineated included the signal contribution of particles in the
blood. We normalize for this effect by comparing between the left
and right carotids, which factors out the signal contribution due to
blood borne particles. Comparison between the CR of SDIO versus
DIO injected mice (Fig. 6) suggests a time-dependence for optimal
SDIO uptake. This is likely to be a function of the degree of
vulnerability of the plaque at the local site as well as the general
pharmacokinetics of the particles. Future studies will aim to
correlate this with ex-vivo assays to further understand the
mechanism of particle accumulation.
We have previously shown the SR-A is a viable target for labeling
macrophages and atherosclerotic plaques [16,17]. Recently, micelles
containing gadolinium chelates and antibodies against SR-A have
been synthesized and applied to MRI of aortic plaques in Apo E/
mice. In vivo MRI revealed that at 24 h post-injection, targeted
micelles provided a 79% increase in signal intensity of atheroscle-
rotic aortas compared with 34% using non-targeted micelles, and
no enhancement occurred using Gd-DTPA. Uptake of the micelles
was shown, through competition experiments, to be a receptor-
mediated process [41]. However, the potential immunogenicity of
antibodies and cost to generate them in a quantity may limit the
use of immunomicelles clinically [10]. Small molecules or polymers
are alternatives to antibodies [42]. SR-A recognizes a wide range of
ligands that are polyanionic, though not all polyanionic molecules.
Our results show that sulfation of dextran coated IO NPs greatly
increased the negative charges on the particle surface (high nega-
tive z value); this allowed the particles to be recognized by SR-A
and accumulate at the injured carotid artery in vivo. Competition
studies support that the particles were taken up by a receptor-
mediated uptake and not merely due to non-specific electrostatic
association.
Macrophages and macrophage scavenger receptors play a key
role in the pathogenesis of atherosclerosis. Macrophages are
present through all stages of atherosclerosis development, from the
initiation of plaques through the formation of complex plaques
containing foam cells, necrotic debris, and thrombi, and have been
specifically associated with plaque stabilitydhigh densities of
macrophages correlate with vulnerability to rupture [5,13]. Our
results show that SDIO can be recognized and specifically taken up
by macrophages via scavenger receptor. Their specific accumula-
tion at the injured carotid, but not the control carotid, suggests the
potential to use SDIO with MRI to detect and distinguish inflamed
atherosclerotic plaques.
4. Conclusion
The use of MRI is a well-established means for injury and
disease diagnosis on the anatomic scale. Current advances in tar-
geted contrast agents allow researchers to gather in vivo anatomic
and molecular information simultaneously. IO NPs modified to
target various moieties in atherosclerotic plaques have demon-
strated their utility as an important tool for enhancing magnetic
resonance detection of atherosclerosis at the anatomical, cellular
andmolecular levels [43]. However, to date, reports of targetedMRI
of macrophages, a key component in the formation and develop-
ment of vulnerable plaques, are relatively rare. In this paper, we
sulfated dextran coated IO NPs and therefore targeted the nano-
particles to scavenger receptors onmacrophages. SDIO has a high r2
value of 95.8 mM1 s1 and an r2/r1 ratio of 5.3 (37 C, 1.4 T),
therefore acts as an efficient T2-weighted MRI contrast agent. We
demonstrate that SDIO nanoparticles are specifically and avidly
taken up by macrophages via a receptor-mediated process that
labels macrophages much more efficiently than non-sulfated
analogues, and produces distinct contrast in both in vitro and
in vivo T2*-weightedMRI images. Highmacrophage density has been
associatedwith atherosclerotic plaques vulnerable to rupture. Thus,
the specific targeting of macrophages with the MR nanoparticle
imaging agent SDIO demonstrates the potential for SDIO to facili-
tate detection and diagnosis plaque stability with in vivo MRI.
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Captions of videos 1-6 
Supplementary video 1.  
Pre-injection MRI of neck/carotid region prior to the administration of SDIO 
probes. Slices above and below the plane of Figure 5ai are provided in the video clip. 
Figure 5ai is the center slice of the volume set, denoted by frames containing white 
borders. Arrows are present to denote the ligated (yellow) right carotid artery and the 
non-ligated (red) left carotid artery. Video frames are zero-filled by a factor of 4 in plane 
and by a factor of 8 across slices to facilitate visualization of the volume. 
 
Supplementary video 2 
MRI of neck/carotid region 4 hours post injection of SDIO probes. Slices above and 
below the plane of Figure 5aiii are provided in the video clip. Slices matching Figure 
5aiii are framed by white borders. As per Figure 5ai, the central slice of this volume is 
matched to the central slice Supplementary video 2. Arrows are present to denote the 
ligated (yellow) right carotid artery and the non-ligated (red) left carotid artery. Video 
frames are zero-filled by a factor of 4 in plane and by a factor of 8 across slices to 
facilitate visualization of the volume. 
 
Supplementary video 3 
MRI of neck/carotid region 24 hours post injection of SDIO probes. Slices above 
and below the plane of Figure 5aiv are provided in the video clip. Slices matching Figure 
5aiv are framed by white borders. As per Figure 5ai, the central slice of this volume is 
matched to the central slice Supplementary video 3.  Arrows are present to denote the 
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ligated (yellow) right carotid artery and the non-ligated (red) left carotid artery. Video 
frames are zero-filled by a factor of 4 in plane and by a factor of 8 across slices to 
facilitate visualization of the volume. 
 
Supplementary video 4 
Pre-injection MRI of neck/carotid region prior to the administration of DIO probes. 
Slices above and below the plane of Figure 5bi are provided in the video clip. Figure 5bi 
is the center slice of the volume set, denoted by frames containing white borders. Arrows 
are present to denote the ligated (yellow) right carotid artery and the non-ligated (red) left 
carotid artery. Video frames are zero-filled by a factor of 4 in plane and by a factor of 8 
across slices to facilitate visualization of the volume. 
 
Supplementary video 5 
MRI of neck/carotid region 4 hours post injection of DIO probes. Slices above and 
below the plane of Figure 5biii are provided in the video clip. Slices matching Figure 
5biii are framed by white borders. As per Figure 5bi, the central slice of this volume is 
matched to the central slice Supplementary video 5.  Arrows are present to denote the 
ligated (yellow) right carotid artery and the non-ligated (red) left carotid artery. Video 
frames are zero-filled by a factor of 2 in plane and by a factor of 8 across slices to 
facilitate visualization of the volume. 
 
Supplementary video 6 
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MRI of neck/carotid region 24 hours post injection of DIO probes. Slices above and 
below the plane of Figure 5biv are provided in the video clip. Slices matching Figure 
5biv are framed by white borders. As per Figure 5bi, the central slice of this volume is 
matched to the central slice Supplementary video 5.  Arrows are present to denote the 
ligated (yellow) right carotid artery and the non-ligated (red) left carotid artery. Video 
frames are zero-filled by a factor of 2 in plane and by a factor of 8 across slices to 
facilitate visualization of the volume. 
 
 
 
 
 
Supplementary Fig. 1. Cell viability of P388D1 after 24-h incubation with different 
concentrations of dextran sulfate. 
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Supplementary Fig. 2. Mean T2 values of cell lysates incubated with 1.0 × 10
-5
 M iron 
of SDIO (♦) or DIO (■) for different incubation times. 
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Appendix C
Cooccurence Matrices to Compare
Multimodal Image Datasets: Further
Considerations
A cooccurence matrix method was proposed in section 3.4 to compare multimodal imaging datasets
voxel-by-voxel. Here we explored the effects of image spatial resolution disparity (as is present
between PET and MRI images) on analysis made using this method and compared it with the direct
voxel-by-voxel comparison method by simulation.
C.1 Methods
ADC maps derived from diffusion MRI data acquired for studies described in chapter 5 were used as
the baseline high-resolution scans. For simulation purposes, we consider only the two-dimensional
case and only for the tumor ROI.
C.1.1 Effects of Spatial Resolution on Voxel-by-voxel Analysis
Datasets that simultate those encountered in PET were generated by applying two-dimensional
Gaussian filters of varying FWHM on the baseline dataset. In the first condition, we applied a
spatially invariant filter on the baseline image. The effect of increasing FWHM (i.e.PSF, FWHM =
0–5 mm) on voxel-by-voxel comparison metrics were examined. Next, we filtered the image with
a spatially variant filter to simultate spatially varying PSFs usually encountered in PET. FWHM
as a function of radial distance from the center was determined from measurements made with the
PET/MRI scanner [198]. FWHM at radial distances of <10 mm, the outer limit of the measurements,
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were calculated from a quadratic fit from the data. The maximum FWHM from this fit was applied
to radial distances of >10 mm. This represented a best case scenario as spatial resolution typically
worsens farther away from the system’s center [291]. Gaussian filtering was applied voxel-by-voxel
using a nonlinear sliding window algorithm available as part of the MATLAB image processing
package.
There are instances where we are interested in comparing regions of low signal in one modality
with high signal in the other modality. To investigate this scenario, we generated blurred images
from baseline images that have been inverted. An inverted baseline image, Baselineinvertedwas gen-
erated from the original baseline image Baselineoriginal by
Baselineinverted(i, j) =
[
Max(Baselineoriginal)−Baselineoriginal(i, j)
]
+Min(Baselineoriginal),
(C.1)
i, j are voxels indices within the tumor ROI.
Two metrics, the Pearson’s correlation coefficient (PCC) and the concordance correlation co-
efficient (CCC) were calculated for voxel-by-voxel comparisons between baseline and Gaussian
filtered images.
C.1.2 Cooccurence Matrix Analysis
The cooccurence matrix method was described in detail in section 3.4.3.4. Here, we examined how
two variables present in this method may affect analysis.
C.1.2.1 PSF Window
One variable that may affect analysis is the PSF window considered around each voxel. cooccurence
matrices were calculated with different PSF windows (|∆x|, |∆y| = 0–5 mm), comparing the baseline
image with four datasets:
1. The baseline image itself, as control (control matrix).
2. Baseline image blurred with static Gaussian filter (FWHM = 1.5 mm) to simulate the PET/MRI
system.
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3. Baseline image blurred with static Gaussian filter (FWHM = 2.2 mm) to simulate the mi-
croPET system.
4. Baseline image blurred with the spatially variant Gaussian filter to simulate actual PET sys-
tems.
Cooccurence matrices were compared to the control matrix using CCC to evaluate the method’s
ability to compare data with different spatial resolutions. We repeated the analysis by comparing
baseline images with inverted blurred images.
C.1.2.2 Binning method
The cooccurence matrix is based on joint 2D histograms. Thus, an important parameter for this
method is the choice of bins. We explored the robustness of the technique by comparing CCC
values returned from matrices calculated with the following bin locations:
1. Minimum value = 0, maximum value = 65th percentile of tumor ADC values.
2. Minimum value = 0, maximum value = 75th percentile of tumor ADC values.
3. Minimum value = 0, maximum value = 85th percentile of tumor ADC values.
4. Minimum value = 0, maximum value = 95th percentile of tumor ADC values.
5. Minimum value = 0, maximum value = 100th percentile of tumor ADC values.
The number of histogram bins was set at 22. This was the average number returned from an optimal
binning algorithm applied to the ADC data [292].
All simulations were performed in MATLAB. ADC images from three different animals ac-
quired during different imaging sessions were used for the simulations.
C.2 Results and Discussion
C.2.1 Direct Voxel-by-voxel Comparison of PET and MRI Images is not Ideal
Voxel-by-voxel comparisons between baseline images and images blurred with a static and spatially
varying Gaussian filter (which forms the ideal case) are shown in figure C.1. Image details, such
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as the shape of the central fluid region in the tumor were lost upon filtering. Less details were lost
when a spatially varying filter was used compared to the static filter. Visual inspection of the voxel-
by-voxel plots did not show any obvious correlation between the baseline and blurred datasets. This
was reflected in the correlation metrics. PCC and CCCs from the blurred to baseline comparisons
decreased signficantly from unity (PCC: -30%–50%, CCC: –60%–70%). This indicated that direct
voxel-by-voxel comparisons of PET and MRI data is not optimal and can mask structures that may
be correlated between the two modalities.
The effect of PSF size was examined by varying the filter FWHM (figure C.2). For the positive
contrast comparison, PCC and CCC were dramatically reduced when FWHM >1 mm, the nominal
resolution achievable by PET. The correlation drop off is more dramatic in the inverted comparison
case: PCC and CCC were already attenuated for mouse 2 and mouse 3 with a filter of FWHM =
0.01 mm. This is expected, since Gaussian filters cause spillover of high voxel intensities into areas
of lower voxel intensities.
C.2.2 Cooccurence Matrix Comparison Provides an Reasonable Alternative to Di-
rect Voxel Comparison
Example cooccurence matrices for baseline-baseline and baseline-spatially variant filtered datasets
are shown in figure C.3. The general pattern between the two matrices are similar. Slight differences
between the two matrices are present. For example, a small portion of the lower ADC voxels on the
blurred image cooccur with high ADC voxels on the baseline image. We quantified this difference
by calculating the CCC for different binning methods at different PSF windows. The results for
baseline/positive contrast and baseline/inverted contrast are shown in figure C.4.
A few trends were observed. Firstly, at the optimal PSF window and binning condition (~1
mm window, bin location condition 2), Baselineoriginal vs. Baselineoriginal-blurred matrices were
consistently similar to Baselineoriginal vs. Baselineoriginal matrices for different animals. This was
demonstrated by the high (>0.7) CCC values at the optimal condition. This suggests that cooc-
curence matrices are able to recover image patterns that are obscured by blurring.
Secondly, cooccurence matrices calculated for Baselineoriginal vs. Baselineoriginal-blurred im-
ages showed consistently higher CCC values compared to Baselineoriginalvs. Baselineinverted-blurred
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(a) Voxel-by-voxel comparisons of images filtered by spatially invariant Gaussian functions. Scatterplots do not reveal
any obvious correlation between the datasets.
Original Slice
0 0.5 1 1.5 2
x 10−3
0
0.5
1
1.5
2 x 10
−3
Original data
N
o 
filt
er
in
g
r = 1, 
CCC = 1
Spatially varying filter
0 0.5 1 1.5 2
x 10−3
0
0.5
1
1.5
2 x 10
−3
Original data
Sp
at
ia
lly
 v
ar
yin
g 
filt
er
r = 0.51, 
CCC = 0.44
Constant filter: 2.2 mm FWHM
0 0.5 1 1.5 2
x 10−3
0
0.5
1
1.5
2 x 10
−3
Constant filter
Sp
at
ia
lly
 v
ar
yin
g
 
filt
er
r = 0.72,
 CCC = 0.29
(b) Voxel-by-voxel comparisons of images filtered spatially variant Gaussian functions. Although tumor details were less
obscured, scatterplots still do not reveal any obvious correlation between the datasets.
Figure C.1: Voxel-by-voxel comparisons between images with different spatial resolutions for a
single ADC dataset. Gaussian blurring drastically reduces image detail and obscures correlation by
direct voxel analysis.
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(a) Correlation of baseline and blurred data.
A coefficient of 1 would indicate exact
matching.
(b) Correlation of baseline and blurred data:
comparison with inverted blurred data. A co-
efficient of -1 would indicate exact matching.
Figure C.2: Correlation of baseline and blurred data at different FWHM.
(a) Cooccurence matrix calculated by comparing the
baseline image with itself.
(b) Cooccurence matrix calculated by comparing the
baseline image with the spatially variant blurred image.
Figure C.3: Cooccurence matrices were generated by binning from ADC values between 0 and the
75th percentile value within the tumor ROI. The PSF window used is 1.75 mm.
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(a) Concordance correlation for different PSF windows with different binning conditions. Baseline images were com-
pared to blurred baseline images.
(b) Concordance correlation for different PSF windows with different binning conditions. Baseline images were com-
pared to blurred inverted baseline images.
Figure C.4: Concordance correlation coefficients for cooccurence matrices compared to the control
matrix. Matrices were calculated using different bin locations (percentile bin denotes the maximum
histogram bin value) and PSF windows. Error bars denote standard error.
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images. This makes sense, since Gaussian filters tend to cause spillover of high intensity voxels into
low intensity regions and hence low intensity structures in the Baselineinverted-blurred images are
masked to a greater extent compared to the high intensity structures observed in the Baselineoriginal-
blurred images.
Thirdly, the highest CCC was achieved in general for all binning conditions was observed with
a PSF window ~1 mm. For images blurred with a spatially variant filter, a secondary high CCC
peak was observed as the PSF window approached 5 mm. 1 mm is approximately half the FWHM
of the Gaussian filters applied to the PET datasets. Thus, this should be the approximate radius
which we expect a cooccurring voxel to lie compared to the voxel of interest. This relationship
between structure resolvability and PSF window is supported by Valckx and Thijssen, who found
that altering the PSF window as a function of speckle size in echographic images can affect the
cooccurence matrix method’s ability to resolve structures [293].
The trend towards high CCC for spatially variant filted images is due to the fact that the tumors
being considered were ~5 mm. Thus, most of the tumor ROI voxels would cooccur with each other
with a large PSF window.
Finally, we observed that the highest CCC are obtained using the 1 mm PSF window for maxi-
mal bin values at the 65th–85th percentile range. Maximal bin values above this resulted in reduced
CCC values. The choice of optimal bin size and binning methods for cooccurence matix analysis is
a subject of active investigation [294, 295, 296]. Both Handrick et al. [295] and Kim et al. [296] re-
ported that nonlinear binning methods which adjust bin sizes depending on the histogram data were
better than linear binning methods at tissue classification of CT images. This is reflected in our re-
sults, as linear binning (minimum value = 0, maximum value = maximum ADC value) showed the
worst CCC with the baseline-baseline cooccurence matrix. The 65th–85th percentile binning per-
formed better, possibly because higher intensity values are clustered into a smaller number of bins.
The optimal binning method may be dependent on the question being asked. For example, in sec-
tion 3.4 we wanted to correlate voxels with high ADC values with voxels with high 64Cu-antibody
uptake. Thus, a binning method that clustered high PET intensities above a threshold value into a
subset of matrix bins that was used is suitable for this purpose. Further investigations are required
to identify more generalized guidelines for choosing the optimal binning method for cooccurence
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matrix generation.
C.3 Conclusion
We explored the effects of PSF window and binning method on cooccurence matrices generated
between images with different spatial resolutions. The optimal PSF window is dependent on the
spatial resolution of the imaging modality being considered. For PET-like images, we found the
optimal PSF window to be approximately half the FWHM of the image. The choice of histogram
bins can also affect cooccurence matrix results. Cooccurence matrices are being increasingly ap-
plied to PET and MRI images [297, 298, 299]. Further studies are needed to refine this method for
the analysis of PET/MRI datasets.
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Appendix D
Synchronous PET/MRI Software Code
D.1 MRI Code Implemented in Paravision Environment
D.1.1 PET_FLASH.ppg, a Modified Bruker FLASH Sequence to Include Syncing
Modules
;****************************************************************
;
; Copyright (c) 2001 - 2003
; Bruker BioSpin MRI GmbH
; D-76275 Ettlingen, Germany
;
; All Rights Reserved
;
; PET_FLASH - a gradient echo imaging method
;
; Set for Synchronised PET/MR
;
;****************************************************************
;
; d0 - TR padding
; d1 - T1 padding
Modifications in italics.
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; d2 - T2 padding
; d3 = PVM_RiseTime
; d4 = PVM_RampTime
; d8 = CONFIG_amplifier_enable
#include<Avance.incl>
#include <DBX.include>
preset off
define delay denab
define delay d4d10u
define delay d5d20u
define delay d0d40u
define delay d4d2
"denab = d3 - de + depa"
"d4d10u = d4 +10u"
"d5d20u = d5 +20u"
"d0d40u = d0 -40u"
"d4d2 = d4 + d2"
"l3 = l1 + ds"
#include <PrepModulesHead.mod>
#include <FlowSatinit.mod>
#include <MEDSPEC.include>
lgrad r2d<2d> = L[1]
zgrad r2d
lgrad r3d<3d> = L[2]
zgrad r3d
#include <PET_MR_SYNC_A.mod>
;MR sequence started and trigger sent to the PET system,
;we now initiate pre-pulse sequence setup
lo to decr times DS
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lgrad slice = NSLICES
zslice
10u recph ph1
; By now, the PET module should be ready. We then start the MR sequence and
; tell the PET system to start acquisition simultaneously.
#include <PET_MR_SYNC_B.mod>
start, 10u
if(PVM_BlBloodOnOff)
{
#include <TriggerPerPhaseStep.mod>
}
#include <blblood.mod>
#include <TriggerPerPhaseStep.mod>
#include <SelSliceIr.mod>
#include <tagging.mod>
;———————————-start of the main loop ———-
slice, 10u fq8b:f1
#include <TriggerPerSlice.mod>
;———————————-preparation modules ————-
#include <FlowSat.mod>
subr SatSlices()
#include <MagTrans.mod>
#include <FatSup.mod>
d6 grad{(0)|(0)|(t9)}
;———————————-slice selection——————
d3 grad{(0)|(0)|(t0)} fq1:f1
d8 gatepulse 1
p0:sp0 ph0
d4d10u groff
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if(PVM_ppgFlag1) ;long TE mode
{
;———————————-slice rephase——————–
d10 grad{(0)|(0)|(t1)}
d4d2 groff
;———————————-read dephase + phase encoding—-
d11 grad{(t2)|r2d(t3)|r3d(t4)}
d4d10u groff
}
if(!PVM_ppgFlag1) ;short TE mode
{
;———————-slice rephase, read dephase, phase encoding—-
d10 grad{(t2)|r2d(t3)|(t1)+r3d(t4)}
d4d2 groff
}
;———————————-frequency encoding—————
denab REC_ENABLE grad{(t5)|(0)|(0)}
ADC_INIT_B(NOPH, ph2) ;ph1 is used (see recph)
aqq ADC_START
;———————————-read spoiler + phase encoding—-
d11 grad{(t6)|r2d(t7)|r3d(t8)} ; 2nd and 3rd dims
d12 grad{(t6)| (0) | (0) }
d3 groff
d0 ADC_END
;———————————-slice and movie loop———————–
#include <FlowSatinc.mod>
if(NI > 1)
{
2.5u islice
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lo to slice times NI
}
d20
;———————————-averaging loop——————-
if(NA > 1)
{
2.5u ipp1 ipp2
2.5u recph ph1
lo to start times NA
2.5u rpp1 rpp2
}
;———————————-2d loop————————–
igrad r2d
lo to start times l3
"l3=l1"
;———————————-3d loop————————–
igrad r3d
lo to start times l2
2.5u
lo to start times NAE
2.5u
#include <Evolution.mod>
2.5u
lo to start times NR
SETUP_GOTO(start)
exit
ph0 = 0
ph1 = 0 2 1 3
ph2 = 0 2 3 1
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D.1.2 PET_MR_SYNC_A.mod
;**********************************************************
;
; Caltech/ UC Davis PET/MR
;
; (c) 2010
;
;
; PET_MR_SYNC_A.mod - PET/MR Synchronous start module
;
;
;**********************************************************
; Need to link to the methods
;Initialise
TTL4_HIGH
;
;Wait for the start signal from the PET program to begin
trignl4
TTL4_HIGH
D.1.3 PET_MR_SYNC_B.mod
;**********************************************************
;
; Caltech/ UC Davis PET/MR
;
; (c) 2010
;
;
; PET_MR_SYNC_B.mod - PET/MR Synchronous start module
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;
;
;**********************************************************
; Need to link to the methods
; Now Other prep stuff done, we start the sequence
TTL4_LOW
trigne4
TTL4_HIGH
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Appendix E
MATLAB Implementation of an Unique
Identifier for Multimodal Data Linkage
%% Make a Multimodal imaging header extension
% Define ecode = 30 Need to register with NIFTI
clear all
% Multimodal ID self first
ecodeA = 30;
% Modalities
%{
PET : standard positron emission tomography dataset
MRI : standard magnetic resonance imaging dataset
DCEMRI: dynamic contrase enhanced MRI dataset
DCEPET: dynamic contrast enhanced PET dataset
DWI :
CFM : Confocal microscopy
unique identifier is the same for all the datasets that belong together.
%}
uid = datestr(now, 30);
ext.section(1).ecode = ecodeA;
MODAL = unicode2native(fullfile(’PET’, ’MRI’, uid)); % This would encode a PET image data
which has an associated standard MRI dataset linked to it.
ext.section(1).edata = MODAL;
216
verify_nii_ext(ext)
% To store this extension.
%nii.ext
217
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